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ABSTRACT 
Occupational exposure of pesticides occurs via inhalation through the lungs or 
by absorption through the skin. The assessment of the possible importance of these 
extrahepatic tissues in the hydrolysis of pesticides is important. 
Although the liver has been shown to be the most metabolically active tissue, 
both the skin and lung have the ability to metabolise pesticides. Therefore, the 
possibility exists that pesticides which are absorbed through the lung and skin may 
undergo first pass metabolism in these tissues. 
In the study, the esterase enzymes responsible for the hydrolysis and 
subsequent detoxification of a number of pesticide substrates were identified and 
quantified. Esterases which hydrolysed the pesticides fluazifop-butyl and carbaryl and 
phenylacetate, a marker substrate for esterase activity, were found to be distributed in 
the microsomal fraction of the liver and lung and in the blood. In vitro studies in the rat 
show that lung, skin and plasma have an important role to play in the first pass 
metabolism of the pesticides fluazifop-butyl and carbaryl. In paraoxon hydrolysis, the 
plasma plays an important role in first pass metabolism, whereas the lung and skin have 
little effect. 
With the use of inhibitors and inducers these esterase enzymes were 
characterised as `A' or `B' esterases. Fluazifop-butyl and carbaryl were hydrolysed by 
carboxylesterase, a `B' esterase, whereas paraoxon was hydrolysed by paraoxonase, 
an `A' esterase. Phenylacetate was found to be hydrolysed by both `A' and `B' 
esterases. 
Parallel studies were carried out in human liver and blood to establish whether 
the rat was an appropriate model for study of the detoxification of pesticides by 
esterases. Studies have shown that there is considerable similarity in the nature of 
human and rat esterase enzymes, although there are significant differences in absolute 
activities. 
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EXPERIMENTAL AIMS 
Occupational exposure to pesticides can occur mainly via inhalation through the 
lungs or by dermal absorption. Many pesticides are esters and undergo hydrolysis by 
esterases following absorption into the body. Following dermal absorption and 
inhalation, absorbed compounds may be hydrolysed in skin, lung and circulation 
before the major site of hydrolysis, the liver Most current knowledge on esterase 
hydrolysis of xenobiotics has been obtained through studies in the liver of animals 
where esterase activity is found to be at its greatest. Although studies on esterase 
activity have been carried out in the plasma of animals, little information is available on 
possible esterase activity in the extra-hepatic tissues of the lung and skin. 
The aim of the study was to determine the distribution of the esterase enzyme in 
the microsomal and cytosolic fractions of the rat liver, lung and skin as well as in the 
plasma and erythrocytes, to establish the importance of these tissues in the 
detoxification by hydrolysis of a number of pesticides. Using specific inhibitors and 
inducers the nature of the esterases involved in the hydrolysis of these pesticides being 
studied was elucidated. To compare rat and human tissues where possible, 
experimental studies were carried out in liver and plasma to assess the rat as a model for 
extrapolation to man. 
SECTION I: GENERAL INTRODUCTION 
CHAPTER 1: XENOBIOTIC METABOLISM 
1.1 INTRODUCTION 
The body is continually exposed to a number of foreign compounds 
(xenobiotics). They may be absorbed by a variety of routes including ingestion, 
inhalation and dermal absorption. Most xenobiotics that are absorbed undergo 
metabolic transformation in the body to enable elimination by excretion. Excretion often 
follows conversion of the xenobiotic to a more soluble metabolite. The ability of the 
body to metabolise xenobiotics was first reported by Wohler in 1824, who showed that 
benzoic acid ingested in food converted to a metabolite which was excreted into the 
urine. 
Enzymes responsible for xenobiotic metabolism form a diverse group, 
which biotransform many exogenous compounds, and some endogenous substrates. 
Drugs and xenobiotics are transformed by a variety of pathways classified as phase I 
and phase II reactions. Phase I reactions or functionalisation reactions serve to 
introduce a functional group into the xenobiotic thereby changing it to a more polar and 
hence more excretable form. Products from phase I reactions may act as substrates for 
phase II metabolism. This involves conjugation with endogenous substrates, resulting 
in increased water solubility and polarity of the compound. The increases in the 
solubility and polarity of the xenobiotic aid in its elimination or excretion from the 
body. Examples of types of phase I and phase II reactions can be seen on table I. I. 
The enzyme system responsible for metabolic transformation of xenobiotics are located 
principally in the liver, although enzymes are present to a lesser extent in other tissues. 
However, most of the fundamental knowledge of xenobiotic metabolism has been 
derived from studies in the rat liver. 
Most current knowledge has been obtained by disruption of the liver by 
differential centrifugation to release subcellular organelles. The enzymes found in the 
endoplasmic reticulum and the cytoplasmic fraction of the subcellular components are 
responsible for xenbiotic metabolism. Phase I oxidative enzymes are oxidases localised 
in the endoplasmic reticulum with the phase II enzyme glucuronyl transferase. 
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Table 1.1. Examples of phase I and phase II drug metabolism reactions 
Phase I Phase II 
Hydrolysis Sulphation 
Oxidation Glucuronidation 
Reduction Glutathione conjugation 
Hydrolytic enzymes are present in both endoplasmic reticulum and cytosol. Other phase 
H enzymes are predominantly located in the cytosol. Intact endoplasmic reticulum 
consists of a network of filamentous membrane bound channels which, on disruption, 
form microsomes. These microsomes retain most of their enzymatic activity. 
1.2 PHASE I XENOBIOTIC METABOLISM 
1.2.1. Hepatic Metabolism 
The liver is the largest single organ, constituting about 2% of the mass of 
the body. It is' enclosed in a connective tissue sheath known as Gilssons capsule. The 
functional mass of the liver contains four main components : (1) the parenchymal cells 
or hepatocytes, which constitute about 60% of the mass of liver, (2) reticuloendothelial 
cells (Kupffer cells); (3) the biliary tracts; and (4) blood vessels. 
The portal vein and hepatic artery enter the liver at the porta hepatis and 
the intrahepatic portion of the bile duct emerges through the same orifice. Branches of 
all the three vessels run together within the liver, constituting Gilssons triad, together 
with connective tissue and lymphatic channels. The simple liver acinus (SLA), the 
stuctural and functional hepatic unit is arranged around the Gilssons triad. The smallest 
structural units of the SLA are the lobules, which number 50 to 60 thousand. Each 
lobule is roughly a hexagonal prism, several millimeters long and with a cross sectional 
area of about 2mm2. Within each lobule, hepatocytes are arranged in sheets or plates to 
form a labyrinth, the walls of which are normally only one cell thick. 
Each hepatocyte is polyhedral, having 5-12 sides, and a diameter of 12- 
25µm. The cytoplasm typically displays copious amounts of both granular and 
agranular endoplasmic reticulum, high concentrations of mitochondria, lysosomes and 
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a well developed Golgi complex- all features indicating a high metabolic activity. 
The hepatocytes carry out a multitude of metabolic activities, including 
the synthesis and release into the blood of various plasma proteins including albumins, 
clotting factors and complement components. Hepatocytes also eliminate endogenous 
and exogenous substances from the blood stream, and are thus important in 
detoxification of the blood. 
1.2.1. i. Hydrolysis 
Hydrolysis by esterases is a major route for the metabolism of 
endogenous compounds as well as xenobiotics. The liver is a major site for esterases 
but there is a wide distribution in other body tissues and fluids. Esters, amides, 
hydrazides and carbamates can be hydrolysed by various esterase enzymes. The basic 
hydrolysis of xenobiotic esters catalysed by esterases is as follows 
RCOOR + H2O ---------> RCOOH + ROH 
where RCOOR represents a xenobiotic ester, RCOOH and R OH the products. 
In 1953 Aldridge classified these esterases into three groups on the basis 
of their interaction with organophosphates: 'A' esterases which hydrolyse 
organophosphates and include arylesterase and paraoxonase; `B' esterase which are 
inhibited by organophosphates and include carboxylesterase, cholinesterase and 
acetylcholinesterase and `C' esterases which do not interact with organophosphates (see 
Table 1.2. ). 
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Table 1.2. Classification of `A' and `B' type esterases. 
Type of Esterase Enzyme Nomenclature .- Active centre 
A-Esterase 
B-Esterase 
arylesterase, paraoxonase 
( E. C. 3.1.1.2. ) 
carboxylesterase (E. C. 3.1.1.1. ) 
cholinesterase (E. C. 3.1.1.8. ) 
acetylcholinesterase (E. C. 3.1.1.7. ) 
cysteine amino acid 
residue 
serine amino acid 
residue 
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Classification of these esterases is by the use of specific inhibitors. 
Organophosphate compounds are non-selective inhibitors of `B' esterases. Inhibition is 
as a result of phosphorylation of the serine amino acid residue at the active centre of the 
enzyme. Inhibitors of carboxylesterase and cholinesterase include physostigmine, 
neostigmine, pyridostigmine and edrophonium. However, bis- (4-nitrophenyl) 
phosphate (BNPP) is a more selective inhibitor of carboxylesterase. The 
organophosphate bis- (4-cyanophenyl) phosphate and 4-nitrophenyl phosphoriate can 
be used to selectively inhibit the carboxylesterase lysophospholipase and medium chain 
monoacylglycerol lipase (Brandt et al, 1980). 
1.2.1. i. a. A Esterases 
The A esterase enzyme has a cysteine amino acid residue at its active 
centre and is at present classified under arylesterase (E. C. 3.1.1.2.; A esterase, 
paraoxonase) (Enzyme Nomenclature, 1984). The term arylesterase was introduced by 
Augustinsson (1958) with respect to an enzyme activity of human plasma which rapidly 
hydrolysed aromatic ester compounds (Whitaker and Mounter, 1953). Enzymes of this 
class are not inhibited by bis-nitrophenol phosphate (BNPP) or physostigmine and 
rapidly hydrolyse aromatic esters such as phenylacetate and organophosphates, 
whereas butyrates are slowly hydrolysed (La Du and Eckerson, 1984). The designation 
of A esterase for arylesterase was based on the capacity of the enzyme to hydrolyse the 
organophosphate insecticide paraoxon, however, there is some doubt concerning the 
capacity of purified serum arylesterase to hydrolyse paraoxon, therefore, paraoxonase 
is currently classified as a separate enzyme. Ca2+ ions are known to increase the 
activity of the A esterase enzyme. 
Human paraoxonase activity has been found to vary considerably among 
individuals. This may be of considerable importance in protection against 
acetylcholinesterase inhibition by organophosphate compounds (Williams, 1987). It 
has been reported that phenylacetate hydrolysis in human serum (caucasian population) 
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is unimodally distributed (Simpson, 1977; Loreentz et al, 1979; Reiner el J, 1987), 
whereas paraoxon hydrolysis has a triphasic distribution (Reiner et al, 1987; 
Geldmachen-V Mallinckrodt et al, 1973; Eckerson ems, 1983 a and b). Published data, 
however, concerning the specificity and number of enzymes are still ambiguous and 
even controversial (Skrinjaric-Spoljar and Reiner, 1968; Geldmachen-V Mallinckrodt el 
al, 1973; Eckerson and La Du, 1984; Mackness et al, 1987). A lack of correlation 
between paraoxon and phenylacetate hydrolysis in the total serum population and in any 
of the modes based upon paraoxon hydrolysis has been reported (Geldmachen-V 
Mallinckrodt, 1988). This however is contrary to that found by Eckerson et al, (1983 a 
and b), who found high correlation for the hydrolysis of paraoxon and phenylacetate in 
all three phenotypes, suggesting that these activities might be the property of the same 
enzyme. However, gel-filtration experiments carried out by Mackness et al, (1987) 
suggest that paraoxon and phenylacetate hydrolysis can be partially separated, 
supporting that different enzymes hydrolyse paraoxon and phenylacetate. 
High A esterase activity is found in the serum of a wide variety of 
mammalian species but the activity is low or absent in avian species (Brealey et al, 
1980; Mackness et al, 1987). The hydrolysis of the toxic metabolites is extremely rapid 
in mammalian serum compared to that of the avian sera (Machin et al, 1978,1975; 
Brealy, 1981). This difference has been shown to responsible for the selective toxicity 
of organophosphates to mammals compared to birds. The hydrolysis of paraoxon by 
paraoxonase was found to be 7-fold greater in rabbit serum than in rat serum, with the 
dose of paraoxon required to produce similar signs of toxicity and similar degrees of 
cholinesterase inhibition in rats and rabbit differing by 4-fold. In the house mouse four 
distinct enzymes for arylesterase have been found, noted genetically as ES-8, ES-16, 
ES-19 and ES-24, whereas in the rat only one has been identified, ES-17 (Chapman et 
al, 1974; von Deimling and Taylor, 1987). 
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1.2.1. i. b. B 'Esterases 
Carboxylesterase 
Carboxylesterases (E. C. 3.1.1.1. ) have 'a - serine amino acid residue at its 
active centre and are subclassified according to their isoelectric points (Mentlein gLd, 
1987). The term carboxylesterase gradually replaced the term aliesterase which was 
first used by Richter and Croft (1942). 
Carboxylesterase comprises the majority of tissue esterase in mammals. 
This class predominates in mammals both qualitatively and quantitatively, and posses a 
high degree of multiplicity and a large number of isoenzymes (Hedrich et al, 1987). 
Similarly, clusters of closely linked carboxylesterase gene loci have been located in the 
mouse (Peters, 1982) and at least six chromasomal gene loci have been located in the 
rabbit (Zutphen et al, 1987). Carboxylesterase is also widely distributed in the tissues of 
vertebrates and insects (Brooks, 1979; Beckendorf and Stephen, 1970). Among various 
tissues of animals, the highest esterase activity with various substrates is found in the 
liver (Junge and Krisch, 1975; von Deimling and Bocking, 1976). Rat kidney has 
moderate carboxylesterase activity in the proximal tubules (Echobichon, 1973; Bocking 
et al, 1976) as well as being found in the small intestine epithelial cells of rats (De Jong 
et al, 1978; Bocking et al, 1976). Besides these tissues, tissues carboxylesterase has 
been found in the lung (Milz and Budd, 1978), testis (Beckendorf and Stephen, 1970), 
adipose tissue (Okuda and Fujii, 1967; Tsujita et al, 1982), the central nervous system 
(Rumsby et al, 1973; Paul and Halaris, 1976) and rat brain (Kishimoto, 1973). 
As in experimental animals, humans have carboxylesterase in muscle 
(Ecobichon and Kalow, 1965), kidney (Ecobichon and Kalow, 1964), brain (Hojring 
and Svensmark, 1976; 1977), liver (Junge et al, 1974) and serum (Brogren and Boeg- 
Hansen, 1975). 
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Rat carboxylesterase have been widely studied (Mentlein et al, 1980; 
Robbi et al, 1983). Using isoelectric focussing, six carboxylesterases have been 
purified from rat liver microsomes. Initially they were identified by their isoelectric 
points (esterase pl 5.0,5.2,5.6,6.0 and 6.4). Although closely related in their 
molecular properties, four of the esterases have different primary structures and 
different substrate specificities to drugs and lipids (Mentlein eta], 1984a and b, 1985). 
All the esterases examined are in multiple forms. These micro heterogenous forms (eg. 
pI 6.2 and 6.4) seem to have almost identical properties. Thus carboxylesterases are 
currently named according to their action on intracellular substrates, with at least one 
endogenous ester found to be hydrolysed in each case. 
The microsomal carboxylesterase, showing about five bands in isoelectric 
focussing around a pI of 5.6, hydrolyses simple aromatic esters very effectively, 
representing the acetanilide cleaving hydrolase of the liver. This corresponds to ES-3 in 
genetic nomenclature for rat liver esterases (Van Zutphen, 1983), has also been termed 
butyrylesterase L-1 (Keneka et al, 1979) or esterase EA (Arndt et al, 1978). This has 
been shown to be identical with the ß-glucuronidase-complexing protein of the rat 
(Medda et al, 1987). Mentlein et al, (1984a and 1985) showed that the esterase cleaves 
at least three different types of endogenous substrate: lysophospholipids, 
monoglycerides and long chain acylcarnitines. 
The carboxylesterases with isoelectric points of 6.2 and 6.4 was found to 
have nearly identical specificity and chemical properties (Mentlein et al, 1984a and b). 
This esterase hydrolyses aspirin, propanidid, malathion, pyrethroid esters and many 
other esters. This corresponds to ES-4 in genetic nomenclature (Mentlein et al, 1987) 
and has been named cholesterol ester hydrolase (Nilson, 1976), ethanol acyltransferase 
(Polokoff and Bell, 1978), monoacylglycerol lipase (Ikeda e al, 1977; Mentlein et al 
1985b) or palmitoyl CoA endogenous substrates (Jamdar, 1979; Berge, 1980; Mentlein 
et al, 1985a). These esterases cleave long chain glycerol and CoA at high rates, while 
action on retinoyl, palmitate and cholesterol esters is much slower (Mentlein and 
Heymann, 1987). 
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The liver carboxylesterase most active against short chain aliphatic esters 
is identified as both ES-8 and ES-10 in genetic nomenclature (Mentlein, 1987). This 
enzyme may exist as a monomer or a trimer. This enzyme shows one or more bands 
around pI 6.0 on isoelectric focussing, also being described as ES-1 by Arndt gt al. 
(1973) or as monoglyceride by Oerlemans et al, (1977). The enzyme hydrolyses 
procaine, clofibrate and other xenobiotics (Mentlein and Heymann, 1984), and is found 
in other organs besides liver, including small intestine, lung, testis, brown fat and heart 
(Mentlein et al, 1987). This esterase cleaves acylglycerols of medium chain length at a 
faster rate than long or short chain derivatives. The term medium chain 
monoacylglycerol lipase is used to describe this enzyme. 
The carboxylesterase termed pI 5.2 (Mentlein and Heymann, 1981) or 
esterase pI by Robbi and Beaufy, (1983) is active with mono and diacyl glycerols and 
is currently termed diacylglycerol lipase (Mentlein et al, 1985). It is found in multiple 
forms (Mentlein et al 1984a; Robbi and Beaufy, 1986) in the liver, although no activity 
has been found in the liver of new born rats (Mentlein et al, 1987). Diacylglycerol 
lipase cleaves phorbol esters that interfere with the regulatory function of 
diacylglycerols in vivo. 
The four groups of carboxylesterase represent the so called non-specific 
esterase activity of rat liver. The four esterases exhibit the highest activity in the liver, 
except for ES-4 which is equally active in the kidney. The carboxylesterases appears to 
be found in the microsomal and cytosolic fractions of the cell. 
Hosokawa et al, (1990) purified seven carboxylesterase isoenzymes to 
electrophoretic homogoneity from liver microsomes of mouse, hamster, guinea-pig, 
rabbit and monkey. The substrate specificity and immunological reactivity of liver 
microsomal carboxylesterase from pig, cow, beagle dog and human were also 
examined. It was found that the ten purified preparations had similar subunit weight 
(57,000-64,000 daltons), but that their isoelectric points varied widely (pI 4.7-6.5). 
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Carboxylesterase activity is similar in the livers of the rat and chicken, but different in 
the adrenal glands, with chicken carboxylesterase activity lower in the rat. 
Species variation in carboxylesterase are responsible for differences in the 
hydrolysis of xenobiotics. Sertkaya and Gorrod, (1988) investigated the hydrolysis of 
three isomeric arylamides; 2-acetamidobiphenyl (2-AABP), 3-acetoamidobiphenyl (3- 
AABP) and 4-acetamidobiphenyl (4-AABP) by 'microsomal carboxylesterase from 
mouse, hamster, guinea-pig, rat and rabbit livers. The 2-AABP was hydrolysed the 
fastest rate in all species except the mouse, the rate of 3 and 4 isomers was similar. The 
mouse arylamide hydrolysing activity was uniformly less sensitive to both 
carboxylesterase inhibitors BNPP and BCPP (bis- (4-cyanophenyl) phosphate) 
suggesting an enzyme distinct from the ES-3 carboxylesterase may be involved. Luttrel 
and Castle, (1988) found that meperidine hydrolysis was not detected in the guinea-pig, 
very low in human and extremely high in the dog. Phenylacetate hydrolysis was also 
measured in liver microsomal preparations, with guinea-pig showing the greatest 
hydrolytic activity and rat showing the least. It was therefore thought that liver 
microsomes from different species may contain different carboxylesterases, having 
different affinities for meperidine. 
Acetylcholinesterase 
Acetylcholinesterase (E. C. 3.1.1.7. ) has a serine amino acid residue at its 
active centre and its function is to hydrolyse acetylcholine (see Figure 1.1. ). 
Acetylcholineesterase has the same type of binding site as cholinesterase, however, 
cholinesterase is a less specialized enzyme than acetylcholinesterase. Unlike 
acetylcholinesterase, it lacks an anionic site in a position that specially adapts it to react 
with acetylcholine, therefore, the acetylcholinesterase hydrolyses acetylcholine at a 
greater rate than cholinesterase. 
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Acetylcholinesterase is found in nervous tissue, striated muscle and red 
blood cells. Monitoring AchE - in the blood is a fairly sensitive method for 
detecting exposure fo organophosphates or carbamate pesticides (Gage, 1967; Wills, 
1972). The enzyme acetylcholinesterase hydrolyses the neurotransmitter acetylcholine 
at the cholinergic nerve synapses (Hayes, 1982). Organophosphate and N-methyl 
carbamate pesticides inhibit acetylcholinesterase, causing first excitation, then 
depression of the parasympathetic nervous system (Miller and Satoh, 1982). 
Acetylcholinesterase at the nerve synapses is the most meaningful index of the risk of 
poisoning, although this would be difficult to measure, therefore, monitoring usually 
involves measuring the acetylcholinesterase activity of red blood cells (rbc's) and 
plasma (Wills, 1973; Roberts, 1979) from blood samples. 
Cholinesterase 
Cholinesterase is at present classified as E. C. 3.1.1.8. (Enzyme 
Nomenclature, 1984). In the serum, cholinesterase has been referred to as 
pseudocholinesterase (Augustinsson, 1948). Other names are butyrylcholinesterase or 
non-specific cholinesterase. The configuration of cholinesterase at the active centre is 
different from other esterases and this results in specificity of the enzyme. The active 
centre consists of two binding sites; an anionic and esteratic serine site, whereas other 
esterases contain only an esteratic serine site. Charged N- and methyl groups of choline 
esters bind to the anionic sites and hydrolysis occurs as a two stage process. Firstly, 
the acyl group binds to the serine residues of the esteratic site, and choline is released. 
Secondly, the transiently acylated enzyme reacts with water to yield the acid and 
regenerate the enzyme. Butyrylcholine and benzoylcholine are prefered substrates. 
Cholinesterase hydrolyses drugs such as suxamethonium (succinyl choline), acetyl 
salicyclic acid, diacetyl morphine, procaine and other local anaesthetics as well as 
steroid esters. 
Suxamethonium, in most individuals is hydrolysed very rapidly to choline 
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by plasma cholinesterase with a half life of about 4 minutes (Durrant and Katz, 1982). 
This duration of reaction is related to plasma cholinesterase (Viby-Morgenson, 1980). 
Genetically atypical cholinesterase has a half-life of elimination of suxamethonium from 
plasma in 4 hours. Use of suxamethonium in these individuals would therefore be life 
threatening (Whittaker, 1980). Procaine, another type of local anaesthetic is rapidly 
hydrolysed to p-aminobenzoic acid and diethylamino ethanol mainly by plasma 
cholinesterase (Reidenberg et al, 1972; Myers et al 1982). Rapid hydrolysis of 
procaine to the inactive products results in its relatively short time of action. 
Heroin is rapidly hydrolysed by serum esterases to 6-mono 
acetylmorphine and the more slowly to morphine following an intravenous dose (Way 
e al, 1960; 1965). Lockridge et al, (1980) found cholinesterase to be the major esterase 
involved in the hydrolysis of heroin in serum. Owen and Nakatsu, (1983) have 
identified three further esterases involved in heroin hydrolysis within the red blood cells 
with at least one to these being similar to that responsible for hydrolysing aspirin. 
Aspirin (acetylsalicyclic acid) is rapidly hydrolysed to salicylate and free 
acetate by cholinesterases following absorption and can be detected in plasma for only 
60-90 minutes after an oral dose (Rowland and Reigelman, 1968). The rate of 
hydrolysis of aspirin is important in determining the pharmalogical and toxic effects of 
the drug since aspirin has different properties to salicylate. It was found that plasma and 
liver aspirin esterase activities in samples from a group of patients varied over a two 
fold range and there was a significant correlation between interindividual plasma and 
liver activities (Williams et al, 1989). Serum aspirin-esterase activity has also been 
studied in a group of epileptic patients under treatment with a number anti-epileptic 
drugs (Puche , 1989). These 
findings suggest that antiepileptic dugs may induce 
plasma esterase activity, thus leading to an increase in serum hydrolytic activity in 
epileptic subjects. 
Many steroid esters have been shown to be substrates for serum 
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cholinesterase. Either hydrolysis of the ester pro-drug liberates the active steroid or 
serum hydrolysis may be employed to hydrolyse active locally applied steroid esters to 
inactive compounds and prevent unwanted side effects. In the same way pro-drugs 
have been developed to overcome problems in absorption and toxicity, with plasma 
esterases used to activate many pro-drugs. 
The human plasma cholinesterase consists of four main molecular forms 
designated as Cl, C2, C3 and C4 according to their electrophoretic mobility in gels 
(Masson, 1989). The major component, C4, is the tetrameric form; Cl and C3 are the 
monomeric and trimeric forms respectively. The C2 dimeric form, which has an 
apparent free electrophoretic mobility higher than that of the other three isomers, and 
moreover, a higher isoelectric point, was found to be a covalent conjugate between the 
cholinesterase monomer and the serum albumin. 
Serum cholinesterase has a broader specificity than acetylcholinesterase 
which is found in nervous tissue, striated muscle and red blood cells. Carbamate 
pesticides produce cholinesterase inhibition which is rapidly reversible within 24 hours. 
Due to the wide range of normal levels, effective cholinesterase monitoring requires the 
periodic comparison of blood cholinesterase activity values to an individual 
cholinesterase activity baseline established prior to exposure to cholinesterase inhibiting 
pesticides. (Wolfsie, 1957; Vandekar, 1980). Inhibition of cholinesterase to levels of 
60-25% of an individuals baseline (ie. -depression from 40-75% below baseline) may 
result in symptoms such as nausea, vomiting, diarrhea, increased 'sweating, 
constriction of pupils, blurred vision and chest tightness. Still greater inhibition may 
result in respiratory difficulty, unconciousness, pulmonary oedema and death due to 
respiratory arrest (Namba et al, 1971; Kalovanova, 1982). 
Cholinesterase activity has been found in the homogenates of the gut 
mucosal cells from seven mammal species and differs from one species to another (Sine 
gLd, 1988). Except rabbit, all the other species contain a (64) globular tetrameric form 
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and either a (61) monomeric form (pig and ox) or a (62) dimeric form (mouse, rat, 
sheep). Both (61) and (62) forms are found with the (64) form in the mucosal cells of 
kittens and cat. The mucosal cells from the studied species essentially possess either 
acetylcholinesterase (rabbit, kitten, cat) or cholinesterase (ox, pig, sheep, rat, mouse). 
1.2.1. ii. Oxidation 
Oxidation is the most common reaction of xenobiotic metabolism and 
occurs in a number of subcellular sites. Enzymes in the endoplasmic reticulum are the 
most important and these enzymes are known commonly as mixed-function oxidases 
(Mason, 1957,1965) or monoxygenases. These enzymes are complex multicomponent 
systems consisting of reduced nicotinamide adenine dinucleotide phosphate (NADP), 
phospholipid, the flavoprotein NADPH cytochrome P450 (c) reductase and the 
haemoprotein cytochrome P450 (Lu and Coon, 1968, Lu et al., 1969, Strobel, 1970). 
1.2.1. ii. a. Components of MFO system 
Cytochrome P450 
The occurance in liver of a carbon monoxide binding pigment was first 
reported independently by Kligenberg in 1958. Studies carried out by Omura and Sato 
(1964) provided evidence that this novel pigment was a haemoprotein. The enzyme 
consists of a family of closely related iso-enzymes embedded in the membrane of the 
endoplasmic reticulum (ER). The name cytochrome P450 is derived from the specral 
absorbance maximum exhibited at 450nm when the enzyme is reduced and complexed 
with carbon monoxide. The haemoprotein serves as an oxygen and substrate binding 
site for the MFO reaction, and, in association with the flavoprotein reductase NADPH 
cytochrome P450 reductase, it undergoes cyclic oxidation and reduction of the haem 
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iron. The general reaction in which cytochrome P450 serves as an oxygenating catalyst 
is as follows: 
R-H + NADPH + 02 + H+ -----------> R-OH + NADPH+ + H2O 
where R-H represents the substrate and NADPH the electron donor. 
NADPH Cytochrome P450 Reductase 
NADPH cytochrome P450 reductase is a flavin containing enzyme 
(flavoprotein), consisting of flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN) prosthetic group. It is responsible for the transfer of reducing 
equivalents from NADPH and H+ to cytochrome P450 and is closely associated with 
cytochrome P450 on the ER membrane. NADPH and H+ donates two electrons, while 
cytochrome P450 accepts one. It is thought the NADPH cytochrome P450 acts as a 
tranducer of reducing equivalents by accepting electrons from NADPH and transferring 
them sequentially to cytochrome P450. 
Lipid 
Since the successful isolation of the components (Lu and Coon, 1968; Lu 
et al. , 1969) and their reconstitution to an enzymatically active system (Lu , 1969b; 
Strobel gam, 1970) the protein-lipid interaction associated with cytochrome P450 has 
been extensively studied. The catalytic activity of cytochrome P450 systems is 
phospholipid dependant, with acetylated phosphatidylcholines, mono and 
dilaurylphosphatidylcholine appearing to be most effective (Strobel gam, 1970). The 
formation NADPH cytochrome P450 reductase and the cytochrome P450 complex is 
regulated by different lipid species. The ratio of cytochrome P450 reductase to 
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cytochrome P450 on the ER memrane is 20: 1. ' The role of lipid appears to be the 
favourable formation of a 1: 1 protein complex (Blanck et al, 1989). 
1.2.1. ii. b. Catalytic cytochrome P450 cycle 
The mechanism by which cytochrome P450 mediates monoxygenase 
reactions is not fully understood. The following scheme represents the current 
understanding of the microsomal cytochrome P450 cycle. 
The initial step of the cycle begins with the substrate binding to the 
enzyme. Cytochrome P450, like many other haemoproteins exists in an equilibrium of 
high and low spin states, with the low state predominating (Schenkman and Gibson, 
1981). Binding of substrate results in the shift of this equilibrium from low spin state to 
high spin state (Tsai gam, 1970), therefore causing an increase in the redox potential of 
the haemoprotein. This facilitates electron transfer from NADPH to the cytochrome 
(Ullrich, 1978). 
Since oxygen can only bind to the ferrous cytochrome P450, the reduction 
of the ferric cytochrome P450-substrate complex, is a very important stage in the 
reaction process. The oxidised P450-substrate complex is reduced by an electron 
originating from NADPH and transferred to the complex by the flavoprotein, NADPH 
cytochrome P450(c) reductase. This is followed by an-oxygen activation process. The 
reduced substrate-enzyme complex reacts with oxygen to form a complex characterized 
by an absorption peak at 448nm (Eastabrook et al, 1971). The exact nature of the 
oxycytochrome is unclear. It is believed to exist in at least two equilibrating forms, 
including superoxide anion bound ferric haemoprotein (Fe3+O2') and oxygen bound 
ferrous haemoprotein (Fe2+02) (Schenkman and Gibson, 1981). 
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The oxycytochrome P450 is further reduced by a second electron 
originating from NADPH via the reductase. The reductase can also donate the second 
electron indirectly via cytochrome b5 (Peterson and Holtzman, 1980). Finally, oxygen 
bound cytochrome P450 dissociates to yield water and one oxygen atom, the latter 
being inserted into the substrate. 
1.2.1. ii. c. Multiplicities of cytochrome P450 
Cytochrome P450 has the capacity to metabolise a wide range of 
compounds, whose only common feature appears to be the degree of lipid solubility. 
This capacity has been attributed at least in part, to the existence of more than one drug- 
metabolising enzyme. This was first postulated by Axelrod in 1956 as a result of his 
observation that there was a marked interspecies variation in the rate of N- 
demethylation of morphine, methadone and meperidine. Conney et al, 1959 not only 
suggested interspecies variation in drug metabolising enzymes but also that the liver of 
a single species contains several enzymes. They observed that in the rat benz(o)pyrene 
increased the rate of microsomal oxidation of some substrates while others were 
decreased or remained unaffected. 
A series of in vitro experiments using inducers of cytochrome P450 
demonstrated the existence of distinct forms of the enzyme in microsomes prepared 
from the livers of treated animals. The polycyclic hydrocarbon 3-methylcholanthrene 
(3-MC) induced a different form of cytochrome P-450 in rat liver, which exhibited 
different spectral and substrate specificities from cytochrome P450 present in untreated 
rats (Sladek and Mannering, 1966; Alvares et al, 1967; Gnosspelius et al, 1969; 
Kuntzman et al, 1969; Mannering, 1971). This was designated cytochrome P448 
(Alvares et a1,1967) due to a reduced carbon monoxide complex absorbance maxima at 
448nm. This change in the spectral characteristics was not due to the binding of the 
inducer due to the haemoprotein but due to the synthesis of new protein since the 
change could be prevented by pretreatment with inhibitors of protein and nucleic acid 
20 
synthesis such as actinomycin D (Kantzman et al, 1969). 
Weibel et al, (1971) showed that 7,8-benzoflavone inhibited- the 
hydroxylation of benzo(a)pyrene by liver microsomes from 3-methylcholanthrene 
treated rats, but not by microsomes from phenobarbitone treated rats. 
Definite proof for the existence of multiple forms of cytochrome P450 
followed the pioneering work of Lu and Coon, (1968), who successfully solubilized 
and characterised the individual compounds of the microsomal mono oxygenase 
system. This system, when constituted was later shown to be capable of catalysing a 
number of substrates (Lu and Levin, 1974). Imai and Sato, (1974 b) purified 
cytochrome P450 which was electrophoretically homogenous. Using a modified 
version of this technique, Guengerich et al, (1982a) purified eight isoenzymes of 
cytochrome P450 from rat liver microsomes to electrophoretic homogeneity. The 
different forms were distinguished by certain criteria including reduced carbon 
monoxide difference spectrum properties, monomeric molecular weights, peptide 
mapping, immunochemical reactivity and catalytic activity towards different substrates. 
Studies using cDNA probes to cytochrome P450 and amino acid 
sequencing methology has enabled recognition of cytochrome P450 gene structure and 
evolution of the gene family. The cytochrome P450 gene superfamily consists of 10 
known gene families, eight of which are present in mammalian tissues, consisting of 
variable numbers of gene subfamilies (Nerbert and Gonzalez, 1987; Nerbert et al, 
1987). Currently, twenty different forms of cytochrome P450 have been isolated and 
identified from rat liver microsomes (Guengerich, 1989). 
Nomenclature of cytochrome P450 genes has been varied, but recently 
they have been standardized, based on the divergent evolution of the gene superfamily, 
using alignment of amino acid sequence to determine gene families and subfamilies 
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(Nerbert et al, 1987). Gene families are recommended to be designated by Roman 
numerals and subfamilies by capital letters. The form of cytochrome P450 inducible by 
poly aromatic hydrocarbons in rat, rabbit, mouse and man resides in the P450I gene 
family (Nerbert and Gonzalez, 1987). The cytochrome P450 previously identified as 
PB-inducible are in the cytochrome P45011 family, with P450IIB the rat PB-inducible 
form. The P450III gene family are steroid-inducible forms of cytochrome P450. The 
microsomal enzymes responsible for 17-alpha and C21 hydroxylation of steroids are 
coded forbygenes in the XVII and XVI families respectively and mitochondrialenzymes 
responsible for 1lß-hydroxylation and cholesterol side-chain cleavage are encoded in 
the XI and XXII families respectively. A unique P450 family, P450XIX, encodes the 
enzyme involved in oestrogen synthesis. 
Some of the members of the first four families (I-IV), are inducible by 
xenobiotic compounds in laboratory animals (Gonzalez, 1989). In all cases there is 
evidence for the existence of at least one representative of each of the inducible families 
of cytochrome P450 in man (Nerbert and Gonzalez, 1989), although whether all such 
isoenzymes are the true orthologues of the inducble forms in animals has still to be 
determined. In many cases the human analogue is similarly inducible to the isoenzymes 
in laboratory animals. Examples of this inducible form are both members of the P4501A 
subfamilies, P450I1E1 and representatives of the P450IIC and P450IIIA subfamilies. 
1.3. PHASE - II XENOBIOTIC METABOLISM 
1.3. i. Conjugation 
Conjugation reactions involve the enzyme catalysed combination of a 
foreign or endogenous compound or its metabolite with a conjugating agent. This 
foreign compound or metabolite may be chemically stable or a reactive electrophilic 
species arising from phase I metabolism, such as an epoxide or N-oxidation product of 
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an aromatic amine, amide or nitrosamine, or a free radical. 
Glucuronic acid 
Conjugation with glucuronic acid or sulphuric acid are quantitatively the 
most important phase II biotransformations (Dutton, 1966; Dutton and Burchell, 1977). 
Glucuronide conjugation involves the UDP glucuronyltransferase and utilises the co- 
substrate UDP glucuronic acid (UDPGA). UDPGA is synthesised from glucose in four 
steps. First, phosphorylation to glucose-6-phosphate, followed by isomerisation to 
glucose- I -phosphate, which is then urylated to form UDP glucose. This is then 
oxidised by NAD+ dependant UDP glucuronic acid dehydrogenase to form UDP 
glucuronic acid. ATP is required for the phosphorylation of glucose for the 
rephosphorylation of UDP to UTP (Dills gj, 1987). 
UDP glucuronyltransferases exists as a multi-gene family in the rat. 
Individual UDPGT rat liver isoenzymes tend to differ in terms of regulation and 
xenobiotic substrate specifity (Burchell and Coughtrie, 1989). Bock gj Al, 1984a 
reported that in the rat, glucuronidation is catalysed by at least five independant forms 
of UDPGT, with substrates nitrophenol, morphine, bilirubin, testosterone and oestrone 
being representative of their specificities. The multiplicity of human liver UDPGT is 
also now accepted on the basis of results from microsomal kinetic and inhibitor studies 
(Bock gLl, 1978,1984b; Miners et a], 1988a and b, 1990), the cloning of UDPGT 
cDNA's (Fournel-Gigleux gam, 1989; Harding gel, 1988; Jackson gam, 1987) and the 
isolation of purified enzymes (Irshaid and Tephly, 1987). 
Two groups of glucuronyl transferase activities have been identified in the 
rat liver, based on differential induction by either phenobarbital (PB) or 3- 
methylcholanthrene (3-MC). 3-MC induction led to an increase in activity towards 
benzo (a) pyrene-3,6-quinol and 1-naphthol (Bock Bock-Hennig, 1987). PB inducible 
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forms preferentially metabolise the substrates 4-nitrophenol, 1-naphthol, 4- 
methylumbelliferone, 2-aminophenol and 3-hydroxybiphenyl (a) pyrene. 3-MC 
inducible forms conjugate morphine and 4-hydroxyphenyl. The enzymes from rat liver 
may also be classified on the basis of perinatal developement, termed clusters of 
glucuronyltransferase activity. The late foetal cluster is similar to the PB inducible 
group of enzymes (Bock gal, 1983). Differential induction of enzymes has been 
demonstrated in human liver microsomes using PB and 3-MC. PB induction led to a 3- 
fold increases in bilirubin conjugation, with moderate increases in activity towards 
quinol, 1-naphthol and 4-methylumbelliferone. Available evidence suggests the 4- 
methylumbelliferone activity comprises at least two closely related isoenzymes with 
similar kinetic properties and broadly comparable chemical substrate specificities 
(Miners goal, 1988). 
Sulphate 
Conjugation with sulphate requires phosphadenosine phosphate (PAPS) 
as the sulphate donor. PAPS biosynthesis is fueled by two molecules of ATP which 
probably accounts for its generation only when required and explains, its low 
intercellular concentration (Wang and Yeo, 1979; Hazelton et al, 1985). Its formation is 
catalysed by ATP-sulfurylase (EC 2.7.7.4. ) and APS-kinase (EC 2.7.1.25. ). 
Conjugation of PAPS with endogenous compounds is catalysed by one or more 
sulphotransferase, present in most tissues (Mulder, 1981). 
Though glucuronidation is quantitively the most important conjugation 
reaction, many substrates which are glucuronidated are also sulphated (Dodgson and 
Rhodes, 1970), therefore these reactions compete for the same substrates. For example 
phenolic substrates undergo both glucuroidation and sulphation (Mulder, 1983). 
Extrahepatic conjugation is significant. When 4-nitrophenol was 
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administered to the rat via the jugular or portal vein, 50% of the resulting conjugate 
formation was found to extra-hepatic and conjugation by the kidney also provide a 
major contribution (Elbers et al, 1980). Conjugation activity has also been detected in 
the lungs, intestines and skin (Moloney et al, 1982. ). 
Sulphation activity varies with age and sex and exhibits a marked organ 
distribution. Liver has the highest sulphotransferase activity in the rat, man and in 
human foetal tissue. 
Glutathione 
The other type of reaction involves the formation of an activated 
xenobiotic followed by conjugation of the conjugated ligand by a transferase enzyme. 
The most important reaction involves conjugation with glutathione. This type of 
conjugation provides a major defence mechanism against toxicities formed inadvertantly 
by phase I oxidation reactions. Substrates for glutathione conjugation possess the 
common feature of having an electrophillic centre that can react with the nucleotide 
glutathione. These conjugates can be excreted in the bile or further metabolised to 
cysteine or N-acetylcysteine (mercapturic acid) conjugates which are then excreted in 
the bile (Jerina, and Bend, 1977). 
1.4. INDUCTION 
The activity of microsomal MFO system and concentration of cytochrome 
P450 can be increased by a variety of xenobiotics, including polycyclic aromatic 
hydrocarbons, steroids and pesticides. The inducibility of some P450's observed after 
exposure to different drugs and chemicals is a main feature of these systems (Distlerath 
and Guengerich, 1988). Investigations have revealed the existence of a multigenic 
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superfamily (Nerbert and Gonzalez, 1987; Nerbert et al, 1989) and made possible a 
classification of the inducers into five different groups, according to the form(s) of 
P450 specifically induced: (a) polycyclic aromatic hydrocarbon (P4501A); (b) 
phenobarbitone (P450IIB); (c) ethanol, acetone, benzene, imidazole and derivatives 
(P450IIE); (d) glucocortioids and macrolide antibiotics (P450IIIA); (e) clofibrate 
(P450IVA) (Gedl, 1989). 
Polycyclic hydrocarbons and phenobarbitone induce P450 in different 
ways. 3-methylcholanthrene and other polycyclic aromatic hydrocarbons, the first step 
in the induction process is the binding to cytosolic receptors which are further 
translocated into the nucleus and stimulate gene transcription (Okey and Vella, 1982). 
Once in the nucleus the inducer-receptor complex binds to the genome and initiates 
transcription and translocation of genes coding for cytochrome P448, UDP 
glucuronyltransferase and glutathione-S-transferase (Bend, 1980). Induction by 
polycyclic hydrocarbons is regulated by the Ah locus at the genome (aromatic 
hydrocarbon responsiveness). The main product of the Ah regulatory genes is the 
cytosolic receptor essential for induction. 
The mechanism of induction of phenobarbitone is not fully elucidated but 
suggests activation of gene transcription for P4505 and e, epoxide hydrolase and 
glutathione transferase (Hardwick and Gonzalez, 1983; Ding and Pickett, 1985). A 30- 
fold increase in cytosolic concentration of mRNA encoding the PB-inducible form of 
cytochrome P450 has been observed (Adesnik et al, 1981). 
Phenobarbital induces hepatic carboxylesterase activities (Nousiainen and 
Hanninen, 1981; Beohr et al, 1966; Kaur and Ali, 1983). Satoh and Moroi, (1973) 
demonstrated a species difference in phenobarbital-induced increases in 
carboxylesterase activity towards isocarboxazid. It has also been shown that the toxicity 
of procaine was modified by pretreatment of rats with phenobarbital, tri-o 
cresylphosphate (Satoh and Moroi, 1977) and ethyl p-nitrophenyl 
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phenylphosphonothioate (EPN) (Satoh and Moroi, 1973; 1975). DDT (Read 'et al, 
1965), PCB (Andersson and Tegelstrom, 1979) and transtilbene oxide also induce liver 
carboxylesterase activity. Kidney and lung carboxylesterase activity cannot be induced 
by phenobarbital (Raftell et al, 1977). Raftell et al, (1977) also reported that 3- 
methylcholanthrene had no inductive effect on microsomal carboxylesterase. Nousainen 
et al, (1984) showed that, in dose- and time-dependant studies, benz(a)anthracene, 
benzo(a)pyrene and 3-methylcholanthrene moderately induced the hepatic cyosolic and 
kidney microsomal carboxylesterase activities. The hepatic microsomal and kidney 
cytosolic enzyme activities were not altered by the polycyclic aromatic hydrocarbons 
investigated. 
Clofibrate (ethyl- A -p-chlorophenoxyisobutyrate) and several other 
structurally diverse hypolipidemic agents have been shown to induce hepatic responses. 
These include hepatomegaly, proliferation of smooth endoplasmic reticulum and 
induction of cytochrome P450IVA-1-dependant fatty acid omega hydroxylase activity, 
peroxisome proliferation with associated changes in enzyme composition and alteration 
in mitochondrial number and structure with concomitant increases in certain enzyme 
levels (Orton and Higgins, 1979; Gibson et al, 1982; Reddy et al, 1982; Sharma et al 
1988). These subcellular changes are toxicologically important as sustained 
proliferation of peroxisomes in rodents is frequently associated with the developement 
of hepatocellular carcinomas. This has led to suggestions that peroxisome proliferarors 
constitute a novel class of non-genotoxic hepatocarcinogens (Reddy et al, 1983; 
Lalwani et al, 1983). The induction of cytochrome P450IVA is mirrored by a 
concomitant parallel increase in lauric acid hydroxylase activity (Sharma et al, 1988). 
Kawashima et al, (1973) reported the induction of hepatic long-chain acyl- 
CoA hydrolase in the cytosolic fraction by administration of clofibric acid to rats, mice, 
or guinea-pigs. Hosokawa et al, (1987) reported that administration of clofibrate caused 
a significant increase in the activities of p-nitrophenylacetate, isocarboxazid, 
butanilicaine and palmitoyl-CoA hydrolases in rat liver microsomes. p- 
Nitrophenylacetate and isocarboxazid hydrolase activities were not induced by 
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clofibrate, whereas palmitoyl-CoA hydrolase activity was significantly induced. These 
results were consistent with the findings on the amounts of three carboxylesterase 
isoenzymes in liver microsomes and cytosol by radial immunodiffusion assay. It was 
found that clofibrate induced all three isoenzymes of carboxylesterase in hepatic 
microsomes, but not in the cytosol. 
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CHAPTER 2: FACTORS AFFECTING XENOBIOTIC METABOLISM 
2.1 GENDER 
In 1953, Nicholas and Barron showed that there was a marked sex 
difference in amylobarbitone induced sleeping time in the rat. Plasma levels of 
hexabarbitone were found to be significantly higher and duration longer in female rats 
than in male rats (Quinn ems, 1958). These differences were found to be reversed by 
castration of the male or by administration of tetosterone to the females. It is now 
known that these differences are due to variations in the activities of the drug 
metabolising enzymes between male and female (especially in the properties of 
cytochrome P450 in liver microsomes (Kato, 1974)). 
The results of Quinn et al, (1958) suggest that the androgenic actions of 
testosterone are involved in maintaining this difference. This has been confirmed by 
Kitagawa et al; (1985) who showed that sex differences in hepatic metabolism of 
aminopyrine, hexabarbitone, aniline and p-nitroanisole between male and female rats 
reach a peak at twelve months of age (males having higher activities than females). This 
fall is due to the loss of male-specific forms of cytochrome P450 (Fujita et al, 1985; 
Kamataki et al, 1985) which coincides with an age related fall in plasma testosterone 
levels (Kitigawa et al, 1985). Testosterone has an indirect effect on the liver by 
influencing the secretion of growth hormone from the pituitary gland which in turn 
regulates liver mixed function oxidase enzymes (Gustafsson and Stenberg, 1976; Mode 
eil, 1982). 
Purified forms of cytochrome P450 from livers of male and female rats 
show a marked difference both immunologically and electrophoretically (Kamataki gl 
9 1982; 1985). One of the most widely studied sexually differentiated cytochrome 
P450 dependant mono oxygenase reactions is testosterone 16-alpha- hydoxylase 
activity. A form of this has been purified from male rat which is highly specific and 
which could not be purified from female rats (Morgan gam, 1980). 
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A variety of carboxylesterase isoenzymes, having different substrate 
specificities have been found in liver microsomes of male and female rats (Mentlein gl 
al, 1980; Blomberg and Raftell, 1974). The overall hydrolytic activity of the liver is 
similar in both sexes, though quantitative differences in the isoenzymes have been 
reported (Raftell gLl , 1977). Sex hormones have been shown to effect the activities 
of esterases in mouse liver and kidney (Andersson and Tegelstrom, 1979; Tegelstrom 
and Ryttman, 1981). It has also been reported that microsomal carboxylesterase was 
altered in castrated male rats, with enzyme activities towards p-nitrophenylacetate and 
malathion being decreased (Hosokawa et al, 1984). Administration of testosterone 
propionate to the castrated rats reversed the observed decreases. However, removal of 
the ovaries in the female resulted in substrate dependant changes in p-nitrophenylacetate 
and malathion hydrolase activity, and a decrease in acetanilide and isocarboxazid 
hydrolysis. Oestradiol benzoate administration led to an increase in acetanilide and 
isocarboxazid hydrolysis and a decrease in p-nitrophenylacetate and malathion 
hydrolysis. It would therefore seem that rat hepatic carboxylesterase activities may be, 
at least in part, affected by sex hormones, which exert different effects on the 
isoenzymes. Hosokawa et al, (1985) demonstrated that adrenalectomy in castrated male 
rats slightly decreased activity towards p-nitrophenylacetate and malathion. Following 
adrenalectomy the magnitude of testosterone-induced changes in the hydrolase activity 
of hepatic microsomes in castrated male rats was markedly decreased. However, when 
5-alpha dihydrotestosterone was administered to adrenalectomized castrated male rats, 
malathion and p-nitrophenylacetate esterase activities were increased. Kidneys of male 
mice have been shown to possess several testosterone-dependant esterases (Bocking et 
al. 1976; Weinker, 1973). Human serum has been shown to possess an oestrogen 
dependant esterase, which is present in relatively high levels in males and is dependant 
in males and is independant of age, while in women the low level increases with age 
(Fabian et al, 1977). 
Sex differences in human metabolism are less generally observed, than the 
environmental and genetic factors. Miners et al, (1986) found that there was a 61% 
salicylic acid clearance in males compared to a control female group, an effect due 
largely to enhanced activity of the glycine conjugation pathway (salicyluric acid 
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formation) in males. These results were consistent with previous studies which have 
demonstrated higher salicyclic acid clearance in males than in females (Graham et al, 
1977; Ho et al, 1985) or higher plasma salicylate concentrations in males compared to 
females (Coppe et al, 1981; Kelton et al, 1981) after administration of aspirin. These 
results however, were not found by Williams et al, (1984). Antipyrine clearance has 
been shown to be significantly higher in men than in women (Blain et al, 1982), but not 
by others. 
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2.2 AGE 
In animals, age has a significant influence on the specific activity of 
xenobiotic metabolising enzymes. Low hepatic MFO activity was found in new-born 
rodents (Jondor gel, 1958; Fouts and Adamson, 1959), increasing rapidly up to 6-10 
weeks when adult MFO activities are reached (Fouts and Devereux, 1972). In man a 
number, of foetal tissues are known to contain cytochrome P450 dependant MFO 
activities (Juchan et , 1980). The activities of these enzymes rise during gestation and 
at birth are approximately 50% adult levels (Pelkonen and Karti, 1973). 
Age related changes in the response of a number of enzymes activities, in 
the liver of old rats compared to young was reported by Adelman, (1971). They 
observed a slower rate of enzyme induction in old rats (24 months) compared to the 
young (2 months) and postulated that this latency represented a biochemical index of 
ageing. Schmucker and Wang (1980) reported an age related decline in non-induced 
NADPH cytochrome P450 reductase activity and cytochrome P450 levels, however, 
PB treatment caused marked increases in these parameters in young (1 month) and 
mature (16 months) but not in old rats (27 months). The rate of enzyme and 
haemoprotein induction, and maximum induced levels. reached after 6 days were 
significantly greater in young and mature but not in old rats. 
In the rat, multiple activities of glucuronyltransferase can be divided into 
two developmental groups, one of which has activities towards indoleamines and 
planar phenolic compounds and which developes prenatally during later gestation. 
Adult levels are reached at birth: The second group includes glucuroyltransferase with 
activities towards complex compounds such as steroid hormones and bilirubin, which 
develops postnatally (Leaky and Burchell, 1987). A single foetal isoenzyme is thought 
to be responsible for all the activities in the first group (Scragg e al, 1985). 
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Animal studies have revealed a fall in the activity of drug metabolising 
enzymes with age, however, studies in man have failed to show this (Woodhouse, 
1984; Wynne et al, 1988; 1989). Williams et al, (1989) found plasma aspirin esterase to 
be similar in a group of healthy elderly adults, a group of young adults and a group of 
frail young adults, but was lower in a sample of frail elderly subjects. Plasma albumin 
levels in healthy elderly were lower than in the young subjects and these levels lower 
still in frail elderly subjects. In the frail elderly reduced plasma cholinesterase activities 
were also seen. 
The clearance of many drugs, including antipyrine, diazepam, theophylin 
and propranolol is reduced in elderly human subject (Greenblatt et al, 1982). The 
body's ability to remove or eliminate a drug or xenobiotic (clearance) is affected by age. 
The ageing process affects the clearing organs, principally the liver and kidneys. 
Hepatic blood flow, a major determinant of the hepatic clearance of drugs and 
xenobiotics (Wilkinson and Shand, 1975) declines with age, partly because of reduced 
cardiac output. An estimated 40-45% reduction in total liver flow may be observed in 
elderly compared to young (Geokas and Haverback, 1969). Likewise, liver size 
decreases with age, Both in absolute terms and as a percentage of body weight. Studies 
on the influence of the menstrual cycle on serum cholinesterase have seen significant 
differences in values of cholinesterase with age (Fairbrother et al, 1989). It was found 
that cholinesterase was lowest in 36-40 year olds and highest in 30-35-years old 
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2.3 GENETIC INFLUENCES -r 
Major , differences in metabolism exist between species an d such 
differences can also occur within one species, although not to such a marked extent. 
These differences can be seen in the various inbred strains of rats and mice and are due 
to the different genetic make-up of the strains. These differences also include 
differences in the induction of xenobiotic metabolising enzymes. Cross breeding of the 
strains has shown that the inheritance of inducibilty is an autosomal dominant trait. In 
rats a marked difference exists in the Gunn rat, which is genetically deficient and 
thereby unable to form many of the glucuronides produced by other strains of rat 
(Scragg et al, 1985). Interbreeding of Gunn and normal strains leads to glucuronidation 
capacities intermediate between the two, indicating that neither trait is dominant. 
Often in man, interfering influences from environmental sources mask 
genetic differences on xenobiotic metabolism. Cytochrome P450 isoenzyme activities 
appear to vary widely in humans and the consequence of inter-individual variations are 
of pharmacological importance. Those who metabolise certain drugs at slower rates 
than normal, " poor metabolisers", are likely to accumulate the potent drug and 
therefore any adverse effects will be enhanced (Maghoub et al, 1977; Kupfer and 
Preisig, 1983). Poor metabolisers, however, may be at decreased risk from some types 
of cancer (Ayesh et al, 1984; Kaisary et al, 1987). 
The first genetic polymorphism to be recognised -among hepatic 
microsomal P450 was a deficiency in the 4-hydroxylation of the anti-hypertensive agent 
debrisoquine (Maghoub et al, 1977). 3-10% of Caucasians are poor metabolisers and 
may suffer side effects from this drug. Polymorphism of P450DB6 was discovered 
following observations of exaggerated hypotensive responses to debrisoquine and the 
occurance of an adverse side effect of perhexiline treatment, peripheral neuropathy. 
Health is not generally impaired as long as these drugs are not taken (Guengerich, 
1989). 
34 
Other genetic polymorphisms in human cytochrome P450 include 
variation in the cytochrome P450MP, involved in the 4-hydroxylation of the anti- 
epileptic drug mephenytoin variation in cytochrome P450NF, involved in nifedipine 
oxidation and cytochrome P450 enzyme involved in metabolism of ethanol phenacetin 
and adrenal steroids (Guengerich, 1989). 
Most individuals possess the typical form of cholinesterase in serum 
(Lehman and Liddell, 1964). Inter-individual variations in cholinesterase activity have 
been reported, and may be a consequence of both genetic and environmental factors 
which give rise to a range of activities. Differences in activities may be important in 
metabolising drugs such as succinyl choline and thereby altering its pharmalogical 
effect. 0.5% of Caucasian population possess an atypical inactive form of 
cholinesterase. The typical and atypical forms are as a result of the homozygous gene 
expression. Heterozygotes of the usual and atypical exhibit intermediate cholinesterase 
activities. 
Inter-ethnic variation can also be seen in plasma paraoxonase activity 
between Caucasians and other ethnic groups. Player et al, (1976) found differences in 
oriental and black African populations. Williams et al, (1986) found lower 
paraoxonase, aspirin esterase and arylesterase activity in a Ghanaian population 
compared to a Caucasian population, whereas the cholinesterase activities were similar. 
Recently a new liver specific rat carboxylesterase enzyme (E. C. 3.1.1.1. ) 
designated esterase-18 (ES-18) has been described in a new strain of rat (Rattus 
norvegieus) (Kluge et al, (1990)). Nakamura et al, (1989) also found strain differences 
in rat carboxylesterase, related to the phenotype differences of esterase-3. 
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CHAPTER 3: PESTICIDES USED IN XENOBIOTIC METABOLISM STUDIES 
3.1. INTRODUCTION 
For centuries biocidal chemicals have been used by man to control those 
plants and animals that are considered to be pests. Major developements recently in 
synthetic organic chemistry and biology have enabled more selective pesticides to be 
produced that can be targeted at particular species of plants or insects, but, being 
`bioactive' these compounds still retain some potential for toxicity to mammals. 
Direct toxic interference with the function of the insect nervous system has 
been a common underlying mechanism of action of many of the traditional insecticides. 
Safer insecticides have been developed that utilize specific differences in metabolic 
pathways between mammals and insects; neurotoxic metabolites are formed in greater 
amounts in insects than in mammals (Vohida et al, 1964; Krueger et al, 1960). 
Unfortunately, insects may eventually develop tolerance or other pathways for 
detoxification and hence develop- resistance to the pesticides (Townsend and Busvine, 
1969). 
3.2. ORGANOPHOSPHATES 
Many organophosphate compounds are pesticides widely used for the 
control of insect vectors. They are not ideal agents because they lack vector selectivity, 
and have caused severe toxicity and death in humans and domestic animals. Their 
toxicity has been recognised since the 1930's, when they were also developed for use 
as chemical warfare agents. A unique feature of all OP's is their structural fit with the 
ChE enzyme. OP's mimic the molecular shape of AChE. AChE has two active sites 
(see chapter 1.2. ), the esteratic and anionic site (see Figure 3.1. ). The inhibition of 
AChE is very similar to the early stages of AChE hydrolysis. The phosphorus moiety 
(R02-P- OR-) of organophosphates bind to the esteratic site the amino acid serine, 
while the remainder of the molecule attaches to the anionic site. The OP is hydrolysed 
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Active enzyme 
his ser 
H NN10, N----H `O 
OR 
X- P1 
---ý 11", OR* 0 
his ser 
HNN 0 
I, OR 
HX P 
Ö\ O R' 
his ser 
HN, N. 
OR `01 OR 
P 
H- 01 1 OR' 
Extremely slow 
Phosphorylated enzyme his ser 
HN ---- H-o 
OR 
O-P.. *, 
OR' 0 
Figure 3.1. 
Reaction of an organophosphorus compound with the esteratic site of 
acetylcholinesterase. 
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so that the alcohol fragment (HOR') leaves the reaction and the phosphorus remains 
attached to the serine, phosphorylating the enzyme. 
A phosphorothionate insecticide such as parathion is an inheritantly weak 
anticholinesterase, which must be activated via a cytochrome P450-dependant 
desulfuration reaction to the reactive phosphate (oxon) metabolite i. e. paraoxon (0,0- 
diethyl-0- (4-nitrophenyl) phosphate) (Gage, 1953; Nakatsugawa and Dahm, 1967; 
Neal, 1967). 
The usual cause of death in mammals from acute organophosphate 
poisoning is respiratory failure as a result of inhibition of acetylcholinesterase at the 
nerve endings and in the respiratory control centre of the brain (0' Brien, 1960). The 
150 to brain acetylcholinesterase (AChE) is reduced by this reaction about three orders 
of magnitude, from about 10-5 to about 10-8M (Forsyth and Chambers, 1989). OP's 
are capable of inhibiting other serine esterases, such as carboxylesterase, at low 
inhibitor concentrations (Chambers gam, 1989). Since the liver absorbs parathion so 
readily (Nakatsugawa et äl, 1980; Tsuda et al, 1987), since it has such a high 
concentration of parathiondesulphurationactivity (Neal, 1967), and since it would be 
responsible for the first- pass metabolism following an oral exposure a large fraction of 
paroxon produced is expected to be generated in the liver. However the liver also 
possesses a high specific activity of carboxylesterase (Chambers gel, 1990). Likewise 
the plasma in some species, such as rat, contains apprecable levels of carboxylesterase, 
which could also sequester hepatically generated paraoxon. Thus, carboxylesterases 
may serve a protective role in phosphorothionate insecticide or ortho phosphate 
intoxication by removing a significant amount of the activated metabolite prior to its 
reaching the main target, AChE in the nervous system. 
Generally, it has been assumed that the majority of the active metabolite is 
produced in the liver and is released into the circulation to find its target, AChE. While 
the liver is typically the most active organ in the body for xenobiotic activation and 
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detoxification reactions, Neal and coworkers suggested that extrahepatic activation of 
parathion to paraoxon may be important to its toxicity (Neal, 1972). While isolated 
hepatocytes absorbed parathion rapidly but reversibly, perfusion studies indicated that 
intact parathion existsin the liver (Tsuda et al, 1987). This parathion released into the 
circulation could play a major role in phosphorothionate poisoning if it were activated at 
a critical target site. 
Phosphorothionate absorbed following dermal exposure, a more likely 
route of occupational and many accidental poisonings, could circulate directly to 
extrahepatic tissues, including the target tissues. Topical application of parathion results 
in a first-pass bioactivation to paraoxon and the production of p-nitrophenol (Carver gI 
al, 1990). It was also reported that cutaneous metabolite profiles can be altered by both 
physical (occlusion) and chemical (1-aminobenzotriazole) means. 
Sultatos et al, (1984) found that albumin could serve as a means of 
transport for parathion in the blood. They reported an esterase-like activity of bovine 
serum albumin for paraoxon. Further, the oxons can phosphorylate other blood 
components such as AChE, carboxylesterase and other B-esterases. Thus, because of 
the potential degradation of the oxons by the blood proteins and phosphorylation of the 
blood proteins by the oxons, relatively small amounts of oxon produced in the liver 
could reach the brain AChE. 
The major route of detoxification of paraoxon, the active metabolite of 
parathion is by hydrolysis (see Figure 3.2. ). Oxon analogues of organophosphate 
insecticides are cleaved by Ca2+ dependant paraoxonase. 
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Figure 3.2. Hydrolysis of paraoxon to p-nitrophenol and diethyl phosphoric acid. 
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3.3 CARBARYL 
Carbaryl (1-naphthyl methylcarbamate) belongs to the carbamate family of 
pesticides (see Figure 3.3. ). It is recomended for use against caterpillars of the winter 
moth, as well as earwigs and capsid bugs. It was introduced by Union Carbide 
Company as a broad spectrum insecticide acting by reversible inhibition of 
acetylcholinesterase (Kolbezen et al, 1954). 
Carbamates have a high affinity for acetylcholinesterase and formation of 
a reversible complex, is therefore, favourable which results in the formation of a 
carbamoylated, enzyme complex. Dissociation of the complex is by hydrolysis which 
proceeds at a slower rate than carbamoylated resulting in a build up of inhibited enzyme 
(Kuhr and Dorough, 1976). It is widely used due to its relatively low anticholinesterase 
activity in mammals, as a result of the more rapid metabolising capacity of mammalian 
liver carboxylesterase compared to the metabolic activity of the insect (Kolbezen et al, 
1954; Best and Murray, 1962; Dorough, 1970) and the reversible nature of the enzyme 
inhibition. 
The metabolic fate of carbaryl is important in the determination of its 
potential toxic hazard. Following oral or dermal exposure, carbaryl has been shown to 
be rapidly absorbed and distributed in various tissues and organs throughout the body. 
Carbaryl is metabolised by rats and excreted in the urine as the hydrolysed 
product 1-naphthol, and as conjugates of 1-naphthol (Carpenter, 1961). The liver has 
been shown to be a major site for carbaryl metabolism in the mammal. Following intra 
venous administration of carbaryl, first pass metabolism by the liver lowered plasma 
carbaryl levels considerably (Houston et al, 1974). Human liver fractions have been 
shown to possess less metabolic activity toward carbaryl than rat, with ring 
hydroxylation the major route of metabolism (Strother, 1972). The extent of hydrolysis 
41 
(see Figure 3.3. ) that acts to detoxify carbaryl is the major difference in carbaryl 
metabolism between species (Knaak et al, 1965). 
Carbaryl metabolism by other tissues have been studied, with liver activity 
the greatest followed by kidney and then lung (Chin et x1,1974). It is also readily 
hydrolysed by serum albumin (Casida and Augustinsson, 1959)' and by blood. 
Carbaryl metabolism by rat liver and skin post mitochondrial fraction has been studied 
by MacPherson gam, (1991). It was shown that carbaryl hydrolysis took place in both 
the liver and skin post mitochondrial fractions, with skin esterase hydrolysis accounting 
for less than 3% of liver when comparing specific activities. Urinary metabolites 
present following exposure to carbaryl by any of the possible routes, represents a 
composite of metabolic activity in a number of tissues, therefore, it is important to 
assess the contribution of local hydrolysis in the skin and lung following absorption 
through the skin and lung as well as the type of esterases causing the hydrolysis of 
carbaryl to 1-naphthol. 
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3.4. FLUAZIFOP-BUTYL 
Fluazifop-butyl [ butyl 3-[ 4-(5-trifluoromethyl-2-pyridyloxy phenoxy ] 
propionate I is anaryloxyphenoxy propionate herbicide and is the active ingredient of 
FUSILADE herbicides which are used to control grass weeds in broadleaved crops (see 
Figure 3.4. ). At room temperature fluazifop-butyl is an oily yellow liquid with a 
melting point of 5°C. It is soluble in most organic solvents but only very slightly 
soluble in water. It has low acute toxicity via oral or percutaneous routes; rat oral MLD 
3300 mg kg-1, rabbit dermal MLD > 5000 mg kg-1, and it is not carcinogenic in rats or 
micein lifetime dietary studies (UK M. A. F. F., 1988). Fluazifop-butyl is a racemic mixture. 
In the rat fluazifop-butyl excretion is rapid following oral administration 
and the majority of the dose is recovered in urine as the acid metabolite fluazifop (Hart 
gam, 1982) (see Figure 3.4. ). There is a sex difference in the rate of elimination; male 
rats tl1233-38 hours, female rats t1 2.5 hours (Batten et al, 1981). 
Woollen et al, (1991) in humans have shown that following oral dosing, 
fluazifop-butyl is rapidly absorbed and hydrolysed to its acid metabolite fluazifop. The 
estimated half-life of elimination of fluazifop from male human blood (12-37h) was 
found to be slower than that from the blood of female rats (2.5h) but faster than from 
male rats (33-38h). BattengUI, (1981) in the dog indicates a half- life of approximately 
20 hours with no sex differences. 
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CHAPTER 4: XENOBIOTIC METABOLISM IN THE LUNG 
4.1. INTRODUCTION 
The respiratory system has two main components: a conducting system, 
designed to process, deliver and remove air; and a gaseous exchange system by which 
blood is oxygenated and decarbonated. The latter, the respiratory acinus consists 
mainly of alveoli. 
The conducting system is divided into the nasopharynx, and 
tracheobronchiolar tree or alternatively described as the upper and lower airways 
(Figure 4.1. ). An important factor in respiratory tract toxicology is the physiochemical 
nature of the material. Inhaled substances may be gases, vapours, liquids or solid and 
particles. Three areas of depositiion of aerosols can be defined broadly within the 
respiratory tract. In the extrathoratic region, comprised of the nasopharynx and larynx, 
particles of more than 6µm aerodynamic diameter, deposit, whereas in the 
tracheobronchial tree particles of 5-7µm aerodynamic diameter come to rest. Particles of 
3-4µm settle in the pulmonary compartment, comprised of bronchioles and alveoli. 
Only the very small particles 1µm aerodynamic diameter or less, are likely to diffuse 
into the alveolar region in large quantities, whereas particles <0.5 gm may avoid 
deposition altogether and be subsequently exhaled (Yu et al, 1972; Itkin and Anand, 
1970; Cockcroft et al, 1978). Gases and vapours on the other hand may diffuse 
throughout the respiratory tract . Factors influencing absorption through the alveoli 
include lipophilicity, surface area and blood supply. 
4.2. METABOLISM 
4.1. i. Introduction 
The respiratory tract, being a major portal of entry of xenobiotics into the 
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Figure 4.1. Gross anatomy of the respiratory system 
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body, is exposed continuously to airborne environmental chemicals as well as to those 
substances which are present in the general circulation. Additionally, xenobiotics which 
are locally biotransformed into reactive metabolites usually exert relatively selective 
toxic effects within the difference segments of the respiratory tract and frequently 
damage either a specific morphological cell type or groups of morphological similar 
cells which are located within a selected area or region of the tissue (Boyd gam, 1974; 
Baron and Kawabata, 1983; Minchin and Boyd, 1983). 
The nasal mucosa is found in the nasopharynx region of the conducting 
system. It is a relatively complex and heterogenous tissue which consists of olfactory 
and respiratory regions. The nasal mucosa contains cytochrome P450 and other 
xenobiotic-metabolism of inhaled chemicals. Moreover it is damaged by many 
xenobiotics which must undergo a cytochrome P450 mediated biotransformation prior 
to exerting their cytotoxic actions (Hecht et al, 1980; Brittebo et al, 1983; Hashek et al, 
1983). 
Histologically, the trachea is a much less complex and heterogenous tissue 
than is the nasal mucosa. Its epithelium consists of ciliated cells, goblet, or mucous 
secreting cells and basal cells, all of which rest on a well-defined basement membrane. 
The tracheal epithelium has been reported to be capable of supporting cytochrome P450 
dependant monoxygenase activities (Kaufman et a1,1973; Autrup et al, 1980) and 
represents a major target for the carcinogenic actions of xenobiotics, especially 
polycyclic aromatic hydrocarbons (Palekar et al, 1968; Trump e al, 1984). 
The bronchus, bronchiole, and alveolar wall represents the major sites for 
xenobiotic metabolism within the lung (Wattenberg and Leong, 1963; Machin and 
Boyd, 1983). Bronchial epithelial cells (Kahn et al, 1981), non-ciliated bronchiolar 
epithelial or clara cells (Boyd, 1977; 1980; Devereux, 1984), and type II pneumocytes 
(Teel and Douglas, 1980; Devereux, 1984) have all been demonstrated to be capable of 
oxidatively metabolizing xenobiotics. Clara cells contain the greatest concentrations of 
cytochrome P450PB-B, NADPH cytochrome P450 reductase, and epoxide hydrolase 
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with respect to findings on cytochrome P450PB-B, it should be recognised that this 
cytochrome P450 appears to be the principle enzyme responsible for catalyzing the 
bioactivation of pulmonary toxicants such as 4-ipomeanal in the rat (Guengerich et al 
1982a). 
4.2. ii. Esterase Hydrolysis in Lung 
The mammalian lung is rich in esterase activity. In various species, high 
esterase activity has been detected histochemically in the bronchial mucosa and, to a 
lesser extent in the alveolar lining cells (Nachlas and Seligman, 1949; Barrnet, 1952; 
Ches ick, 1953). The multiple nature of these esterase enzymes was demonstrated by 
electrophoretic seperation (Market and Hunter, 1959). 
Lung esterase again received attention when a relationship between 
esterase activity and the lamellated bodies (LB), considered to store the surfactant 
factor, was established (Vatter et al, 1968). The identification of the LB-associated 
esterase and its biological significance was attempted (Hichcock-O'Hare gam, 1971; 
1976; Bocldng et al, 1981). At least 13 different esterases were distinguished and 
identified in the house mouse, mainly by their catalytic properties, susceptibility to 
inhibition, developemental patterns and phenotypic variation amongst different strains 
(von Deimlin e al, 1983). Each of the 13 esterases of the lung also occurs in one or 
several other tissues. At least 8 esterases were found which belong to the isozyme 
system of carboxylesterase under the control of genes located on chromosome 8. These 
esterases account for about 90% of the esterase activity in the lung. It is thought that the 
main sites of carboxylesterase isoenzymes are the columnar epithelium of the 
bronchioles, the alveolar septal cells and the type II alveocytes. These sites have been 
shown to be associated with organophosphate-sensitive esterases in the rat (Milz and 
Budd, 1978). 
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CHAPTER 5: XENOBIOTIC METABOLISM IN THE SKIN 
5.1. STRUCTURE 
5.1. i. Introduction 
The skin together with its appendages, effectively comprise the outer 
surface of the vertebrate animal. The skin protects the internal body structure from the 
external environment, for example, pollution, radiation and temperature variation by 
providing physical protection and by limiting the passage of substances, most 
importantly water, into and out of the body. Although the skin possess selective barrier 
properties many chemicals are able to penetrate the barrier and, once absorbed, enter the 
systemic circulation. 
The skin is divided into three distinct layers; epidermis, statum corneum 
and dermis (Figure 5.1. ) 
5.1. ii. Epidermis 
The epidermis consists of several layers, including the basal (stratum 
gerninativum) layer, keratinocytes, the granular layer (stratwm gerulosum) and the 
stratum corneum. The epidermis is a proliferating layer of actively metabolising and 
dividing cells. In man the epidermis is 25µm thick, compared to the total skin thickness 
of 2mm. This compares to a thickness of 18µm and a total skin thickness of 800µm in 
the rat (Scott et al, 1991). The epidermis is constantly renewed as basal cells gradually 
migrate outwards, __ , undergoing morphological and 
histochemical changes, to 
form the stratum corneum. This process is called keratinization and leads to the 
formation of keratinocytes. As keratinocytes migrate to the surface they form keratin, 
which forms the outer layer of the skin, the stratum corneum. The process of cell 
division, migration and differentiation takes 28 days in normal adult skin and serves as 
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a protection against damage to the skin by friction and against foreign objects which 
may have penetrated the outer layers. 
5.1. iii. Stratum Corneum 
The stratum corneum consists of 10-15 layers of dead keratinized cells in 
humans. The stratum corneum in man is about 20µm, compared to 16µm in the rat. 
These are laterally arranged with the lateral edges interdigitating with adjacent cells. 
This arrangement forms alternate layers of hydrophobic and hydrophillic regions, with 
the keratin outer cell layers forming lipophilic regions and the intercellular contents 
forming hydrophilic regions. This arrangement is thought to be important in the 
selective permeability properties of the stratum corneum (Schaffer, 1982). 
S. 1. iv. Dermis 
The dermal layer represents the bulk of the skin. Dermis consists of a 
matrix of connective tissue, collagen, elastin and reticulin embedded in 
mucopolysaccarides. Blood vessels, lymphatics and nerves cross the matrix and skin 
appendages such as sebaceous glands and hair follicles penetrate it. 
The dermal layer in man is divided into the upper papillar layer and the 
deeper reticular layer. The papillar layer is well supplied by capillaries which enables 
the skin to regulate body temperature, to remove waste products from and nutrients to 
the skin. The tough resilient qualities of the skin are provided by the reticular layer. It is 
composed of coarse collagen bundles, elastic fibres and mucopolysaccarides. Most 
substances penetrating the stratum corneum are absorbed into the blood via the vessels 
located in the dermis and therefore enter the systemic circulation. 
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5.1. v. Skin Appendages 
Skin appendages include eccrine and apocrine sweat glands, hair follicles, 
sebaceous glands and nails. Hair follicles develop from invaginations of epidermis into 
the dermis. One or more sebaceous glands are attached to a hair follicle to form a 
pilosebaceous unit. These glands are holocrine and synthesise lipids which are expelled 
onto the skin surface as sebum, which is thought to play a role in protection from 
dehydration and infection and to keep skin supple. Apocrine and eccrine sweat glands 
arise as secretory coils in the dermis and form the ducts into the epidermis. They may 
open into the hair follicle or onto the skin surface to secrete sweat onto the skin surface 
to dissipate excessive body heat by evaporation. 
5.2. METABOLISM 
5.2. i. Introduction 
Skin has traditionally has been seen as an inert structural barrier 
preventing entry of toxic substances and loss of critical body constituents. The skin 
posses a range of metabolic activity, including the ability to metabolise endogenous 
substances such as lipids, carbohydrates and proteins (Rongone; 1977; Bickers and 
Kappas, 1980) and exogenous xenobiotic compounds (Bickers and Kappas, 1980; 
Noonan and Wester, 1985). 
5.2. ii. Esterase Hydrolysis in the Skin 
Esterases which split various esters, including esters of drugs, are 
measurable in all parts of the skin. Fredriksson, (1958) showed in vitro. that guinea- 
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pig skin contains an enzyme belonging to the group of phosphorylphosphatases, 
capable of hydrolysing the anticholinesterase agent sann (isopropoxy-methyl- 
phosphonyl-fluoride). In vivo studies in the cat suggested that sann may undergo 
cutaneous first pass metabolism during percutaneous absorption, thereby inactivating 
the compound before it enters the systemic circulation. Fredriksson, (1961) 
investigated the capacity of skin from man, cat, rabbit and rat to hydrolyse paraoxon 
and metabolise parathion. Paraoxon was hydrolysed to p-nitrophenol in all species 
tested, apart from the rat, whilst parathion was not metabolised by the skin from any of 
the species tested. Fredriksson et al, (1969) showed that the organophosphate pesticide 
soman (pincoloxy-methyl-phosphonyl fluoride) and tabun (dimethyl-amido-ethoxy- 
phosphonyl-cyanide) were hydrolysed in vitro, by guinea-pig skin. The hydrolysis of 
diflucortone valerate in the rat, guinea-pig and human skin has been demonstrated in 
vivo, with a marked species difference in the rate of metabolism exhibited, rat and 
guinea-pig skin metabolising the compound at a greater rate than human skin (Tauber 
and Toda, 1976). MacPherson et al, (1991) found that carbaryl hydrolysis took place in 
the skin post mitochondrial fraction. 
Based on the presence of esterases in the skin, a number of ester prodrugs 
have been developed which can be topically applied to the skin where they are 
hydrolysed. The pharmalogical concept is relatively new and can be used to treat skin 
diseases or for systemic circulation. Work by Cheung et al, (1985) demonstrated the 
presence of esterase activity in the skin, very similar to that found in the liver. It was 
also discovered that the betamethasone-17 steroid ester was resistant to esterase 
hydrolysis, whereas the 21-steroid ester was rapidly hydrolysed. By being more 
resistant to the cutaneous esterases, the 17-steroid ester, upon application to the skin 
would tend to form better resevoirs in the skin and therefore act for longer periods of 
time. Using alkyl p-nitrobenzoate esters as substrates Pannatier et al, (1981) found 
considerable hydrolytic activity in the skin preparations from mice. Using ethyl p- 
nitrobenzoate as a substrate, it was found that the mouse liver homogenate is 
approximately 10 times more active than the skin on a weight of tissue basis. 
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Esterase activity has been used as a means of activating or inactivating 
prodrugs following topical application. For example, Yu et al, (1979) showed that the 
prodrug vidaribine 5' valerate is metabolised by skin esterases to form the antiviral 
agent vidarabine in vivo following topical application to human skin. Loftsson et al, 
(1982) showed that acetyl salicyclic acid was similtaneously transported and 
hydrolysed in vitro in hairless mouse. Studies using metroidazole and 5-fluorouracil 
prodrugs show that leaching of esterases takes place rapidly during permeation, using 
excised human skin preparations. The receptor phase drug metabolism due to leaching 
enzymes may be of great importance in evaluating permeation studies of hydrolysable 
drugs or prodrugs such as esters (Bundgaard et al, 1982). 
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CHAPTER 6: XENOBIOTIC METABOLISM IN THE BLOOD 
4 
6.1. Introduction 
Blood is an opaque fluid with a viscosity somewhat greater than that of 
water. When oxygenated, as in the systemic arteries, it is bright scarlet, and when 
deoxygenated, as in systemic veins, it is dark red to purple. Blood is a heterogenous 
fluid consisting of a clear liquid, plasma, and formed elements, corpuscles. 
Plasma is a clear, slightly yellow fluid which contains many substances in 
solution or suspension. Plasma is rich in sodium and chloride ions and also contains 
potassium, calcium, magnesium, phosphate, bicarbonate and many other ions, glucose 
and amino acids. The colloids include the high molecular weight plasma proteins, 
composed chiefly of those associated with clotting, particularly prothrombin, the 
immunoglobulins, and compliment proteins, involved in immunological defence and 
glycoproteins, polypeptides and steroids concerned with hormonal activities. Since 
most of the metabolic activities of the body are reflected in the composition of the 
plasma, routine chemical analysis of this fluid has become of great importance. 
The red blood corpuscles (erythrocytes or red blood cells) form the greater 
proportion of the blood cells (99% of the total number), with a count of 4.1-6 x 106 / 
mm3 in adult males and 3.9-5.5 x 106 / mm3 in adult females. Each cell is a biconcave 
disc with a diameter of 6.3-7.9 pm and a rim thickness of 1.9 µm; in wet preparations 
the mean diameter is 8.6 µm. Erythrocytes lack nuclei and are pale red by transmitted 
light with paler centres because of their biconcavity. Erythrocytes are bounded by a 
plasma membrane and consist internally of a single protein, haemoglobin, apart from a 
few remnants from their initial developement. The plasma membrane is about 60% lipid 
and glycolipid, and 40% protein and glycoprotein. 
6.2. Esterase Hydrolysis in Blood (see chapter 1.2. ) 
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SECTION II : GENERAL METHODS 
CHAPTER 7: PREPARATION OF ANIMAL TISSUE 
7.1. ANIMALS 
Male Wistar rats weighing 180g were obtained from the Comparative 
Biology Centre, The Medical School, Newcastle University. The rats were housed in 
steel cages and subjected to an artificial light cycle of twelve hours duration. The rats 
had free access to water and standard rodent chow (lab. diet 41D). 
7.2. REMOVAL OF RAT TISSUE 
Male Wistar rats were killed by cervical dislocation. With the use of 
scissors and forcep, the liver and lung were removed. The whole of the dorsal area was 
shaved using electric clippers (Ostler) and the skin removed. The tissues were then 
placed in plastic bags and put immediately on ice. Tissues were later frozen and stored 
at -80°C. 
10ml of blood was removed from anaesthetized rats by cardiac puncture 
and placed in heparinised tubes. Plasma and blood were separated by centrifugation 
using a Mistral 3000 centrifuge, at 880 xg for 5 minutes. The plasma white cells were 
removed and stored at -80°C before analysis. The red blood cells were washed using 
an equal volume of isotonic saline. After centrifugation at 880 xg for 10 minutes the 
upper saline layer was removed and discarded. This procedure was again repeated. The 
red blood cells were then stored at -80°C before analysis. 
7.3. PREPARATION OF TISSUE HOMOGENATE 
Liver and lung tissues were washed in ice cold 0.34M sucrose buffer, 
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pH7. The skin was placed in a petri dish on ice and the subcutaneous fat and vascular 
tissue was removed from the dermis. 1g portions of each of the tissues were weighed 
and finely minced using scissors and forceps in l Omis of 0.34M sucrose buffer, pH7.0. 
Tissue homogenates were prepared using a cooled polytron homogenizer 
(Kinematic) using two bursts of 10 seconds duration at full power, with cooling 
between the bursts for skin and two bursts at 2 seconds duration at full power for liver 
and lung. Tissue homogenates were centrifuged in a Sorvall RC 5B refrigerated 
centrifuge at 1,800 xg for 5 minutes at 4°C to remove tissue debris. The supernatant 
was further centrifuged at 10,000 xg for 10 minutes at 4°C to remove mitochondria 
and nuclei. 
7.4. PREPARATION OF SUBCELLULAR FRACTIONS 
The post-mitochondrial fraction was then centrifuged in a Sorval ultra- 
centrifuge at 100,000 xg for one hour and ten minutes. The supernatant (cytosol) was 
removed-and the resulting pellet (microsomes) was resuspended by homogenizing the 
pellet in 50mM trisma HCl buffer pH 7.5, using a glass to glass homogenizer. The 
resulting pellet from the second spin was resuspended into lml of 50mM trisma HCl pH 
7.5 for lung and skin and 5 mis for liver. The microsomal and cytosolic fractions were 
stored in aliquot tubes at -80°C before analysis. 
7.5. PROTEIN ESTIMATIONS 
Microsomal and cytosolic protein estimations were made using a variation 
on the Lowry et al, (1956) method, by Peterson, (1977). 
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To analyse the protein concentrations a calibration curve had to be set up. 
From a neat protein stock BSA(0.6mg/100ml)in 100 dilution was made. This gave a final 
stock solution of 0.6µg/µ1. The following protein standards were used: 0,6,30,60 
and 90µg. These standards were placed into l0mis round bottomed tube. This was 
made up to lml with distilled water. O. lml of deoxy-cholic acid (D. O. C. ) was added, 
mixed and allowed to stand for 10 minutes. After the 10 minutes, 0. lml of T. C. A. 
(72%) was added and then mixed. The tubes were then placed in a centrifuge and 
vortexed at 5000 xg for 15minutes. At the end of this the supernatant was discarded 
and the tubes were turned upside down to dry. lml of distilled water was added 
followed by lml of reagent A (equal volumes of the following: copper-tartrate- 
carbonate (C. T. C. ), 0.8M NaOH, 10% S. D. S. and water). This was all mixed together 
and allowed to stand for 10 minutes. 0.5mls of reagent B (20m1 folin-ciocalteau phenol 
reagent + 100mis of distilled water) was added and then alowed to stand for 30 
minutes. The absorbance at each concentration was read at 750nm on a UV Kontron 
spectrophotometer. 
Having established the calibration curve, the protein recoveries for the 
different tissue fractions were calculated by taking a fixed amount of either microsomal 
or cytosolic tissue and repeating the above proceedure. 
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CHAPTER 8: ENZYME KINETICS 
8.1. INTRODUCTION 
The kinetic feature that most distinguishes enzyme-catalysed reactions 
from simple chemical reactions is that they show saturation. Nearly all enzyme- 
catalysed reactions show a first-order dependance of rate on substrate concentration at 
very low concentrations, but instead of increasing indefinitely as the concentration 
increases, the rate approaches a limit at which there is no dependance of rate on 
concentration and the reaction becomes a zero order with respect to substrate (see 
Figure 8.1. ). Work by Michaelis and Menton, (1913) is usually taken as the starting 
point when discussing enzyme kinetics. Their mechanism supposes that the first step in 
the reaction is the binding of the substrate (A) to the enzyme (E) to form an enzyme- 
substrate complex (EA) which then reacts to give the product (P) with the regeneration 
of the free enzyme: E+A- kl--> EA --k2--> E+P where kl is the initial rate 
of conversion of E+A to EA and k2 is the first order conversion of EA to E+P. From 
this fundamental equation the' Michaelis-Menton equation' was derived: 
v= koeoa (8.1) 
Km+a 
From this equation two kinetic parameters can be measured: (1) V max- the maximum 
rate of hydrolysis at enzyme saturation; . and 
(2) Km- substrate concentration 
enzyme has- at 1/2 the Vmax. Before these kinetic parameters could be measured 
conditions of linearity for protein and time had to be established. Once these had been 
established a ten fold range in substrate concentrations was used to obtain values for 
Km and Vmax. 
In the experiments two types of plot were used to determine the kinetic 
parameters: double-reciprocal plot and direct line plot. 
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Figure 8.1. Hydrolysis of fluazifop-butyl by rat liver microsomes. Calculation of Vmax ( 
µmol/ min/g wet weight) and Km (µM) by simple Michaelis Menton Kinetics. 
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8.2. DOUBLE-RECIPROCAL PLOT 
The most natural way of plotting steady-state kinetic data is to plot v 
against the substrate concentration s, as in Figure 8.1, and this is certainly the clearest 
way to display the behaviour. However, this is not a good way to determine kinetic 
parameters, because the line is curved and it does not approach the limit fast enough to 
judge accurately where the limit is. To overcome this the Michaelis-Menton equation 
was transformed into the equation for a straight line by taking reciprocals of both sides 
of equation 9.1. 
1=1+ Km. 1 (8.2) 
v Vmax Vmax s 
A plot of IN against 1/s is a straight line, with a slope of 1/kaeo which is 
equal to Km/V, an intercept on the ordinate (1/v) axis of 1/kaeo which equal to 1/V, and 
an intercept on the abscissa (i/s) axis of -ka/ko equal to -1/Km (Figure 8.2. ). The 
objection to the double-reciprocal plot, as it is commonly known, is that it distorts the 
appearance of any experimental error in the primary observations of v, so that one 
cannot judge which points are most accurate when drawing a straight line through the 
set of points. 
In the experimental studies described here the double-reciprocal plot was 
initially used, however, this proved to be inaccurate at times especially at lower 
substrate concentrations (larger deviation), therefore the direct line plot was favoured. 
8.3. DIRECT LINE PLOT 
The direct linear plot (Eisenthal and Cornish-Bowden, 1974) requires 
each observation to be plotted as a straight line and the parameter values appear as a 
point rather than a slope and intercept of a line. The Michaelis-Menton equation is 
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Figure 8.2. Hydrolysis of fluazifop-butyl by ratliver microsomes. Calculation of Vmax 
µmol/ min/g wet weight) and Km (p. M) by double reciprical plot. 
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rearranged as such: 
V=v+ (v/s) Km (8.3. ) 
If V and Km are treated as variables and v and a as constants, this equation defines a 
straight line with intercepts v on the V axis and -s on the Km axis. This line relates all 
possible pairs of (Km, V) values that exactly satisfy an observation of rate v at substrate 
concentration s. A second line drawn in the same way for a second observation relates 
all parameter values that satisfy this second observation. Only one point is on both 
lines, their point of intersection, and its coordinates define the unique pair of parameter 
values that satisfy both observations exactly. 
In the absence of experimental error, we should expect that n such lines 
for a set of n observations would all intersect at a unique point, the coordinates of 
which would give the values of Km and V. A real experiment, however, is subject to 
error, and gives a family of intersection points, as seen on Figure 8.3. It is nonetheless 
possible to estimate the parameter values because each intersection point provides one 
estimate of Km and one estimate of V. These can be marked on the axes and the best 
estimate of each parameter can be taken as the median (middle) value of the set. The 
use of non-parametric assessment does not assume a normal distribution of the data. In 
taking the median value the plot is insensitive to outliners. As well as this the direct linear 
plot is independant of weighting. 
Initially in the study all three approaches were used to determine the 
apparent Km and Vmax values, however, the direct line plot was favoured because it 
was found to be more accurate at lower substrate concentrations than the double- 
reciprocal plot. 
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Figure 8.3. Hydrolysis of fluazifop-butyl by ratliver microsomes. Calculation of Vmax ( 
tmol/ min/g wet weight) and Km (µM) by direct linear plot. 
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CHAPTER 9: ENZYME ASSAYS 
9.1. INTRODUCTION 
The following enzymatic assays were set up to examine the hydrolysis, by 
esterase enzymes, of a number of xenobiotic esters to establish localisation and 
distribution of esterase activity in the liver, lung, skin and blood of the rat. Activities for skin 
[were a combination of activities from the dermis and epidermis. 
Using the analytical techniques of HPLC and spectrophotometry, the 
formation of product was measured over a range of substrate concentrations to establish 
the Km and Vmax (see chapter 9) for the hydrolytic reactions, after conditions of 
linearity with protein and time had been established. 
9.2. FLUAZIFOP-BUTYL ESTERASE 
9.2. i. Chemicals 
Fluazifop-butyl [ butyl 3-[ 4-(5-trifluoromethyl-2-pyridyloxy phenoxy ] 
propionate ] has the empirical formula of C19H20F3NO4 and a molecular weight of 
383.4 . Fluazifop-COOH has the empirical formula C14H11F3NO2000H and a 
molecular weight of 308 . Both chemicals were gifts from Central Toxicology 
Laboratory, ICI. 
9.2. ii. Incubation 
Microsomal and cytosolic protein, between 0.1-30mg of liver, lung and 
skin original wet weight or 10-50µl of plasma and red blood cells were incubated with 
fluazifop-butyl (0.05-1mM). Incubations were carried out in a final volume of 500µl 
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50mM trisma buffer pH 8, containing 0.1 mM calcium chloride at 37° C. 
Reactions were started by the addition of fluazifop-butyl (5-2Oµ1 of a 
10mM and 1mM stock in acetonitrile) and stopped with the addition of 500µ1 of 6% 
perchloric acid (w/v in H20), containing 10µg/m1 p-toluic acid (internal standard). 
Tubes were vortexed and centrifuged at 5440 xg for 5 minutes . 80g l of the clear 
supernatant was injected onto HPLC. 
Using a fixed concentration of fluazifop-butyl (1mM) and time of 
incubation (10 mins), varying amounts of protein from liver (see Figure 9.2.1. ), lung 
(see Figure 9.2.2. ) and skin (see Figure 9.2.3. ) were used in the incubations to 
establish conditions of linearity for protein. The amount of plasma was also varied, 
with a constant time and constant fluazifop-butyl concentration (see Figure 9.2.4. ). 
Having established the appropriate amount of protein for the incubation the time of 
hydrolysis was varied (0-30 minutes) with a fixed fluazifop-butyl concentration 
(1mM), to establish conditions of linearity for time for the following tissues: liver (see 
Figure 9.2.5. ); lung (see Figure 9.2.6. ) ; skin (see Figure 9.2.7. ) and plasma (see 
Figure 10.2.8. ). 
The conditions of linearity for protein, with constant time (10 mins) and 
fluazifop-butyl concentration (1mM) were 0.4,5 and 30mg of liver, lung and skin 
original wet weight or lOµ1 of plasma. The conditions of linearity for time, with 
constant protein and fluazifop-butyl concentration were 4 minutes for liver and plasma 
and 10 minutes for lung and skin. The sensitivity of the fluazifop-butyl assay was 
lnmol/ 10 min. No spontaneous hydrolysis of fluazifop-butyl was seen. 
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Figure 9.2.1. 
Rate of fluazifop-butyl (1mM ) hydrolysis to fluazifop (nmol/minute) in the presence 
of varying rat liver microsomes (a) and cytosol (. ) ( 0-2 mg tissue wet 
weightf ncubation ). 
Each point represents a mean of duplicate determinations. 
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Figure 9.2.2. 
Rate of fluazifop-butyl (1mM) hydrolysis to fluazifop ( nmol/minute ) in the presence 
of varying rat lung microsomes (a) and cytosol (") ( 0-4 mg tissue wet 
weight/incubation ). 
Each point represents a mean of duplicate determinations. 
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Figure 9.2.3. 
Rate of fluazifop-butyl ( 1mM) hydrolysis to fluazifop ( nmol/minute ) in the presence 
of varying rat skin microsomes (o) and cytosol (") ( 0-30 mg tissue wet 
weightlincubation ). 
Each point represents a mean of duplicate determinations. 
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Figure 9.2.4. 
Rate of fluazifop-butyl (1mM) hydrolysis to fluazifop (nmol/minute) in the presence 
of varying rat plasma ( 0-20 µl plasma/incubation ). 
Each point represents a mean of duplicate determinations. 
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Fluazifop-butyl (1mM ) hydrolysis to fluazifop ( nmol/incubation ) by rat liver 
microsomes (o) and cytosol (") ( 0.4mg/incubation) for varying times of hydrolysis . 
Each point represents a mean of duplicate determinations. 
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Figure 9.2.6. 
Fluazifop-butyl (1mM ) hydrolysis to fluazifop ( nmol/incubation ) by rat lung 
microsomes (o) and cytosol (. ) (5mg/incubation) for varying times of hydrolysis. 
Each point represents a mean of duplicate determinations. 
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Figure 9.2.7. 
Fluazifop-butyl (1mM ) hydrolysis to fluazifop ( nmol/incubation ) by rat skin 
microsomes (o) and cytosol (") ( 30mg/incubation) for varying times of hydrolysis. 
Each point represents a mean of duplicate determinations. 
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Figure 9.2.8. 
Fluazifop-butyl (1mM ) hydrolysis to fluazifop (nmol/incubation ) by rat plasma (10 
µl/incubation) for varying times of hydrolysis . 
Each point represents a mean of duplicate determinations. 
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9.2. iii. HPLC separation of Fluazifop-butyl and Fluazifop-COOH 
A Kontron system with dual wavelength UV detection fitted with a 
Spherisorb ODS (5µ, 15cm) C18 reverse phase HPLC column was used for the 
fluazifop-butyl assay with a mobile phase of orthophosphoric acid (0.072% w/v) / 
acetonitrile (40/60) at a rate of 1ml/min. Fluazifop-butyl and fluazifop-COOH were 
measured at 270nm, with the internal standard being measured at 250nm. The retention 
time of internal standard 2.5 minutes, fluazifop-COOH 3.5 minutes and fluazifop-butyl 
12.5 minutes (see Figure 9.2.11. ). 
Calibration curves for fluazifop-butyl and fluazifop-COOH were 
established. Fluazifop-COOH and fluazifop-butyl standards (0-120µM final 
concentration in H2O) mixed with an equal volume of perchloric acid, containing 
lOgg/ml p-toluic acid (internal standard) were injected onto the column (80µl) without 
neutralisation to enable the calculation of fluazifop-COOH (see Figure 9.2.9. ) and 
fluazifop-butyl (see Figure 9.2.10. ) in the assay. 
9.3. CARBARYL ESTERASE 
9.3. i. Chemicals 
Carbaryl (1-naphthyl methylcarbamate) has an empirical formula of 
C12HIIN02 and a molecular weight of 201.2 . 1-Naphthol 
has an empirical formula 
of C10H80 and a molecular weight of 144.2 . Both chemicals were gifts from Central 
Toxicology Laboratory, ICI. 
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Figure 9.2.9. 
A typical standard curve of fluazifop following direct injection ( 8Oµ1) of standards (0- 
150µM ). 
Each point represents a mean of duplicate determinations. 
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Figure 9.2.10. 
A typical standard curve of fluazifop-butyl following direct injection ( 80µl ) of 
standards (0-1000µM ). 
Each point represents a mean of duplicate determinations. 
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Figure 9.2.11. Typical chromatogram showing seperation of fluazifop-butyl, fluazifop 
and internal standard by reverse phase HPLC, using a mobile phase of 60: 40 
acetonitrile: orthophosphoric acid ( 0.072w/v ) pumped at a rate of lml/minute. 
Detection is by UV spectrophotometry at a wavelength of 250nm for internal standard 
and 270nm for fluazifop and fluazifop-butyl.. 
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9.3. ii. Incubations 
Microsomal and cytosolic protein, between 0.1-30mg of liver, lung and 
skin original wet weight or 10-50µl of plasma and red blood cells were incubated with 
carbaryl. Carbaryl (5-50µM) was added to eppendorf tubes in 15µl methanol, because 
it would not dissolve in H20. The methanol was evaporated off under nitrogen before 
the protein was added to the tube to prevent the methanol having an inhibitory effect on 
carbaryl hydrolysis. Incubations were carried out in a final volume of lml of 0.1M 
phosphate buffer pli 7.25, at 37°C. Control incubations containing 0.1M phosphate 
buffer pli 7.25 and carbaryl, were conducted in parallel to access spontaneous 
hydrolysis. 
Reactions were started by the addition of tissue and stopped with the 
addition of 500µl absolute ethanol. Tubes were vortexed and centrifuged at 5440 xg 
for 5 minutes. 50µl of supernatant was injected onto reverse phase HPLC. 
Using a fixed concentration of carbaryl and time of incubation, varying 
amounts of protein from liver (see Figure 9.3.1. ), lung ( see Figure 9.3.2. ) and skin 
(see Figure 9.3.3. ) were used in the incubations to establish conditions of linearity for 
protein. The amount of plasma was also varied, with a constant time and constant 
carbaryl concentration (see Figure 9.3.4. ). Having established a fixed amount of 
protein for the incubation, the time of hydrolysis was varied (0-30 minutes) with a 
fixed carbaryl concentration, to establish conditions of linearity for time for the 
following tissues: liver (see Figure 9.3.5. ); lung (see Figure 9.3.6. ); skin (see Figure 
9.3.7. ) and plasma (see Figure 9.3.8. ). 
The conditions for linearity for protein were 5,10 and 30mg for liver, 
lung and skin original wet weight or 20µl of plasma with constant time (20 mins) and 
carbaryl concentration (25µM). The conditions of linearity for time were 20 minutes for 
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Figure 9.3.1. 
Rate of carbaryl (1mM) hydrolysis to 1-naphthol ( pmol/minute ) in the presence of 
varying concentrations of rat liver microsomes (o) and cytosol (") (0-10 mg/incubation 
)" 
Each point represents a mean of duplicate determinations. 
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Figure 9.3.2. 
Rate, of carbaryl ( 25µM) hydrolysis to 1-naphthol (pmol/minute ) in the presence of 
varying concentrations of rat lung microsomes (o) and cytosol (. ) (0-20 mg/incubation 
)" 
Each point represents a mean of duplicate determinations. 
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Figure 9.3.3. 
Rate of carbaryl ( 25µM) hydrolysis to 1-naphthol (pmol/minute) in the presence of 
varying concentrations of rat skin cytosol (-) (0-20 mg/incubation ). 
Each point represents a mean of duplicate determinations. 
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Figure 9.3.4. 
Rate of carbaryl ( 25µM ) hydrolysis 1-naphthol ( pmol/minute ) in the presence of 
varying amounts of rat plasma (0-50 µl/incubation ). 
Each point represents a mean of duplicate determinations. 
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Figure 9.3.5. 
Carbaryl (25µM ) hydrolysis to 1-naphthol ( pmol/incubation ) by rat liver microsomes 
(a) and cytosol (") (5mgrncubation) for varying times of hydrolysis . 
Each point represents a mean of duplicate determinations. 
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Figure 9.3.6. 
Carbaryl (25µM ) hydrolysis to 1-naphthol ( pmol/incubation ) by rat lung microsomes 
(o) and cytosol (") ( 10mg/incubation ) for varying times of hydrolysis. 
Each point represents a mean of duplicate determinations. 
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Figure 9.3.7. 
Carbaryl (25µM ) hydrolysis to 1-naphthol ( pmol/incubation) by rat skin microsomes 
() and cytosol (") ( 30mg/incubation) for varying times of hydrolysis . 
Each point represents a mean of duplicate determinations. 
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Figure 9.3.8. 
Carbaryl (25µM ) hydrolysis to 1-naphthol (pmol/incubation ) by rat plasma ( 
20p i/incubation ) for varying times of hydrolysis. 
Each point represents a mean of duplicate determinations. 
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liver, lung, skin and plasma with constant protein and carbaryl concentration. 
The results for the spontaneous hydrolysis of carbaryl can be seen on 
Table 9.1. The sensitivity of the assay was 20pmol. 
9.3. iii. HPLC separation of Carbaryl and 1-Naphthol 
A Spherisorb ODS (5g, l5cm) C18 reverse phase HPLC column was 
used for the carbaryl assay with a mobile phase of water / acetonitrile (60/40) at a rate 
of 1.4ml/min, pumped by a Waters 510 HPLC pump. I-naphthol was measured in the 
eluent using a fluoresence spectrophotometer (Perkin-Elmer 3000) set at an excitation 
wavelength of 296nm and emission wavelength of 460nm. The retention time of 1- 
naphthol was 6.2 minutes (see Figure 9.3.10. ). 
A calibration curve for I-naphthol was established. I-Naphthol standards 
(0-2nmoles) in 15gl methanol was added to eppendorf tubes and the methanol was 
evaporated off under nitrogen. Incubations were carried out in a final volume of IMI 
OAM phosphate buffer ph7.25.500ýd of absolute ethanol was mixed to the incubation 
and this was injected onto the column without neutralization to enable the calculation of 
I-naphthol (see Figure 9.3.9. ). 
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Table 9.1. Spontaneous hydrolysis of carbaryl 
Substrate concentration (µM) Activity (pmol incubation ) 
10 
25 
50 
mean±SEM (n=2) 
limit of sensitivity > 0.3nmol/min 
28±5 
60±7 
132+10 
372+25 
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Figure 9.3.9. 
A typical standard curve of 1-naphthol following direct injection ( 50gl ) of standards ( 
0-500pmol ). 
Each point represents a mean of duplicate determinations. 
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Figure 9.3.10 Typical chromatogram showing seperation of I naphthol by reverse 
phase HPLC, using a mobile phase of 40: 60 acetonitrile: water pumped at a rate of 
4nil/ininute. Detection is by fluorescence spectrophotometry at an excitation wavelength 
of 296nm and an emission wavelength of 460nm. 
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9.4. PARAOXONASE 
9.4. i. Chemicals 
Paraoxon [ 0,0-diethyl-0- (4-nitrophenyl) phosphate I has an empirical 
formula of ClOH14NO6P and a molecular weight of 275.2, -. p-Nitrophenol has an 
empirical formula Of C6H5NO3 and a molecular weight of 139.1 . Both chemicals 
were obtained from Sigma Chemical Company. 
9.4. ii. Incubation 
Microsomal and cytosolic protein, between 0.1-30mg of liver, lung and 
skin, original wet weight, or 10-50gl of plasma or red blood cells was incubated along 
with paraoxon (0.05-ImM). Incubations were carried out in a final volume of 500gl of 
5OmM trisma. buffer pH8.0, containing O. lmM calcium chloride at 370C. 
Reactions were started by the addition of paraoxon (5-50gl of lOmM 
stock , in freshly prepared trisma buffer) and stopped with the addition of 500gI of 6% 
perchloric acid, containing lOgg/ml p-toluic acid (internal standard). Tubes were 
vortexed and centrifuged ar 5440 xg for 5 minutes. 80gi of supernatant was injected 
onto reverse phase HPLC. Control incubations containing 50mM trisma buffer and 
paraoxon were conducted in parallel to assess spontaneous hydrolysis. 
Using a fixed concentration of paraoxon and time of incubation, varying 
amounts of n-krosomal protein from liver (see Figure 9.4.1. ), lung (see Figure 9.4.2. ) 
and skin (not detected) were used in the incubations to establish conditions of linearity 
for protein. The amount of plasma was also varied, with a constant time and paraoxon 
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Figure 9.4.1. 
Rate of paraoxon ( ImM ) hydrolysis to p-nitrophenol ( nmol/n-dnute ) in the presence 
of varying concentrations of rat liver microsomes ((D) ( 0-30 mg/incubation 
Each point represents a mean of duplicate determinations. 
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Figure 9.4.2. 
Rate of paraoxon (I mM ) hydrolysis to p-nitrophenol ( nmol/minute ) in the presence 
of varying concentration of rat lung microsomes (a) ( 0-20 mg/Incubation 
Each point represents a mean of duplicate determinations. 
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concentration (see Figure 9.4.3. ). Having established a fixed amount of protein for the 
incubation the time of hydrolysis was varied (0-30 minutes) with a fixed paraoxon 
concentration, to establish conditions of linearity for time for the following tissues: liver 
(see Figure 9.4.4. ); lung (see Figure 9.4.5. ); skin ( not detected) and plasma (see 
Figure 9.4.6. ). 
The conditions for linearity for protein were 0.5,20 and 30mg for liver, 
lung and skin original wet weight or lOgI of plasma with constant time (10 mins) and 
paraoxon concentration (lmM). The conditions of linearity for time were 15 minutes 
for liver, lung, skin and plasma with constant protein and paraoxon concentration. 
The results for the spontaneous hydrolysis of paraoxon can be seen on 
Table 9.2. The sensitivity of the assay was 0.5nmol/incubation. 
9.4. iii. HPLC separation of Paraoxon and p-Nitrophenol 
A Kontron system with dual wavelength UV detection fitted with a 
Spherisorb ODS (5g, l5cm) C18 reverse phase HPLC column was used for the 
paraoxon assay, with a mobile phase of orthophosphoric acid (0.072% w/v) / methanol 
(45/55) at a flow rate of I ml/min. Paraoxon and p-nitrophenol was measured at 330nm, 
with internal standard being measured at 250nm. The retention times: p-nitrophenol 4.5 
minutes; internal standard 6.4 minutes and paraoxon 10 minutes (see Figure 9.4.9. ). 
Calibration curves for paraoxon and p-nitrophenol were established. 
Paraoxon and p-nitrophenol standards (0-120ýtM final concentration) mixed with an 
equal volume of perchloric acid was injected onto the column (80gl) without 
neutralisation to enable the calculation of p-nitrophenol (see Figure 9.4.7. ) and 
paraoxon (see Figure 9.4.8. ). 
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Figure 9.4.3. 
Rate of paraoxon ( ImM ) hydrolysis to p-nitrophenol ( nmol/minute ) in the presence 
of varying amount of rat plasma ( 0-20 glfincubation ). 
Each point represents a mean of duplicate determinations. 
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Figure 9.4.4. 
Paraoxon (ImM ) hydrolysis to p-nitrophenol ( nmol/incubation ) by rat liver 
microsomes (b) ( 0.5mg/incubadon ) for varying times of hydrolysis. 
Each point represents a mean of duplicate determinations. 
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Figure 9.4.5. 
Paraoxon (ImM ) hydrolysis to p-nitrophenol ( nmol/incubation ) by rat lung 
microsomes (ý) ( 20mg/incubation ) for varying times of hydrolysis . 
Each point represents a mean of duplicate determinations. 
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Figure 9.4.6. 
Paraoxon (ImM ) hydrolysis to p-nitrophenol ( nmolfincubation ) by rat plasma ( 
I Ogl/incubation ) for varying times of hydrolysis. 
Each point represents a mean of duplicate deten-ninations. 
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A typical standard curve of p-nitrophenol following direct injection ( 80PLI ) of 
standards ( 0- 1 OgM and 0- 120gM ). 
Each point represents a mean of duplicate determinations. 
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Figure 9.4.8. 
A typical standard curve of paraoxon following direct injection ( 80gl ) of standards ( 
0-120gM ). 
Each point represents a mean of duplicate determinations. 
102 
o so 100 
T solvent front 
IAaI12 
2468 10 12 
Figure 9.4.9. Typical chromatograrn showing seperation of paraoxon, p-nitrophenol 
and internal standard by reverse phase HPLC, using a mobile phase of 50: 50 methanol: 
orthophosphoric acid ( 0.072w/v ) pumped at a rate of I ml/minute. Detection is by UV 
spectrophotometry at a wavelength of 250nm for paraoxon and internal standard and 
310nm for p-nitrophenol. 
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Table 9.2. Spontaneous hydrolysis of paraoxon 
Substrate concentration (gW Activity (nmol/min) 
20 
50 
80 
1000 
mean+-SEM (n=2) 
44 
lin-& of sensitivity > 0.3nrnol/n-ýn 
0.53±0.02 
1.10±0.03 
1.90±0.1 
2.5±0.15 
1(4 
9.5. PHENYLACETATE ESTERASE 
Chemicals 
Phenyl acetate (empirical formula C8H802 and molecular weight 136.1 ) 
and phenol (empirical formula C6H60 and molecular weight 94.1. ) were obtained 
from Sigma Chemical Company. 
9.5. ii Incubations 
The phenylacetate method of Kitchen et al, (1983) was used in the 
experiment. Microsomal and cytosolic protein, between 0.1-30mg of liver, lung and 
skin, original wet weight or 10-50gl of plasma or red blood cells was incubated along 
with phenylacetate (0.05-ImM final concentration). Incubations were carTied out in a 
final volume of 3mls of 50m. M trisma buffer pH 8.0, containing 0.1 mM calcium chloride 
at 370C. Reactions were started by the addition of phenylacetate. The cuvettes were 
inverted and placed in the spectrophotometer. Control incubations containing 50mM 
trisma buffer, but no tissue fraction were conducted in parallel. 
The amount of protein or plasma was varied until a linear plot was 
obtained over 3 minutes. The reason for this was to stop all the hydrolysis of the 
phenylacetate by the arylesterase enzyme taking place at the begining of the reaction. 
The conditions for linearity for protein were 2,20 and 30mg for liver, 
lung and skin original wet weight or I Ogl of plasma). 
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The results for the spontaneous hydrolysis of phenylacetate can be seen 
on Table 9.3. The sensitivity of the assay was 0.25gmol/incubation. 
9.5. iii. Monitoring of Phenol 
The formation of phenol was monitored continuously at a wavelength of 
272nm on a Kontron UV spectrophotometer with temperature control, set at 370C. 
Measurements were converted from absorbance units / min to nmoles phenol / min / 
cuvette by the absorption coefficient for phenol. 
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Table 9.3. Spontaneous hydrolysis of phenylacetate 
Substrate concentration (mND Activity (nmol/min) 
0.4 3.4±0.5 
1.0 6.1+-+0.6 
2.0 11.4±0.8 
3.0 17.5±1.0 
4.0 24.2±1.6 
mean+-SEM (n=2) 
limýt of sensitivity > 0.23nmol/min 
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SECTION Ill: EXPERIMENTAL STUDIES 
CHAPTER 10: PRELIMINARY STUDIES OF ESTER HYDROLYSIS IN RAT 
10.1. INTRODUCTION 
Many studies of esterase activity have been restricted to the microsomal 
fraction of the cell. However, recent studies have indicated, for a number of substrates 
that esterases are also present in the cytosol. The subcellular distribution of esterases 
involved in the hydrolysis of the pesticides of interest has not been defined. 
Preliminary experiments were therefore carried out using the substrate 
phenylacetate (PhAc) to detern-dne the distribution of phenylacetate esterase in the 
microsomal and cytosolic fractions of a number of tissues from the rat. 
10.2. SUBCELLULAR DISTRIBUTION OF ESTERASE 
10.2. i. Distribution of phenylacetate esterase during subcellular 
fractionation of rat liver 
I'lie following experiment was designed to determine the distribution of 
phenylacetate esterase activity in the subcellular fractions of the rat liver as well as to 
establish enzyme assay reproducibility within a single rat tissue. Esterase values in the 
following liver tissue fractions were examined: post mitochondrial , microsomes, 
cytosol and pre-mitochondrial sediment (containing mitochondria, nuclear fraction and 
cell wall debris). Esterase activity was examined in the pre-mitochondrial sediment of 
the rat tissue to establish how much activity, if any is trapped when the n-iitochondria, 
nuclear fraction and cell wall debris are initially spun down when preparing the post- 
mitochondrial fraction from the tissue homo-enate. 0 
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Methods 
Liver tissue was obtained from one male Wistar rat (190g). Four Ig 
portions of liver were taken from the same rat liver. Homogenates and subcellular 
fractions were prepared as previously described (see chapter 7). 
In all cases lmg original wet weight of liver was taken from each of the 
fractions and incubated with a final concentration of 0.4-4mM phenylacetate. 
Incubations were in a final volume of 3n-A in OAM trisma buffer ph8.0, containing 
O. ImM calcium chloride at 371C, in a cuvette. Reactions were started with the addition 
of phenylacetate (5gl-20gl of 6OOmM phenylacetate in DMSO). Cuvettes were inverted 
and then placed in the spectrophotometer. 
Results were expressed in gmol/nWg wet weight of tissue. Vmax and 
Km values were calculated by double reciprocal plot for liver sample. To determine the 
inter-assay variability of phenylacetate estemse in the subcellular fractions the 
coefficient of variation, over a range of substrate concentrations was were determined. 
This involved calculating the mean and standard deviation for the 4 liver samples at 
each of the substrate concentrations used in the experiment. Having calculated the 
coefficient of variation for the 4 liver samples at each of the substrate concentrations, 
these values were then the meaned. These calculations were carried out for each of the 
subcellular fractions. 
Results 
Results show that phenylacetate esterase is distributed in both microsomal 
and cytosolic fractions of the liver. In the liver it can be seen that 90% of the post- 
mitochondrial fraction esterase activity is due to the microsomal fraction, with the other 
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10% of esterase activity being found in the cytosol. High phenylacetate esterase activity 
was also seen in the pre-mitochondrial sediment. The apparent Km's were found to be 
similar in the post-mitochondrial and microsomal fractions, whereas it was found to be 
lower in the cytosolic and pre-mitochondrial fractions. These results can be seen on 
Table 10.1. 
Coefficients of variation were carried out to determine the inter-assay 
variability for each of the tissue fractions. Coefficient of variations were found to be 
lower in the post-mitochondrial and cytosolic fractions and higher in the microsomal 
and pre-mitochondrial sediment fractions. These can be seen on Table 10.1. 
Discussion 
The results show that most of the phenylacetate esterase activity in the 
liver is found in the n-dcrosomal fraction of the cell, with the cytosol having a 1/10 of 
the activity of the microsomes. It was also found that there was a great amount of 
phenylacetate esterase activity in the pre-mitochondrial fraction of the liver samples, 
indicating that a lot of the esterase activity from the microsomal or cytosolic esterase 
enzymes was being trapped down with the initial spins to produce the post- 
mitochondrial fraction. 
Apparent Km's seem to vary between tissue fractions. The apparent Km 
for microsomal arylesterase is more similar to the homogenate Km than the Km for 
cytosol. 71is is not surprising considering the majority of arylesterase activity is found 
in the microsomal fraction. 'I'lie Km value of the pre-mitochondrial fi-action cannot really 
be compared to the other Km values because incorporated into the fi-action are a 
combination of both microsomal and cytosolic esterase enzymes. 
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Table 10.1. The hydrolysis of phenylacetate to phenol by rat liver post-mitochondrial, 
microsomaI, cytosolic and pre mitochondrial sediment fractions. Results were expressed at the 
Vmax ( gmol/min/g wet weight tissue ) and the apparent Km (mM) by the double recipmcal 
plot. I 
T'issue fraction Vn= 
(gmol/min/g) 
Km 
(MM) 
CV for assay 
Post-mitochondrial 949±28 1.92±0.06 3.2 
Nlicrosomes 780±52 1.33±0.04 14.5 
Cytosol 101±3.2 0.40±0.04 2.7 
Pre-mitochondrial 518±88 0.93±0.2 18 
mean±SEM (four Ig portions fi-om same rat) 
CV. coefficient of variation. 
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In using 
- 
the experimental assay on one single day basis there will 
be a 3.2%, 14.5% and a 2.7% difference in phenylacetate esterase activities in the 
tissue post mitochondrial fraction, microsomes and cytosol respectively in liver tissue. 
'Me results also show that a lot of phenylacetate esterase activity is in fact trapped when 
the tissue debris and mitochondria are spun down. A variation of esterase activity in the 
order of 18% between assays was seen. This result could go to explain why there is a 
14% difference in arylesterase activities seen in the microsomal fraction, indicating that 
a proportion of microsomal esterase is being trapped down on the first spin. 
10.2. ii. NADPH cytochrome c(P450) reductase 
NADPH cytochrome c(P450) reductase was also measured in these 
studies as a marker for microsomal protein contamination. Measurements were carried 
out to determine whether there was any microsomal contamination of the cytosolic 
fraction when the subcellular fractions are spun down from tissue homogenate, to 
eliminate microsomal contamination as a source of cytosolic esterase activity. 
Method 
Liver and lung was obtained from 4 male Wistar rats (190g). 
Homogenates were prepared in 50mM trisma buffer, p1l 7.4 and from this microsomal 
and cytosolic fractions were prepared as previously described. 
The method of Gibson and Skett, (1986) was used in the experiment. 
50gl of the rat microsomal fraction from liver (0.28mg protein) and lung (0.1mg 
protein) were incubated with 250ýtl of cytochrome c (50mg to lOmIs water) and 
2.15mls of OAM trisma buffer pH 7.4, in a3 mls cuvette. This was run in parallel with 
50gl of the rat cytosolic fraction from liver (0.34mg protein) and lung (0.26mg 
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protein). 50gl of cytosol was incubated with 25%il of cytochrome c and 2.15 mls of 
0.1M trisma buffer pH 7.4, in a3 mls cuvette. 
Reactions were started with the addition of 2% NADPH (10mg to 0.5ml 
H20, prepared fresh) solution. The cuvettes were inverted and placed in a UV Kontron 
spectrophotometer and the rate of cytochrome c reduction was measured. 
Results 
Ile rate of cytochrome c reduction was expressed in nmol/min/mg of 
microsomal protein (see Table 10.2. ). From 
, 
the results it can be seen that cytosolic 
NADPH cytochrome c reductase was 4% of the microsomal, value in the liver and 3.3% 
for the lung. 
Discussion 
Results suggest the esterase activities found in the cytosolic fraction of the 
tissues studied previously is in fact as a result of cytosolic esterase activity, rather than 
as a result of microsomal esterase contamination of the cytosolic fraction. 
10.2. iii. Microsomal and cytosolic esterase distribution in rat tissues 
Having already established that phenylacetate esterase activity is 
distributed in the microsomal and cytosolic fractions of the rat liver, other tissues in the 
rat were studied to detennine the localisation of phenylacetate esterase activity in the rat. 
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Table 10.2. The NADPH cytochrome c(P450) reductase activity in rat liver and lung 
microsomal and cytosolic fractions. Results were expressed in gmol/min/mg tissue 
protein. 
Tissue NADPH cytochrome c reductase activity 
(gmol / min / mg protein) 
liver 52.4±26 
Nficrosomes Lung 32.018 
Liver 2.0±0.6 
Cytosol Lung 0.5±0.1 
mean+-SEM (n---4) 
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Methods 
Liver, lung, kidney, skin, brain, muscle and gut were removed from the 
same rat. Ig portions of each tissue were homogenized in I Oml of 0.1 M trisma buffer. 
Nficrosomal and cytosolic fractions were prepared as previously described (see chapter 
7). Mcrovilli where scrapped off from the 1g portion of the gut and used in the experiment. 
Tissue homogenate equivalent to 1.5mg (kidney, lung, muscle and gut), 
3mg (brain and liver) and 15mg of liver original wet weight was incubated with a final 
concentration of 0.4-4mM phenylacetate. Microsomal protein equivalent to 1.5mg 
(liver, kidney, lung and muscle ), 15mg (skin and brain) and 5mg (gut) original wet 
weight and cytosol protein equivalent to 1.5mg (liver, kidney and lung) and 15mg 
(skin, muscle, brain and gut) original wet weight was incubated with a final 
concentration of 0.4-4mM phenylacetate. Incubations were carried out in a volume of 
3mls of 50mM trisma buffer pH 8.0, containing 0.1 mM calcium chloride, in a cuvette. 
Reactions were started by the addition of phenylacýtate (5gl-20ýfl of 600mM 
phenylacetate in DMSO). The cuvettes were inverted and placed in the 
spectrophotometer. Phenol production was measured as previously described (see 
chapter 9.5. ) 
Results were expressed in gmollmin/g wet weight of tissue. Vmax and 
Krn values were calculated by double reciprocal plot for the tissue samples. 
Results 
Post-mitochondrial, microsornal and cytosolic phenylacetate esterase 
activity were measured in all the tissues studied. Phenylacetate esterase was expressed 
at Vmax and can be seen on Table 10.3. The hydrolysis of phenylacetate in the post- 
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Table 10.3. The hydrolysis of phenylacetate to phenol by rat post-mitochondrial, microsomal 
and cytosolic fractions in the tissues of the liver, lung, Iddney, sIdn, brain and gut. Results 
were expressed at the Vmax ( pmol/inin/g wet weight tissue or mI ) and the apparent Km (mM) 
calculated fi-om the double reciprwal plot. 
Tissue Vmax Km 
(jimol / min / g) (ýLm) 
Liver 947 1.96 
Kidney 52 0.65 
Post-mitochondrial Lung 35 1.20 
Skin 17 2.63 
Muscle 4 2.10 
Brain 5 1.80 
Gut 181 1.50 
Liver 865 2.4 
Kidney 24 0.62 
Microsomes Lung 17 2.5 
Skin 13 0.65 
Brain 4 1.8 
Gut 0.9 1.2 
Liver 102 2.2 
Kidney 17 0.34 
Cytosol Lung 17 2 
Skin 12 0.4 
Brain 0.9 1.4 
Gut 154 1.96 
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mitocondrial fraction of the liver was 5 times that of gut, 18 times that of kidney, 27 
times that of lung, 50 times that of skin, 200 times that of brain and 230 times that of 
muscle. Highest microsomal esterase activity was found in the liver and this was 
greater than 400 times that of the kidney. Esterase activity was similar in the skin and 
lung and lower in the brain and gut. In the cytosol the liver had the greatest amount of 
activity. The kidney, lung and skin cytosolic esterase activity was similar with lower 
activity in the brain. In the gut cytosol esterase activity was found to be very high. 
Vmax ratio's of esterase activity between the microsomal and cytosolic fractions were 
found to be different in the tissues studied. In the liver and brain most activity was 
found in the microsomes, whereas in the skin and gut most activity was found in the 
cytosol. In the lung and kidney there was equal distribution of esterase between the 
microsomes and cytosol. 
Apparent Km's for the post-mitochondrial fractions varied between 2.6 to 
0.65mM. The apparent Km's were found to be highest in the skin and similar in the 
liver, lung, skin and gut but lower in the, kidney. The apparent Km's for the 
microsomal fractions varied between 2.4 and 0.65. There was a similar spread of Km 
values in the liver, lung, brain and gut and apparently lower in the skin and kidney. A 
similar spread of apparent Km's for cytosolic esterases was seen as in the microsomal 
fractions with similar values in the liver, lung, brain and gut and lower values in the 
skin and kidney. These results can be seen on Table 10.3. 
Discussion 
The hydrolysis of phenylacetate by phenylacetate esterase occurs mainly 
in the post-mitochondrial fraction of the liver, although significant amounts of 
hydrolysis occured in the extrahepatic tissues of the Iddney, lung, sIdn, brain, muscle 
and the gut. The fact that most esterase activity is found in the liver is not surprising, 
considering the function of the liver is to metabolise exogenous and endogenous 
compounds in the body. 
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The gut arylesterase activity was high because of the contamination due to 
other enzymes, such as proteases, in the lumen of the gut. To be able to compare 
arylesterase activities with the other tissues trypsin would have to be incubated with the 
gut post-mitochondrial fraction. The trypsin would inhibit the protease enzymes but not 
the hydrolysis of phenylacetate. 
Most reported information on esterase activity has been centred on the 
microsomal fraction of the tissue, whereas little is available on cytosolic esterase 
activity in different tissues of the rat. Results presented here show that there is indeed 
esterase activity in both the microsomal and cytosolic fraction of the tissue studied. In 
the case of the skin and gut the majority of arylesterase activity was found in the 
cytosolic fraction, rather than the microsomal fraction. In the gut the majority of activity 
in the cytosol would be as a result of proteases rather than esterase activity. Results 
from the tissues studied would seem to indicate that the cytosol fraction contains an 
appreciable amount of esterase activity. When considering the overall contribution of 
esterases to the hydrolysis of phenylacetate both the cytosol and microsomal fi-actions 
contribute. 
Phenylacetate is a non-specific substrate for arylesterase activity. Results 
from the apparent Km's show that the arylesterase enzymes in the different fractions 
have a low affinity for phenylacetate in the liver, lung, brain and gut tissues, with a 
higher affinity in the skin and kidney. 
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CHAPTER 11: XENOBIOTIC METABOLISM IN THE RAT 
11.1. INTRODUCTION 
Having already established distribution and subcellular localisation in 
various tissues of the rat using the non-specific esterase substrate phenylacetate, the aim 
was to determine esterase activity in tissues of the liver, lung, skin and plasma for the 
pesticide substrates of interest. 
There are three main routes of exposure to pesticides: via the alimentary 
canal, the respiratory tract and through percutaneous absorption. Absorption of 
pesticides via the alimentary canal is small and and first pass metabolism of the 
pesticide would involve the liver, therefore this route of exposure was not considered 
further. As has already been stated one of the livers function is to metabolise exogenous 
and endogenous compounds in the body. Most esterase hydrolysis has been reported 
in the liver, however, little information is available on esterase hydrolysis in the tissues 
of the lung and skin. Exposure to pesticides occurs via inhalation or through dermal 
absorption and so the skin and lung would be exposed to the pesticide first. 
Experiments were therefore set up to determine whether local hydrolysis of the 
pesticides studied in the tissues of the lung and skin took place or if in fact hydrolysis 
of these pesticides was entirely due to esterase enzymes in the plasma and liver. 
Once initial exposure to a pesticide has taken place, by absorption 
through lung or skin, it is then transported via the systemic circulation to the liver. The 
proposed routes areas follows: 
Intra-dennal: skin ------ > blood ------ > liver 
Inhalation: lung ------ > blood ------ > liver 
The following pesticides were selected for study: paraoxon an 
organophosphate pesticide (see chapter 3.2. ); fluazifop-butyl an alkoxy phenoxy 
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propionate herbicide (see chapter 3.4. ); carbaryl an anticholinesterase insecticide (see 
chapter 3.3. ) and phenylacetate. Using these pesticides, attempts will be made to 
establish the extent of pesticide metabolism within the liver, lung, sIdn and blood. 
Furthermore what role they play in the overall detoxification of the pesticides. 
11.2. PROTEIN ESTIMATION IN RAT TISSUE 
Protein estimations in the microsomal and cytosolic fructions of the liver, 
lung and skin were carried out to determine the recoveries of protein in the experiment 
after the tissue subceUular fractions were prepared from the initial tissue homogenate. 
Methods 
Liver, lung, skin and blood were obtained from 6 male Wistar rats 
(190g). Homogenates, subcellular fractions and separation of blood were prepared as 
previously described in general methods (see chapter 7). 
Protein recoveries were made using a variation on the Lowry et al , (1956) 
method, by Peterson, (1977) (see chapter 7.5. ). 
Results 
Microsornal content of the sIdn was found to be a 1/10 and lung a 1/4 that 
of liver. The cytosolic protein content of the liver was similar to that of the lung, but 
lower in the skin. Microsomal protein recoveries were 3% liver, 1% lung and 0.2% 
skin, with cytosolic protein recoveries 3% liver, 2% lung and 1% skin . These results 
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can be seen on Table 11.1. 
11.3. FLUAZIFOP-BUTYL HYDROLYSIS 
Fluazifop-butyl was selected for study because it is - known to be readily 
hydrolysed by esterases to fluazifop acid. Little information however is available on 
what actual type of esterase acts to hydrolyse fluazifop-butyl to fluazifop-COOH (see 
chapter 3.4. ). In the studies presented localisation and subcellular distribution of 
esterase activity was examined in the liver, lung, skin and plasma of the rat. 
Methods 
Liver, lung, skin and blood were obtained form 6 male Wistar rats 
(190g). Preparation of microsomal and cytosolic fractions as well as blood separation 
was as previously described (see chapter 7). 
Microsomal. and cytosolic protein equivalent to 0.4,5 and 30mg of liver, 
lung and skin original wet weight (or 10gl of plasma and 50gl of lysed red blood cells) 
were incubated with a final concentration of 0.02-ImM fluazifop-butyl. Incubations 
were carried out in a final volume of 500gl in 50mM trisma buffer pH8.0, containing 
O. ImM calcium chloride at 370C. Reactions were started by the addition of fluazifop- 
butyl (5gl-20gl of I and lOmM stock, in acetonitrile) and stopped after 4 minutes for 
liver and plasma and 10 minutes for lung, skin and red blood cells by the addition of an 
equal volume of 6% perchloric acid, containing 109g1ml p-toluic acid (internal 
standard). Tubes were vortexed and centrifuged at 5440 xg for 5 minutes to remove 
protein. 801il of the supernatant was injected onto reverse phase HPLC (see chapter 
9.2. ). 
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Table 11.1. Protein recoveries for rat liver, lung and skin subcellular fractions. Results 
were expressed mg/g tissue protein. 
Tissue Protein recovery (mg / g) 
Liver 27.8±2.25 
Nlicmsomes Lung 8.65±1.5 
Skin 2.2±0.15 
Liver 32.5±1.0 
cytosol Lung 49.2±4 
Skin 8.8±1.25 
mean+-SEM (n=6) 
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Results were expressed in tenns of wet weight tissue, so that the results in 
the microsomal and cytosolic fracdons could be compared. Values for Vmax and 
apparent Km were calculated by direct linear plot for each tissue (see chapter 9.2. ). 
Results 
Fluazifop-butyl was hydrolysed to fluazifop by microsomal and cytosolic 
fractions from liver, lung and skin as well as by plasma and erythrocytes (see Table 
11.2 and Figure 11.1). Hydrolysis by liver rrýcrosomal esterase was 16 times that of 
lung and 300 times that of skin. Cytosolic esterase was greatest in the liver and similar 
to that of the microsomal activity. Liver cytosolic esterase was found to be 4 times that 
of lung and 17 times that of skin. Considering microsomal and cytosolic esterase 
activities together, the rat liver contains most fluazifop-butyl esterase activity followed 
by the plasma and then the lung, skin and erythrocytes. 
Apparent Km's for microsomal esterase varied between 14 and 33ýM, 
with Krn values in the liver and the skin similar and slightly higher in the lung. In the 
cytosol Km values varied between 22 and 63gM, with Km values lowest in the liver 
and highest in the lung (see Table 11.2. ). 
Discussion 
Fluazifop-butyl was hydrolysed by microsornal and cytosolic esterases in 
the liver, lung and skin as well as in the plasma and erythrocytes. Although most 
activity was found in the liver and plasma there was significant amounts of activity in 
the lung and skin. 
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Table 11.2. The hydrolysis of fluazifop-butyl to fluazifop by the rat liver, lung and skin 
subcellular fractions as well as by plasma and erythrocytes. Results were expressed as the 
Vmax ( pmollmin/g wet weight tissue or ml ) and the apparent Krn (pM) by direct linear 
plot. 
Type of Tissue Vmax Km 
(ýunol / min / g) 0-IM) 
Liver 6.29±0.4 14.4±2 
Nficrosomes Lung 0.38±0.1 33±5.5 
Skin 0.02±0.0015 14±2.8 
Liver 6.84+-0.85 22±4.5 
Cytosol Lung 1.5±0.32 63±14 
Skin 0.4±0.06 42±2.8 
Plasma 5.8±0.48 18.2±2.2 
Erythrocyte 0.03±0.015 33±1.2 
mean-+SEM (n=6) 
limit of sensitivity > 0.5nmol/nWg(rrd) 
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Figure 11.1. 
The hydrolysis of fluazifop-butyl to fluazifop in the presence of varying 
amounts of substrate by rat liver, lung and skin microsomal (M ) and cytosolic 
( [3 ) fractions as well as by plasma (Tj) and erythrocytes (0). Activities are 
presented as the Vmax ( gmol/niWg wet weight tissue ) determined by direct 
linear plot. 
Each point represents the mean of duplicate determinations and vertical lines 
represent mean±SEM ( n=6 ). 
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Liver Lung Skin Plasma Erythrocyte 
Fluazifop-butyl is applied in spray form and would therefore potentially 
come into contact with both uncovered skin and lung following inhalation. Exposure 
through inhalation is not thought to be a major route of exposure due to the spray 
particle size of fluazifop-butyl (Chester and Hart, 1986). The spray particles would be 
deposited in the upper airways of the lung rather than passing into the ý lung and 
therefore be absorbed orally. Following oral absorption first pass metabolism would 
take place in the liver. Therefore following exposure to fluazifop-butyl, local hydrolysis 
in the sIdn would play an important role in the hydrolysis of fluazifop-butyl to fluazifop 
_before 
it reached the systemic circulation and liver. 
The apparent Km's of the esterase enzyme for the fluazifop-butyl 
substrate were found to vary by 2-3 fold, being measured in gM. Previous calculated 
Km values for the arylesterase enzyme were measured in the mM range. The fact that 
the esterase enzyme is 5-10 fold more specific for fluazifop-butyl than for phenylacetate 
could indicate that either the esterase enzymes have different affinities for the same 
enzyme or that the enzymes acting on the two substrates are different. To determine the 
classification of the esterases hydrolysing fluazifop-butyl in the different tissues 
specific inhibitory studies need to be carried out (see later). 
11.4. CARBARYL HYDROLYSIS 
Carbaryl is a reversible anticholinesterase type insecticide belonging to the 
carbarnate family of insecticides (see chapter 3.3. ). Carbaryl is thought to be 
hydrolysed to 1-naphthol by the 'B' esterase, carboxylesterase (Kolbezen et al, 1954; 
Best and Murray, 1962). In ths study the localisation and subcellular distribution of 
carbaryl esterase hydrolysis was measured in the tissues of the liver, lung and skin as 
well as the plasma and erythrocytes. 
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Methods 
Liver, lung, skin and blood were obtained from 6 male Wistar rats 
(190g). Microsornal and cytosolic fractions as well as seperation of blood into plasma 
and erythrocytes were prepared as previously described (see chapter 7). 
ýA final concentration of 0-5OgM of carbaryl in 15gl of methonol was 
added into glass conical bottomed tubes. The methanol was evaporated off under 
nitrogen. NEcrosomal and cytosolic protein euivalent to 5,10 and 30mg of liver, lung 
and skin original wet weight or 20ýtl of plasma and 50ptl of erythrocytes was added to 
the tubes. Samples were then vortexed for 5 seconds. Incubations were carried out in a 
final volume of Iml in OAM phosphate buffer pH7.25 at 370C. Reactions were started 
with the addition of tissue to the carbaryl and stopped after 20 minutes by protein 
precipitation following addition of ethanol (500ýd per incubation) and then centrifuged 
at 5400 xg for 5 minutes. 50gl of supernatant was injected onto reversed phase HPLC 
(see chapter 9.3. ). 
Results were expressed in nmol/min/g of tissue wet weight or ml of 
plasma or red blood cells. Values for Vmax or apparent Km's were calculated by direct 
linear plot. 
Results 
In all the tissues studied increases in activity with substrate concentration 
was seen over the range studied. Activity increases could be described by Michaelis 
Menton Kinetics. Values for Vmax and apparent Km were calculated and can be seen 
on Table 11.3. 
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Table 11.3. The hydrolysis of carbaryl to I -naphthol by the rat liver, lung and sIdn 
subcellular fractions as well as by plasma and erythrocytes. Results were expressed as the 
Vmax ( nmol/min/g wet weight tissue or ml, ) and the apparent Krn (ýLM) by direct linear 
plot. 
Type of Tissue Vmax 
(pmol / min g) 
Km 
(PM) 
Liver 2.07±0.25 20±3.5 
NUcrosomes Lung 1.64±0.25 30±3.5 
Skin 0.19±0.035 32±4.2 
Liver 6.70±0.75 53±4.5 
Cytosol Lung 1.36±0.25 26±1.2 
SIdn 0.50±0.12 36±3.8 
Plasma 2.98±0.25 64±4 
Erythrocyte nd nd 
mean±SEM (n=6) 
limit of sensitivity > 0.3nmol/min/g(ml) 
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Carbaryl was hydrolysed to I-naphthol by nkrosomal and cytosolic 
esterase enzymes from the liver, lung and skin as well as by the plasma. The Vmax for 
liver microson-lal esterases was similar to that of lung and 10 times that of skin. Liver 
cytosolic esterase activity was 2 times that of plasma, 5 times that of lung and 12 times 
that of skin. Cytosolic esterase activity was found to be greater than microsomal 
esterase activity in the liver and skin and similar in the lung. Values for Vmax can be 
seen on Figure 11.2. 
The apparent Km's for microsomal esterase varied between 20 and 32gM. 
Values were found to be similar in skin and lung but lower in liver. Apparent Km 
values in the cytosolic esterases varied between 26 and 64gM. Cytosolic esterases had 
higher Km values than the microsomes, indicating a lower affinity. In the cytosol 
values were found to be similar in the liver and skin and lower in the lung. The 
apparent Km in the plasma was found to be be the same as that of the lung cytosol. 
These results can be seen on Table 11.3. 
Discussion 
Carbaryl was hydrolysed by n-dcrosomal and cytosolic fractions in the 
liver, lung and skin as well as the plasma. Most activity was found in the liver and 
plasma, however, there was also significant hydrolysing activity in the tissue of the 
lung and skin. Therefore, following exposure to carbaryl in rat, first pass metabolism 
would be expected to occur in the lung and skin before the carbaryl reached the 
systemic circulation and the liver . The skin is a more important route of exposure to 
carbaryl than the lung. Carbaryl in its spray form is 15-20ýtrn in diameter (Johnstone, 
1969; 1971) and so would be deposited in the upper airways, rather than being 
absorbed through the lungs. The deposited carbaryl in the upper airways would then be 
absorbed through the gut and be taken to the liver where it would be hydrolysed. 
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The hydrolysis of carbaryl to I-naphthol in the presence of varying amounts of 
substrate by rat liver, lung and skin microsomal (0) and cytosolic ( El ) 
fractions as well as by plasma (M) and erythrocytes (0). Activities are presented 
as the Vmax ( nmol/min/g wet weight tissue ) determined by direct linear plot. 
Each point represents the mean of duplicate detenninations and vertical lines 
represent mean-+SEM ( n=6 ). 
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Carbaryl hydrolysis was found to be greatest in the cytosolic fraction of 
the liver. A possible reason for this is that there is competition for carbaryl metabolism 
in the microsomal fraction of the liver. Carbaryl is metabolised by the oxidative 
pathway as well as being hydrolysed by the esterase in the liver microsomes, whereas 
in the Ever cytosol metabolism is entirely due to hydrolysis. Following hydrolysis of 
the carbaryl to 1-naphthol, the 1-naphthol is removed by phase II conjugation. The 
oxidative metabolism of carbaryl or the phase II conjugation of 1-naphthol was not 
investigated in this study. However, work has been carried out by MacPherson et al, 
(1991) on oxidative metabolism of carbaryl in the liver homogenate of the male Wistar 
rat. In the cytosol however, metabolism of carbaryl is due to hydrolysis by the 
esterase enzyme. 
The apparent affinities of the esterase enzyme for carbaryl are very similar 
to those found for fluazifop-butyl, in the RM range. Previous work (Kolbezen et a], 
1954; Best and Murray, 1962; Dorough, 1970) has suggested that the low anti- 
cholinesterase activity of carbaryl in mammals compared to insects is as a result of the 
capacity of the mammalian liver carboxylesterase to rapidly metabolize the carbaryl. 
Specific inhibitory studies using the carboxylesterase inhibitor BNPP would need to be 
carried out to determine whether in fact carboxylesterase is responsible for hydrolysing 
carbaryl to I-naphthol. 
11.5. PARAOXON HYDROLYSIS 
Paraoxon is an organophosphate pesticide developed after the second world 
war as a nerve gas. It is the active oxon of the pesticide parathion formed following 
activation by oxidative metabolism (see chapter 3.2. ). Paraoxon is hydrolysed to p- 
nitrophenol and diethylphosphoric acid by the 'A' esterase, paraoxonase. In this study 
the localisation and subcellular distribution of paraoxonase was studied in the tissuesl of 
the liver, lung and skin as well as in the plasma and erythrocytes. 
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Method 
Liver, lung, skin and blood were obtained from the same 6 male Wistar 
rats (190g). Microsomal and cytosolic fractions as well as separation of blood to 
plasma and erythrocytes was carried out as previously described. 
NEcrosomal and cytosolic protein equivalent to 0.5,20 and 30mg of liver, 
lung and skin original wet weight or lOgI plasma and 50gl of lysed erythrocytes was 
added with a final concentration of 0.1 -1 mM paraoxon. Incubations were carried out in 
a final volume of 500gl in 50mM trisma buffer pH8.0, containing O. ImM calcium 
chloride at 370C. Reactions were started with the addition of paraoxon (5-50gl of a 
lOmM stock, freshly prepared in trisma buffer) and stopped after 15 minutes by the 
addition of an equal volume of 6% perchloric acid, containing lOgg/ml p-toluic acid. 
Tubes were vortexed and centrifuged at 5440 xg for 5 minutes. 80gl of supernatant 
was injected onto reverse phase HPLC (see chapter 9.4. iii. ). Results were expressed in 
gmol p-nitrophenol/min/g of tissue wet weight or ml of plasma or erythrocytes. Values 
for Vmax and apparent Km were calculated ftom direct linear plot (see chapter 8). 
Results 
In all the tissues studied increases in activity with substrate concentration 
were seen over the range of concentrations studied. Activity increases could be 
described by Michaelis Menton Kinetics. Values for Vmax and the apparent Km's were 
calculated and presented in Table 11.4. 
Most paraoxonase activity was found in the liver microsomes and the 
plasma of the rat. There was 150 times more activity in the liver microsomes than in the 
lung, whereas in the sIdn microsomes or the erythrocytes no activity was detected (limit 
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Table 11.4. The hydrolysis of paraoxon to p-nitrophenol by the rat liver, lung and skin 
and subcellular fractions as well as by plasma. Results were expressed as the Vmax 
ýunol/min/g wet weight tissue or ml ) and the apparent Km, (gM) by direct linear plot. 
Tissue Vmax Km 
(pmol / min /g tissue) W) 
Liver 0.333±0.025 200±8 
Nlicrosome Lung 0.002±0.00025 380±30 
Skin nd nd 
Plasma 0.246+-+0.012 225±15 
Erythrocyte nd nd 
mean+-SEM (n=6) - 
limit of sensitivity > 0. ýarnol/rnin/g(rnl) 
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of detection > 0.3nmol/min/g(ml)). In the cytosolic fractions of the liver, lung and skin 
no paraoxonase activity was detected (limit of detection > 0.3nmol/min/g(ml)) (see 
Figure 11.3. ). 
The apparent Km's for microsomal paraoxonase varied between 200 and 
380gM, with the liver having a lower apparent Km value than the lung. The apparent 
Krn value in the plasma was fo und to be 225gM and this value was similar to that 
found in the liver microsomes. These results can be seen on Table 11.4. 
Discussion 
It is known that parathion is readily absorbed both through the lungs and 
skin. It was observed that paraoxon hydrolysis only took place in the microsomal 
fraction of the liver and lung tissue. No paraoxonase activity was found in any 
cytosolic fraction. In these tissues the parathion is activated to the active oxon paraoxon 
(Norman and Neal, 1975). It is this paraoxon which irreversibly inhibits cholinesterase 
and other 'B' esterases. Hydrolysis of paraoxon by paraoxonase occurs mainly in the 
liver microsomes and plasma. There was some activity found in the lung microsomes 
but none was found in the skin microsomes. In the rat, following exposure, little 
paraoxon hydrolysis would be expected to take place in the extra-hepatic tissues of the 
lung and the skin. Although there is some paraoxonase activity in the lung microsomes 
this would not be sufficient to hydrolyse the paraoxon before it started to inhibit 
acety1cholinesterase in the body. Plasma paraoxonase activity has an important role to 
play in paraoxon hydrolysis. Respiratory failure occurs as a result of acetyl 
cholinesterase inhibition at the lung and the respiratory centre of the brain (Charnbers 
Z gl, 1989). The more paraoxon hydrolysis taking place in the plasma during first pass 
metabolism would reduce the effect of paraoxon on the respiratory centre of the brain 
Although there is substantial paraoxonase activity in the liver microsomes, it would 
only play an important role in detoxification of paraoxon if in fact the absorbed 
paraoxon was taken to the liver for detoxification before it reached the respiratory centre 
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Figure 11.3. 
The hydrolysis of paraoxon to p-nitrophenol in the presence of varying amounts 
of substrate by rat liver (0), lung (a) and skin (CI) microsomes as well as by 
plasma ( IM ) and erythrocytes ( 0). Activities are presented as the Vmax 
gmol/min/g wet weight tissue) determined by direct linear plot. 
Each point represents the mean of duplicate determinations and vertical lines 
represent mean±SEM ( n=6 ). 
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in the brain, however, following initial exposure the absorbed paraoxon is taken 
straight to the brain, by-passing the liver. Only on subsequent passes would the liver 
play an important role in the detoxification, or if in fact the paraoxon was ingested 
orally in which case first pass metabolism would take place in the liver. 
, 
The absence of paraoxon hydrolytic activity in the cytosolic fractions 
indicates the involvement of different esterases compared to those hydrolysing 
fluazifop-butyl and carbaryl. The apparent Km's of the paraoxonase enzyme for the 
paraoxon are around 6-10 fold greater than those for carbaryl and fluazifop-butyl. 
Although the distribution of paraoxonase and phenylacetate esterase is very similar, 
there is however, a small amount of phenylacetate esterase activity taking place in the 
cytosolic fractions of the liver, lung and skin (see later). Inhibitory studies of 
phenylacetate hydrolysis will be able to determine if in fact the esterase enzymes acting 
to hydrolyse paraoxon and phenylacetate are similar. 
11.6. PHENYLACETATE HYDROLYSIS 
As has already been discussed phenylacetate is a non-specific substrate for 
esterase. Phenylacetate is hydrolysed by arylesterase to phenol and acetic acid. 
Localisation and subcellular distribution of arylesterase activity in the tissues of the 
liver, lung and skin as well as in the plasma and erythrocytes of the blood. 
Methods 
Liver, lung, skin and blood was obtained from the same 6 male Wistar 
rats (190g). Microsomal and cytosolic fractions as well as separation of blood into 
plasma and erythrocytes was prepared as previously described (see chapter 7). 
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Microsomal. and cytosolic protein equivalent to 2,20 and 30mg of liver, 
lung and skin original wet weight or 10gl of plasma and 50gl of lysed red blood cells 
were incubated with a final concentration of 0.5-4mM phenylacetate. Incubations were 
carried out in a volume of 3mls in 50mM trisma. buffer pH8, containing 0.1 mM calcium 
chloride at 370C, in a cuvette. Reactions were started with the addition of phenylacetate 
(5gl-20gl of 600mM phenylacetate stock in DMSO). The cuvettes were inverted and 
then placed in the spectrophotometer (see chapter 9.5. iii. ). Results were expressed in 
terms of gmol/min/g wet weight of tissue or ml of plasma or erythrocytes. Values for 
Vmax and apparent Km were calculated using the direct linear plot. 
ResuIts 
In all the tissues studied increases in activity with substrate concentration 
were seen over the range of concentrations studied. Activity increases could be 
described by Michaelis Menton Kinetics. Values for Vmax and the apparent Km's were 
calculated and can be seen on Table 11.5. 
Phenylacetate was hydrolysed to phenol by microsomes and cytosol from 
liver, lung and skin as well as by plasma. Hydrolysis by liver n*rosomal arylesterase 
was 160 times that of lung and 200 times that of skin. Liver cytosolic arylesterase was 
2 times that of lung and 9 times that of lung (see Figure 11.4. ). Although liver cytosol 
contains the greatest cytosolic arylesterase activity, it was found to be 20 times less 
active than liver microsomal arylesterase. The plasma contains a high amount of 
arylesterase activity compared to that of the lung and skin. 
Ile apparent Km's for microsomal esterases varied between 0.95 and 
1.46mM. Apparent Krn values were similar in the liver and lung and lower in the skin. 
Ile apparent Km values for cytosolic esterase varied between 0.34 and 1.33mM. 
Apparent Km values were found to be lowest in the skin cytosol and highest in the lung 
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Table 11.5. The hydrolysis of phenylacetate to phenol by rat liver, lung and skin subcellular 
fractions as well as by plasma and erythrocytes. Results were expressed as the Vmax 
ýtmol/rnin/g wet weight tissue or ml ) and the apparent Krn (mM) by direct linear plot. 
Type of Tissue Vn= Km 
(umol / min /g tissue) (MM) 
Liver 800±75 1.43±1.4 
Nficrosomes Lung 4.86±3.1 1.46±0.58 
Skin 1.13±0.025 0.95±0.1 
Liver 30.7±3.0 0.9±0.5 
Cytosol Lung 14.2±5.5 1.33±0.55 
Skin 3.44±1.4 0.34±0.05 
Plasma 290±40 2.34±0.4 
Erythrocytes nd nd 
mean+-SEM (n=6) 
limit of sensitivity of assay > 0.3gmol/min/g(ml) 
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Figure 11.4. 
The hydrolysis of phenylacetate to phenol in the presence of varying amounts of 
substrate by rat liver, lung and skin microsomal ( ID ) and cytosolic ( E] ) 
fractions as well as by plasma (0) and erythrocytes ( 11 ). Activities are 
presented as the Vmax ( grnol/min/g wet weight tissue ) determined by direct 
linear plof. 
Each point represents the mean of duplicate determinations and vertical lines 
represent mean+-SEM ( n=6 ). 
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cytosol. The apparent Km value for plasma was found to be apparently higher than any 
Krn value in either the microsmal or cytosolic tissues studied. These results can be seen 
on Table 11.5. 
Discussion 
Liver arylesterase activity was very much greater than activities in the 
extra-hepatic tissues of the lung, skin and plasma. Ilese results confirm preliminary 
studies carried out with phenylacetate as substrate. The distribution of microsomal 
arylesterase is very similar to that of paraoxonase for the microsomal component and 
supports the involvement of 'A' esterases in both reactions. 
'Fhe apparent affinity of arylesterase for phenylacetate was about 5 fold 
less than the affinity of paraoxonase for paraoxon. Reported information on 
arylesterase and paraoxonase is conflicting. Some believe that arylesterase and 
paraoxonase belong to the same enzyme (ie. Eckerson and La Du, 1983), whereas 
others believe that they are in fact different 'A' esterase enzymes (ie. Reineret al, 1987; 
Mackness et al, 1987). Although there was a5 fold difference in Km values this was 
not enough to indicate a difference in enzymes acting on phenylacetate and paraoxon, 
particularly when considering the contrasting studies in the literature. Studies carried 
out in this study would seem to point to a more specific enzyme acting to hydrolyse 
paraoxon than phenylacetate, however, until purification and separation of the 'A' 
esterase enzyme have been carried out and the 'A' esterase fully characterized no real 
conclusion can be made. 
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CHAPTER 12: INHIBITORY STUDIES IN THE RAT 
12.1. INTRODUCTION 
Inhibitory studies were carried out to confirm the type of esterase enzymes 
acting to hydrolyse fluazifop-butyl, carbaryl and phenylacetate in the tissues of the 
liver, lung and skin as well as in the plasma. The classical inhibitors of paraoxon, 
BNPP, mercury chloride and physostigmine were used to establish what type of 
esterase was responsible for hydrolysing the different substrates. Paraoxon inhibits 'B' 
esterases including cholinesterase and carboxylesterase, BNPP is a differential inhibitor 
for carboxylesterase activity and physostigmine, an anticholinesterase, inhibits 
cholinesterase and to some extent carboxylesterase. Mercury chloride inhibits enzymes 
which contain an -SH group (cysteine) at the active centre of the enzyme i. e. an 'A' 
esterase (Brandt et al, 1980). 
12.2. FLUAZIFOP-BUTYL ESTERASE 
Studies were therefore designed to determine whether fluazifop-butyl was 
hydrolysed by carboxylesterase or by cholinesterase. Inhibition studies on fluazifop- 
butyl esterase were carried out in both microsomal and cytosolic fractions of the liver, 
lung and skin as well as in the plasma. 
Methods 
Liver, lung, skin and plasma were obtained from the same 6 male Wistar 
rats (190g). Microsomal and cytosolic fraction as well as plasma separation from blood 
was were prepared as previously described. 
Incubations were carried out in a final volume of 500gl in 50mM trisma 
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buffer pH8.0, at 371C. Microsomal and cytosolic protein equivalent to 0.4,5 and 30mg 
of liver, lung and skin original wet weight or Mýtl of plasma were incubated along with 
O. ImM paraoxon, O. ImM BNPP, O. lmM physostigmine (final concentration) and 
fluazifop-butyl. O. lmM 4-hydroxymercuribenzoate was incubated along with lOgI of 
plasma and fluazifop-butyl. Final concentrations of 300gM for liver, 50[LM for lung, 
30gM for skin and 200gM for plasma of fluazifop-butyl were used in the incubations. 
Control incubations without any inhibitors in the incubation were carried out in parallel. 
Reactions were started by the addition of fluazifop-butyl (10-20gl of aI and 10 mM 
stock in acetonitrile) and stopped after 10 minutes by the addition of 6% perchloric 
acid, containing lOgg/ml p-toluic acid (internal standard). Tubes were vortexed and 
centrifuged at 5440 xg for 5 minutes. 80gl of the supernatant was injected onto 
reversed phase HPLC ( see chapter 9.2. ). 
Incubations containing the inhibitors of paraoxon, BNPP physostigmine 
and 4-hydroxymercuribenzoate were compared directly to control incubations. 
Conversion to product in the presence of inhibitor was determined as previously 
described (see chapter 9.2. ii. ). Inhibition was estimated by expressing remaining 
activity in the presence of the inhibitor as a percentage of the control activity. 
Results 
Using the inhibitor paraoxon the percentage of remaining activities of the 
control were 2±0.25,10±0.75 and 17±3 for liver, lung and skin microsomes and 2±1, 
9±6.5 and 2±2 for liver, lung and skin cytosol as well as 4±0.25 for plasma. Using the 
inhibitor BNPP the percentage of remaining activities of control were 33±8,67±6.5 
and 40±4.5 for liver, lung and skin microsomes and 20±2,41±2.5 and 26±2.5 for 
liver, lung and skin cytosol as well as 63±3 for plasma. Using the inhibitor 
physostigmine the percentage of remaining activities of the control were 64±3.5,100 
and 80±2 for liver, lung and skin microsomes and 69±4.8,95±3.5 and 86±2.5 for 
liver, lung and skin cytosol, as well as 84±2 for plasma. Using the inhibitor 4- 
142 
hydroxymercuribenzoate, 'the % of remaining activity of the control was 100±0 for 
plasma. These results can be seen on Table 12.1. 
Inhibition of the microsomal fraction by paraoxon varied from complete 
inhibition in the liver to around 85% inhibition in the s1dn. Inhibition of the microsomal 
fraction by BNPP varied between 70% in the liver and skin to 35% in the lung. 
Inhibition of the microsomal fraction by physostigmine varied from 30% in the liver to 
no inhibition in the lung (see Figure 12.1. ). Results of inhibition of the cytosolic 
fraction by paraoxon,, BNPP and physostigmine were found to be similar to those 
found in the microsomes (see Figure 12.2. ) 
Discussion 
Paraoxon caused almost complete inhibition in the tissues studied, in both 
microsomal and cytosolic fractions as well as in the plasma. Paraoxon inhibits '13' 
esterases by irreversibly phosphorylating the serine residues at the active centre of the 
enzyme. Results indicate that the microsomal and cytosolic esterases responsible for 
fluazifop-butyl hydrolysis are '13' esterases. Results using mercuric chloride, an 'A' 
esterase inhibitor seem to back up the results seen with paraoxon. In the plasma no 
inhibition of fluazifop-butyl hydrolysis was seen, indicating that no 'A' esterases are 
acting to hydrolyse fluazifop-butyl. However, high inhibition was seen 
in the liver cytosol 
(93%) whichdo not seem to fit with the other inhibitory results. 
BNPP also phosphorylates the serine residue at the active centre of the '13' 
esterase, but less efficiently than paraoxon. BNPP is a differential inhibitor of 
carboxylesterase. There is very little information on the classification of cytosolic 
esterases, most information dealing with carboxylesterase activity has been centred on 
the microsomal fraction of the cell (Junge and Krisch, 1975). Results in this study, 
however, indicate that carboxylesterase activity is also found in the cytosolic as well as 
microsomal fraction of the cell. Mentlein et al, (1986) found a differential effect on 
143 
Table 12.1. Inhibition of fluazifop-butyl hydrolysis to fluazifop in rat liver, lung and skin 
subcellular fractions as well as plasma by O. ImM BNPP, physostigmine, HgC12 and 
paraoxon. Results were expressed as the % remaining activity of control. 
Tissue Substrate % Remaiýg activity 
(PM) 
control +BNPP +Physostigmine +HgC12 +Paraoxon 
Liver 300 100 33±8 64±5 60±7.5 2±0.25 
Nlicrosomes Lung 30 100 67±6.5 100 - 10±0.75 
Skin 20 100 40±4.5 80±2 17±3 
Liver 300 100 20±2 69±4.8 
Cytosol Lung 60 100 41±2.5 95±3.5 
Skin 40 100 26±2.5 86±2.5 
Plasma 200 100 63±3 84±2 
mean±SEM (n=6) 
7±1.2 2±1 
9±6.5 
2±2 
100±0 4±0.85 
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Figure 12.1. 
Inhibition of fluazifop-butyl hydrolysis to fluazifop in rat liver (M), lung ( ?2) 
and skin ( 0) microsomes by O. ImM BNPP, physostigmine, HgC12 and 
paraoxon. Results were expressed as the % remaining activity of the control. 
Each point represents the mean of duplicate determinations and vertical lines 
represent mean-+SEM ( n=4 ). 
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Figure 12.2. 
Inhibition of fluazifop-butyl hydrolysis to fluazifop in rat liver (N), lung ( 12 ) 
and skin ( El ) cytosol as well as by plasma ( E] ) by 0.1 mM BNPP, 
physostigmine, HgC12 and paraoxon. Results were expressed as the % 
remaining activity of the control. 
Each point represents the mean of duplicate determinations and vertical lines 
represent mearL+-SEM ( n=4 ). 
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carboxylesterase isoenzymes in rat liver microsomes. Results show that there was 
between 60-80% inhibition in the tissues of the skin and liver and 40% inhibition in the 
plasma of fluazifop-butyl hydrolysis. In the lung rnicrosomes there was only about 
20% inhibition, whereas in the lung cytosol, inhibition was about 60%. A possible 
reason for the low inhibition of carboxylesterase in the lung microsomes could be as a 
result of a different population of carboxylesterase isoenzymes which contribute to 
fluazifop-butyl hydrolysis. The more specific phosphate inhibitors such as 4-cyano bis- 
nitrophenol phosphate would have been used to further assess the carboxylesterase, 
but it was not possible to obtain this. These results were similar to those found by 
Gaustad et a], (1991). They found that in the lung of the guinea-pig, BNPP had little 
effect on a specific carboxylesterase isoenzyme (pI<4.2). Hydrolysis was a two phase 
reaction with two different first order rate constants for BNPP inhibition. This 
indicated two different forms of the isoenzyme with different sensitivities towards the 
enzyme. Plasma was around 40% inhibited by BNPP. This seems to agree with the 
fact that the rat, unlike the human contains carboxylesterase in the plasma. 
Physostigmine is a specific inhibitor of cholinesterase but also 
carboxylesterase to a lesser extent. Results show that there was between 0-30% 
inhibition of the liver and skin microsomal and cytosolic esterase, but no inhibition in 
the lung fractions. It would therefore seem that taking into consideration the BNPP and 
physostigmine results, although there is cholinesterase in the tissues of the liver and 
skin it is not important in the metabolism of this substrate. What inhibition that is seen 
would be more likely to be inhibition of the carboxylesterase. 
It would therefore seem that the esterase enzyme acting to hydrolyse 
fluazifop-butyl to fluazifop in the microsomal and cytosolic fractions of the rat liver, 
lung, and skin as well as in the plasma are the carboxylesterases. 
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12.3. CABARYL ESTERASE 
Previous studies of carbaryl metabolism suggested that it was hydrolysed 
to 1-naphthol by carboxylesterase enzyme (Kolbezen et al, 1954; Best and Murray, 
1962). Inhibitory studies were therefore designed to look at inhibition of carbaryl 
hydrolysis in the microsomal and cytosolic subcellular fractions of the liver, lung and 
skin as well as in the plasma to determine whether fluazifop-butyl was hydrolysed by 
carboxylesterase or if in fact it was also hydrolysed by cholinesterase. 
Methods 
Liver, lung and skin as well as plasma was obtained from the same 4 male 
Wistar rats (I 90g). Ig portions of tissue was homogenized into I Omls of 50MM trisma 
buffer, ph8.0. Microsomal and cytosolic fraction as well as plasama, separation from 
blood was prepared as previously described ( see chapter 7). 
A final concentration of 25gM carbaryl in 15gl of methanol was added to 
round bottomed conical tubes. The methanol was evaporated off under nitrogen. 
Microsomal and cytosolic protein equivalent to 5,10 and 30mg of liver, lung and sldn 
original wet weight or 20gl of plasma were incubated along with , 0.1 mM BNPP and 
physostigmine (final concentration). Incubations were carried out in a final volume of 
Iml in OAM phosphate buffer pH7.25, at 370C, Control incubations without any 
inhibitors in the incubation were carried out in parallel. Reactions were started with the 
addition of the tissue and stopped after 20 minutes by protein precipitation following 
the addition of ethanol (500gl per incubation) and then centrifuged at 5440 xg for 5 
minutes. 501LI of supernatant was injected onto reversed phase HPLC as described (see 
chapter 9.3. iii. ). 
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Incubations containing the inhibitors of BNPP and physostigmine were 
compared directly to control incubations. Conversion to product in the presence of 
inhibitor was determined as previously described (see chapter UAL). Inhibition was 
estimated by expressing remaining activity in the presence of the inhibitor as a 
percentage of the control activity. 
Results 
Using the inhibitor BNPP, the percentage of remaining activities of 
control were 72±3,59±4 and 76±7.5 for liver, lung and skin microsomes and 79±3.2, 
70±6.2 and 64±8.8 for liver, lung and skin cytosol as well as 56±3 for plasma. Using 
the inhibitor physostigmine the percentage of remaining activities of control were 96±2, 
74±5 and 89±5 for liver, lung and skin microsomes and 97±1.8,98±1.5 and 88±7 for 
liver, lung and skin cytosol as well as 93±2.5 for plasma. These results can be seen on 
Table 12.2. 
Inhibition of the microsomal fraction by BNPP varied between 30-40% 
for the liver, lung and skin. Inhibition of the microsomal fraction by physostigmine 
varied between 20-40% for the liver, lung and skin (see Figure 14.3. ). Inhibition of the 
cytosol fraction by BNPP varied between 5-25% for the liver, lung and skin. Inhibition 
of the cytosolic fraction by physostigmine varied between 2- 10% for the liver, lung and 
skin as well as by 7% in the plasma (see Figure 12.4. ). 
Discussion 
From the results it can be seen that physostigmine seems to have little 
inhibitory effect on carbaryl. hydrolysis in the skin, liver, lung and plasma except for 
the lung microsomes which is inhibited by 26%. Apart from the lung it would seem that 
149 
Table 12.2. Inhibition of carbaryl hydrolysis to 1-naphthol in rat liver, lung and skin 
subcellular fi-actions as well as plasma by O. ImM BNPP and physostigmine. Results were 
expressed as the % remaining activity of control. 
% Remaiýg acdvity 
Tissue Substrate (gM) control +BNPP +Physostigmine 
Liver 25 100 72±3 96±2 
Microsomes Lung 25 100 59±4 74±5 
Skin 25 100 24±7.5 89±5 
Liver 25 100 80±4.2 97±1.8 
Cytosol Lung 25 100 70±6.2 97±1.5 
Skin 25 100 64±8.8 88±7 
Plasma 25 100 56±3.5 93±2.5 
mean+-SEM (n---4) 
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Figure 12.3. 
Inhibition of carbaryl hydrolysis to 1-naphthol in rat liver (0), lung (0) and 
skin microsomes by O. ImM BNPP and physostigmine. Results were 
expressed as the % remaining activity of the control. 
Each point represents the mean of duplicate determinations and vertical lines 
represent mean+-SEM ( n=4 ). 
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Figure 12.4. 
Inhibition of carbaryl hydrolysis to 1-naphthol in rat liver ( 0), lung (Z2) and 
skin ( El ) cytosol as well as by plasma ( 01) by O-ImM BNPPand 
physostigmine. Results were expressed as the % remaining activity of the 
control. 
Each point represents the mean of duplicate determinations and vertical lines 
represent mean+-S EM ( n=4 ). 
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cholinesterase has little effect on carbaryl hydrolysis. There is between 20-36% 
inhibition of carbaryl hydrolysis by BNPP with the microsomal and cytosolic fractions 
of the liver, lung and skin as well as by the plasma. It would therefore seem that 
carbaryl was hydrolysed by carboxylesterases. 
12.4. PHENYLACETATE ESTERASE 
Inhibitory studies were conducted to detennine the nature of esterases 
hydrolysing phenylacetate in the subcellular fractions of the liver, lung and shin tissues 
as well as the plasma. 
Methods 
Liver, lung and skin as well as plasma were obtained from the same 6 
male Wistar rats (190g). Ig portions of tissue were homogenized in l0mls of MmM 
trisma buffer, ph8.0. Microsomal and cytosolic fractions as well as plasma separation 
were prepared as previously described (see chapter 7). 
Incubations were canied out in a final volume of 3mls in 5OmM trisma 
buffer pH8, at 370C. Microsomal and cytosolic protein equivalent to 2,20 and 30mg of 
liver, lung and skin original wet weight or lOgI of plasma with a final concentration of 
O. ImM paraoxon, O. ImM mercury chloride, O. lmM BNPP or O. lmM physostigmine. 
A final concentration of 2mM phenylacetate was used in the incubation. Control 
incubations without any inhibitors in the incubations were carried out in parallel. 
Reactions were started with the addition of phenylacetate (10gl of 600mM 
phenylacetate stock). The cuvettes were inverted and then placed in the 
spectrophotometer (see chapter 9.5. ). 
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Incubations containing the inhibitors of paraoxon, BNPP, mercury 
chloride and physostigmine were compared directly to control incubations. Conversion 
to product in the presence of inhibitor was determined as previously described (see 
chapter 10.5. ii. ). Inhibition was estimated by expressing remaining activity in the 
presence of the inhibitor as a percentage of the control activity. 
Results 
Table 12.3. presents the results of phenylacetate esterase inhibition in the 
rat liver, lung and skin subcellular fractions as well as plasma by O. lmM paraoxon, 
BNPP, physostigmine and mercuric chloride. 
Inhibition of microsomal arylesterase by BNPP varied from 16% in the 
liver to 0% in the skin microsomes, whereas inhibition due to physostigmine varied 
from 13-19% in the liver and lung to 40% in the skin microsomes (see Figure 12.5. ). 
Inhibition of cytosolic arylesterase by BNPP varied from 25-35% in the liver and skin 
to 0% in the lung cytosol, whereas inhibition due to physostigmine varied from 20- 
40% in the liver and skin to 96% in the lung (see Figure 12.6. ). Inhibition by mercury 
chloride, an inhibitor of cysteine containing groups ('A' esterases) was found to be 
40%, 15% and 27% in the liver, lung and skin microsomes and 7%, 38% and30% in 
the liver, lung and skin cytosol. 
In the plasma there was 19% inhibition of phenylacetate hydrolysis by 
BNPP and only 11% inhibition due to physostigmine. 
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Table 12.3. Inhibition of phenylacetate hydrolysis to phenol in rat liver, lung and skin 
subcellular fractions as well as plasma by O. ImM BNPP, HgC12, physostigmine and 
paraoxon. Results were expressed as the % remaining activity of the control. 
Tissue Substrate % Remaining activity 
(11M) 
control +BNPP +HgCI2 +Physostigmine +Paraoxon 
Liver 2 100 84±3.5 60±16 87±1 50±3.8 
Microsomes Lung 2 100 94±5 85±12 81±5 37±8.5 
Skin 2 100 100 73±14 60±10 38±8.6 
Liver 2 100 75±12 93±1.2 57±14 33±7.5 
Cytosol Lung 2 100 100 62±17 4±2.5 48±5 
Skin 2 100 65±5 30±10 78±1.8 35±5 
Plasma 2 100 81±4 59±2.5 89±4 83±5 
mean+-SEM (n=6) 
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Figure 12.5. 
Inhibition of phenylacetate hydrolysis in rat liver (M), lung (0) and skin (I. E.. '-P 
microsomes by O. ImM BNPP, physostigmine, HgCý and paraoxon. Results 
were expressed as the % remaining activity of the control. 
Each point represents the mean of duplicate determinations and vertical lines 
represent mean±SEM ( n=4 ). 
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Figure 12.6. 
Inhibition of phenylacetate hydrolysis in rat liver (M), lung (0) and skin (a) 
cytosol as well as by plasma (EI) by 0.1 mM BNPP, physostigmine, HgCý and 
paraoxon . Results were expressed as the % remaining activity of the control. 
Each point represents the mean of duplicate determinations and vertical lines 
represent mean+-S EM ( n=4 ) 
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Discussion 
Paraoxon caused between 50-60% inhibition of phenylacetate hydrolysis 
in the liver, lung and skin microsomes and between 50-80% inhibition in the cytosolic 
fi-actions . It would therefore seem that a lot of phenylacetate hydrolysis is taking place 
as a result of 'B' esterases. Inhibition of phenylacetate hydrolysis by mercury chloride 
was seen in microsomal and cytosolic fractions from the liver, lung and skin, indicating 
the presence of the arylesterase enzyme. Results using paraoxon and mercury chloride 
seem to compliment each other i. e. a high paraoxon inhibition of phenylacetate 
hydrolysis in liver cytosol (67%) is complimented by a low inhibition by mercury 
chloride (7 %). 
Inhibition of hydrolysis by BNPP or physostigmine was very low, 
varying from 0-19% between the different tissues. The skin microsomes, however had 
40% inhibition of the phenylacetate esterase indicating that a lot of phenylacetate 
hydrolysis in the skin rrftrosomes is due to cholinesterase. If phenylacetate esterase in 
the skin microsomes is due to cholinesterase rather than 'A' esterase activity, the 
microsomal esterase distribution in paraoxon and phenylacetate hydrolysis is very 
similar, with esterase activity being found in the liver, lung and plasma. 
In the liver cytosol there was little inhibition of phenylacetate esterase by 
mercury chloride, an 'A' esterase inhibitor, but inhibition by paraoxon. It would 
therefore seem that in the liver cytosol hydrolysis of phenylacetate was due to '13' type 
esterases. In the lung and skin cytosol inhibition of phenylacetate esterase seems to be 
due to a combination of both 'A' and '13' type esterase. 
In the plasma there was not much inhibition of phenylacetate hydrolysis 
by either BNPP or physostigmine. This would seem to indicate that most of the 
phenylacetate hydrolysis in the plasma is due to arylesterase activity rather than by '131 
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esterase. 
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, CHAPTER 13: INDUCTION STUDIES IN RAT 
13.1. INTRODUCTION 
The effects of the classical inducers, phenobarbitone, B-naphthoflavone 
and clofibric acid on the hydrolysis of paraoxon, fluazifop-butyl , carbaryl and 
phenylacetate by esterase in rat liver, lung and skin was investigated. Most work on 
the induction has involved the monoxygenases and conjugating enzymes, whereas there 
has been little investigation of esterase induction. 
It has been reported by Satoh and Moroi, (1973) that hepatic microsomal 
carboxylesterases are induced by phenobarbital, whereas 3-methylcholanthrene type 
inducers have no effect. Work by Raftell et al (1977) found no induction of the lung 
carboxylesterase by phenobarbital. Therefore experiments were set up to examine these 
findings as well as to establish if carboxylesterase induction took place in the skin 
microsomes as well as in the cytosolic fractions of the liver, lung and skin. 
Animal Induction 
Liver, lung, skin and blood were obtained from 18male Wistar rats Male 
Wistar rats were treated by intraperitoneal injection with phenobarbitone (80mglkg in 
0.9% aqueous NaCI for 3 days), B-naphthoflavone (50rng/kg in corn oil for 3 days), 
clofibric acid (200mg/kg in H20 adjusted to ph8.5 with NaOH for 3 days) or saline 
(for 3 days). Animals were killed approximately 24 hours after the last treatment and 
liver, lung and skin were obtained. 
Preparation of liver and lung tissues from each of the induced tissues 
were weighed. Nficrosomal and cytosolic fractions of the liver, lung and sIdn were 
prepared as previously described (see chapter 7.3. ). Hydrolysis of fluazifop-butyl, 
carbaryl, paraoxon and phenylacetate was measured. 
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Statistical Analysis 
In the study results were statistically analysed by analysis of variance and 
then further by Tukey's HSD (Honestly Significant Difference) test (Tukey, 1949). 
This is used for testing the null hypotheses that all possible pairs of treatment means are 
equal when the samples are all of the same size. 
Tukey's test, which is usually referred to as the HSD test, makes use of a 
single value against which all differences are compared. This value called the HSD, is 
given by 
MSE 
HSD = cO, N-k n 
wherect is the chosen level of significance, k is the number of means in the experiment, 
N is the total number of observations in the experiment, n is the number of 
observations in a treatment, MSE is the error mean square from the analysis of variance 
table, and q is obtained by entering the values ofcK, k and N-k into the 5% points of the 
studentized range. 
All possible differences between pairs of means are computed and any 
difference which yields an absolute value that exceeds HSD is declared to be 
significant. 
13.2. PROTEIN ESTIMATION 
Protein estimations in the microsomal and cytosolic fractions of the liver, 
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lung and skin were carried out in the presence of the classical inducers of 
phenobarbitone, 13-naphthoflavone and clofibric acid to detennine whether hyperplasia, 
or hypertrophy took place in the tissues studied. 
Methods 
Protein estimations were determined by the method of Peterson et a], 
(1977) (see chapter 7.5. ). 
Results 
The tissue weights following the addition of phenobarbitone, B- 
napthoflavone and clofibric acid can be seen on Table 13.1. Although the results show 
that there is an increase in size of liver (hypertrophy) and lung with the inducers this 
increase was not satisticaUy significant for any treatment. 
ResuIts for protein recoveries were measured in mg/g of tissue protein. 
The protein estimations following the addition of phenobarbitone, B-napthoflavone and 
clofibric acid can be seen on Table 13.2. The results of the protein recoveries show 
that although there was some increase tissue protein (hyperplasia) it was not 
statistically significancant for any of the treatments. The greatest increase in protein 
recovery was seen in the liver microsomes with phenobarbitone, as would be expected. 
See appendix (Table 17.8-10. ) for raw data. 
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Table 13.1. Induction of rat liver and lung tissues by phenobarbitone, 8- 
naphthoflavone and clofibric acid. Results were expressed in grammes. 
Inducers 
Tissue saline phenobarbitone, B-naphthoflavone clofibricacid HSD 
(n=4) (n=5) (n=4) (n=5) 
Liver 12.2±0.8 12.5±0.7 14.0±0.3 14.4±0.56 2.65 
Lung 1.28±0.2 1.62±0.08 1.50±0.02 1.56±0.1 0.52 
mean+-SEM 
* significantly different p<0.05 
163 
Table 13.2. Protein recoveries for rat liver, lung and skin subcellular fractions after induction 
with phenobarbitone, B-naphthoflavone and clofibric acid. Results were expressed as mgjg of 
tissue protein. 
T'issue saline 
(n=4) 
phenobarbitone 
(n=5) 
Inducers 
13-naphthoflavone 
(n=4) 
clofibric acid 
(n=5) 
HSD 
Liver 16.4±1.5 19.6±3.4 16.6±0.9 14.6±1.1 15.8 
Nlicrosomes Lung 12.1±1.0 9.60±1.1 9.20±0.3 11.3±0.3 2.6 
Skin 1.50±0.12 1.10±0.18 1.33±0.26 1.26±0.12 0.54 
Liver 49.1±1.8 49.3±3.6 43.3±2.6 52.5±5.2 15.8 
Cytosol Lung 51.3±2.6 56.2±3.4 58.7±8.8 58.7±4.4 23.7 
Skin 19.3±0.1 21.0±0.2 21.5±0.08 19.4±0.2 5.8 
mean+-SEM 
* significantly different p<0.05 
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13.3. FLUAZIFOP-BUTYL ESTERASE 
The induction of fluazifop-butyl hydrolysis by phenobarbitone, 8- 
naphthoflavone and clofibric acid was studied using the microsomal and cytosolic: 
fractions of the liver, lung and skin. 
Methods 
Microsomal and cytosolic protein from the induced tissues, equivalent to 
0.1,5 and 30mg of liver, lung and skin original wet weight was incubated with 
fluazifop-butyl. Final concentrations of fluazifop-butyl of 250,30 and 40gM for liver, 
lung and skin microsomes and 300,60 and 20[tM for liver, lung and skin cytosol were 
used in the incubations. The fluazifop-butyl concentrations used were the values at the 
Vmax, calculated from the previous studies of fluazifop-butyl (see chapter 11.3. ). 
Incubations were carried out in final volume of 500gl in 50mM trisma buffer pH8.0, at 
370C. Reactions were started by the addition of fluazifop-butyl (10-30gl of aI and 
10mM stock in acetonitrile) and stopped after 10 minutes by the addition of an equal 
volume of 6% perchloric acid, containing 10lig/n-A p-toluic acid (internal standard). 
Tubes were vortexed and centrifuged at 5440 xg for 5 minutes. 80gl of the supernatant 
was injected onto reversed phase HPLC. 
Measurements for fluazifop formation were as previously described (see 
chapter 9.2. iii. ). Activities were expressed as ýtmol/rnin/g wet weight tissue. The 
effects of inducers were compared by analysis of variance and then by Tukey's HSD 
test (see earlier). 
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Results 
Analysis of variance, followed by Tukeys HSD test were used to 
detennine any significant difference between the control activities and activities for the 
induced tissues. Any values which yields an absolute value that exceeds HSD was 
declared to be significantly different. These results can be seen on Table 13.3. It was 
found that phenobarbitone significantly induced (p<0.05) fluazifop-butyl hydrolysis 
only in the liver microsomes and the lung cytosol. 8-naphthoflavone did not induce 
fluazifop-butyl hydrolysis in any of the tissues, whereas the only effect of clofibric acid 
was to significantly reduce (p<0.05) fluazifop-butyl hydrolysis in the skin microsomes. 
See appendix (Table 17.11-13. ) for raw data. 
13.4. CARBARYL ESTERASE 
The results of the inhibitory studies previously presented have suggested 
that carbaryl hydrolysis is hydrolysed by carboxylesterases in liver, lung and skin. it 
has also been suggested that carboxylesterase is responsible for the hydrolysis of 
fluazifop-butyl, therefore induction of both carbaryl and fluazifop-butyl hydrolysis 
should be similar, although different isoenzymes could be involved. 
Methods 
Carbaryl esterase activity was measured in the same tissue fi-actions as 
fluazifop-butyl esterase (see chapter 13.3. ). 
A final concentration of 25gM of carbaryl in 15gl of methanol was added 
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Table 13.3. Induction of fluazifop-butyl hydrolysis in rat liver, lung and skin subcellular 
fractions by phenobarbitone, 8-naphthoflavone and clofibric acid. Results were expressed 
in gmol fluazifop/min/g wet weight. 
Inducers 
T'issue saline phenobarbitone 3-naphthoflavone clofibricacid. HSD 
(n---4) (n=5) (n--4) (n=5) 
Liver 1.10±0.8 1.94±0.26* 0.96±0.08 1.10±0.06 0.52 
NEcrosomes Lung 0.28±0.012 0.27±0.03 0.28±0.03 0.30±0.012 0.083 
Skin 0.0024±0.0004 0.0016±0.0002 0.002±0.0002 0.0113±0.0002* 0.001 
Liver 0.86±0.14 0.97±0.1 0.66±0.1 1.10±0.12 0.79 
Cytosol Lung 1.31±0.048 1.46±0.028* 0.98±0.16 1.31±0.06 0.09 
Skin 0.60±0.012 0.58±0.048 0.58±0.028 0.59±0.022 0.11 
mean±SEM 
* significantly different p<0.05 
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into glass conical bottomed tubes. The methanol was evaporated under nitrogen. 
Mcrosomal or cytosolic protein equivalent to 5,10 or 30mg of liver, lung or skin 
original wet weight was added to the tubes. Samples were then vortexed for 5 seconds. 
Incubations were carried out in a final volume of I ml in 0.1 M phosphate buffer ph7.25 
at 370C. Reactions were started by the addition of the tissue fraction to the carbaryl and 
stopped after 20 minutes by protein precipitation following addition of ethanol (500gl 
per incubation) and then centrifuged at 5400 xg for 5 minutes. 50gl of supernatant was 
injected onto reverse phase HPLC (see chapter 9.3. iii. ). Activities were expressed as 
nmol/min/g wet weight tissue. The effects of inducers were compared by analysis of 
variance and then by Tukey's HSD test (see earlier). 
Results 
Analysis of variance, followed by Tukeys HSD test were used to 
deterrnine any significant difference between the control activities and activities for the 
induced tissues. Any values which yields an absolute value that exceeds HSD was 
declared to be significantly different. These results can be seen on Table 13.4. The 
results show that although phenobarbitone and clofibric acid increased liver and lung 
microsomal esterase, the difference did not reach statistical significance at the 5% level 
by analysis of variance. There was no statistical significant in cytosolic esterase 
hydrolysis in any of the tissues studied. No significant difference was found in esterase 
hydrolysis of carbaryl, between the saline and induced skin. See appendix (Table 
17.14-16. ) for raw data. 
13.5. PARAOXON HYDROLYSIS INDUCTION 
The induction of paraoxon hydrolysis by paraoxonase was examined to 
see how phenobarbitone, 8-naphthoflavone and clofibric acid type inducers, induce 'A' 
esterase. Induction of paraoxon hydrolysis was examined in the microsomal and 
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Table 13.4., Induction of carbaryl hydrolysis in rat liver, lung and sidn subcellular fractions by 
phenobarbitone, 8-naphthoflavone and clofibric acid. Results were expressed in nmol I- 
naphthol/min/g wet weight. 
Tissue saline 
(n=4) 
phenobarbitone 
(n=4) 
Inducers 
8-naphthoflavone 
(n=4) 
clofibricacid. 
(n=4) 
HSD 
Liver 1.14±0.12 1.90±0.28 1.04±0.12 1.66±0.3 0.93 
Nlicrosomes Lung 0.72±0.1 0.90±0.2 0.66±0.06 0.90±0.16 0.6 
Skin 0.06±0.014 0.029±0.008 0.037±0.01 0.029±0.0002 0.04 
Liver 1.30±0.06 0.90-+0.32 0.99±0.26 0.77±0.1 0.9 
Cytosol Lung 0.68±0.12 0.48±0.1 0.76±0.22 0.83±0.08 0.58 
Skin 0.30±0.04 0.28±0-02 0.26±0.04 0.19±0.04 0.136 
mean-+SEM 
* significantly different p<0.05 
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cytosolic fractions of the liver and lung. 
Methods 
Paraoxonase activity was measured in the same tissue fractions as 
fluazifop-butyl estemse (see chapter 13.3. ). 
NEcrosomal Protein equivalent to 0.5 and 20mg of liver and lung original 
wet weight was incubated with a final concentration of paraoxon of 0.2mM for liver 
and 0.3mM for lung. Incubations were carried out in a final volume of 500gI in 50MM 
trisma buffer ph8.0, containing O. ImM calcium chloride, at 370C. Reactions were 
started with the addition of paraoxon (10 or 15gl of lOm. M paraoxon stock in 50MM 
trisma buffer ph8.0, freshly prepared) and stopped after the addition of an equal 
volume of 6% perchloric acid, containing lOggln-A p-toluic acid. Tubes were vortexed 
and centrifuged at 5440xg for 5 minutes. 80gl of the supernatant was injected onto 
reverse phase BPLC, as described (see chapter 9.4. iii. ). Activities were expressed as 
nmol/riiin/g wet weight tissue. The effects of inducers were compared by analysis of 
variance and then by Tukey's HSD test (see earlier). 
Results 
Analysis of vaiiance, followed by Tukeys HSD test were used to 
detemine any significant difference between the control activities and activities for the 
induced tissues. Any values which yielded an absolute value that exceeds HSD was 
declared to be significantly different. These results can be seen on Table 13.5. 
Results show that there was significant induction of paraoxonase activity 
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Table 13.5. Induction of paraoxon hydrolysis in rat liver and lung fi-action by phenobarbitone, 
B-naphthoflavone and clofibric acid. Results were expressed in nmol p-nitrophenol/min/g wet 
weight. 
Inducers 
Tissue saline phenobarbitone 8-naphthoflavone clofibricacid HSD 
(n=4) (n=5) (n=4) (n=5) 
Liver 70±0.6 130-+16* 80±0.4 
Nlicrosomes Lung 8.2±0.6 9.1±0.4 9.6±0.4* 
mean+-SEM 
significantly different p<0.05 
95.5±0.6 32 
9.8±0.2* 1.2 
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by phenobarbitone in the liver microsomes. Although both B-naphthoflavone and 
clofibric acid increased paraoxonase activity in the liver microsomes , the increase was 
not statistically significant. In the lung microsomes there was a significance increase in 
paraoxonase activity with B-naphthoflavone and clofibric acid - (p<0.05). 
Phenobarbitone also increased activity compared to the control, but this difference did 
not acifie-ve significant difference at the 5% level. See appendix (Table 17.17-18. ) for 
raw data. 
13.5. PHENYLACETATE ESTERASE INDUCTION 
The induction of phenylacetate hydrolysis by phenobarbitone, B- 
naphthoflavone and clofibfic acid was also studied using the same microsornal and 
cytosolic fractions of the liver, lung and skin. 
Methods 
Phenylacetate activity was measured in the same tissue fractions as 
fluazifop-butyl esterase (see chapter 13.3. ). 
Microsomal and cytosolic protein equivalent to 2mg liver and 10mg lung 
and skin original wet weight was incubated with a final concentration of 2mM 
phenylacetate. Incubations were carried out in a final volume of 3mls in 50mM trisma, 
buffer pH8.0, containing 0.1 mM calcium chloride at 370C, in a cuvette. Reactions were 
started by the addition of phenylacetate (10ýfl of 600mM phenylacetate stock in 
DMSO). The cuvettes were inverted and then placed in the spectrophotometer (see 
chapter 9.5. iii. ). Activities were expressed as nmol/min/g wet weight tissue. Ile 
effects of inducers were compared by analysis of variance and then by Tukey's HSD 
test (see earlier. ). 
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Results , 
Analysis of variance, followed by Tukeys HSD test were used to 
deterinine any significant difference between the control activities and activities for the 
induced tissues. Any values which yields an absolute value that exceeds HSD was 
declared to be significantly different. These results can be seen on Table 13.6. 
Results show that there was a significant induction by phenobarbitone 
pre-treatment of arylesterase activity in the liver microsomes and lung cytosol. No other 
arylesterase induction was seen in any microsomal or cytosolic fractions of any of the 
other tissues studied. However, there was a reduction in arylesterase activity in the skin 
cytosol following B-naphthoflavone and clofibric acid pre-treatment, however, this was 
not statistically significant at the 5% level (analysis of variance). See appendix (Table 
17.19-21. ) for raw data. 
13.7. DISCUSSION 
Ile observed results seem to indicate that in the microsomal fraction of 
the tissues studied only phenobarbitone significantly induced fluazifop-butyl 
hydrolysis. This agrees with work carried out by Satoh and Morio, (1973), who using 
the substrate isocarboxazid, found that only microsomal hepatic carboxylesterase was 
induced by phenobarbitone. In the cytosolic fraction the lung cytosol carboxylesterase 
was also induced by phenobarbitone. Previous work done on fluazifop-butyl 
hydrolysis (see chapter 11.3. ) has shown that most hydrolysis takes place in the lung 
cytosol, rather than the microsomal fraction of the tissue. Earlier inhibitory studies 
using BNPP also showed that 60% of carboxylesterase activity was inhibited in the 
cytosol compared to 33% in the microsomal fraction of the lung. The fact that there 
seems to be induction of carboxylesterase in the lung cytosol could be as a result of a 
population of inducible isoenzymes found in the lung cytosol whichare not present in 
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Table 13.6. Induction of phenylacetate hydrolysis in rat liver, lung and skin subcellular 
fractions by phenobarbitone, 3-naphthoflavone and clofibric acid. Results were expressed in 
Pmol phenol/min/g wet weight. 
Tissue saline 
(n=4) 
phenobarbitone 
(n=5) 
Inducers 
8-naphthoflavone 
(n=4) 
clofibricacid 
(n=5) 
HSD 
Liver 180±8.4 226±20* 155±5 172±6.6 44.9 
Microsomes Lung 4.3±0.32 4.1±0.26 3.8±0.32 4.1±0.2 0.94 
Sldn 0.135±0.12 0.12±0.01 0.127±0.1 0.18±0.036 0.07 
Liver 58±4 53±8 51±6 64±4 24.8 
Cytosol Lung 15±0.6 21.4±2* 10.8±2 13.5±1.6 5.9 
Skin 6.9±0.28 7.3±0.86 5.7±0.24 5.2±0.14 1.66 
mean+-SEM 
* significantly different p<0.05 
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the lung microsomes. 
No induction of fluazifop-butyl hydrolysis by 13-naphthoflavone was 
found to take place in any of the tissues studied. These results agree with previous 
work carried out by Raftell et al, (1977), who found that the 3-methylcholanthrene type 
inducer had no effect on hepatic microsomal carboxylesterase. No induction of 
fluazifop-butyl hydrolysis took place in any of the tissues studied using clofibric acid as 
an inducer. These results were contrary to those found by Kawashima et a], (1973) and 
Hosokawa et al. (1987). Kawashima -etal, 
(1973) reported the induction of hepatic 
long-chain acyl-CoA hydrolase in the cytosolic fraction by administration of clofibric 
acid to rats, mice, or guinea-pigs. Hosokawa et al, (1987) reported that administration 
of clofibrate caused a significant increase in the activities of p-nitrophenylacetate, 
isocarboxazid, butanilicaine and palmitoyl-CoA hydrolases in rat liver microsomes. p- 
Nitrophenylacetate and isocarboxazid hydrolase activities were not induced by 
clofibrate, whereas palmitoyl-CoA hydrolase activity was significantly induced. These 
results suggest that fluazifop-butyl is hydrolysed by a different esterase isoenzyme 
from those studied by Kawashima et al, (1973) and Hosokawa et al, (1987). Another 
possible reason for the lack of induction of carboxylesterase activity by clofibric acid 
could be that the dosage schedule may have not completely induced the enzymes. 
It was observed that no induction of carboxylesterase took place in the 
skin tissue. This could indicate that either there was no induction taking place in the 
skin or that the inducers were not taken up by the skin tissue efficiently enough from 
the circulation. 7bis could be as a result of a reduced blood supply to the skin compared 
to that of the lung or liver. 
Although carbaryl hydrolysis is apparently induced by phenobarbitone 
and clofibric acid in the liver microsomes, the large inter-animal resulted in the 
differences not achieving statistically significant at the 5% level. See appendix for 
individual data. The reproducibility of the carbaryl assay was poor due to the high 
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spontaneous carbaryl hydrolysis. The coefficient of variation between the assays was 
21% (see chapter 9.3. ii. ). For fluazifop-butyl hydrolysis, the inter-assay variation was 
much smaller and so, only small variations in the sample populations were seen (see 
appendix). 
If in fact carbaryl hydrolysis was induced by phenobarbitone in the liver 
microsomes, the effects on carbaryl and fluazifop-butyl hydrolysis would be very 
similar. In the future a larger group of animals should be used for induction studies in 
carbaryl hydrolysis due to the large variation between rat samples. 
Induction of paraoxonase activity by phenobarbitone was seen in the liver 
microsomes. In the lung, B-naphthoflavone and clofibric acid induced paraoxonase 
activity . This could be as a result of 8-naphthoflavone and clofibric acid inducing a 
number of specific isoenzymes not present, previously before induction. 
Induction of arylesterase activity was seen in the liver microsomes 
following phenobarbitone pre-treatment. Phenobarbitone also induced phenyl acetate 
esterase activity in the lung cytosol. Previously, inhibitory studies have shown that the 
esterase enzyme hydrolysing arylesterase in the lung cytosol and liver microsomes are 
in fact both 'A' and 'B' type esterase (phenylacetate esterase activity was inhibited 52% 
by paraoxon and 38% by HgC12 in lung cytosol and inhibited 50% by paraoxon and 
40% by HgC12 in the liver microsomes). This result is in agreement with fluazifop- 
butyl esterase induction where it was also found that phenobarbitone induced fluazifop- 
butyl esterase, a 'B' esterase in the cytosol of the lung and microsomes of the liver. 
No other induction of phenylacetate esterase following pre-treatment with 
the classical inducers in the n-krosomal or cytosolic fractions of any of the other tissues 
studied was observed. A possible reason for the lack of induction of phenylacetate 
estemse in the lung and skin microsomes by phenobarbitone could be as a result of the 
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lack of inducible carboxylesterase isoenzymes compared to that of the liver microsmes. 
The use of inducers has helped to identify the esterases involved in the 
hydrolysis of fluazifop-butyl, carbaryl, paraoxon and phenylacetate. 
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CHAPTER 14: XENOBIOTIC METABOLISM IN THE HUMAN 
14.1. INTRODUCTION 
Having established the nature of the esterases in the detoxification of a 
number of pesticides in the rat, studies using human liver and blood were carried out 
for comparison. Species differences exist between rat and human in the nature and 
specificity of xenobiotic metabolising enzymes. For extrapolation it was possible to 
study human liver and blood samples. The aim of the experiments were to establish 
human liver and blood hydrolytic activity for paraoxon, fluazifop-butyl and 
phenylacetate and to determine the distribution of hydrolytic activity in the liver 
microsomal and cytosolic fractions and plasma and erythrocytes. 
Having established the distribution of hydrolytic activity for paraoxon, 
fluazifop-butyl and phenylacetate inhibitory studies were then carried out to distinguish 
the enzymes involved in their hydrolysis, to compare with those found in the rat. 
14.2. SUBJECTS STUDIED 
Samples of human liver were given by Dr F. Kumali, Wolfson Unit of 
Clinical Pharmacology, Newcastle. Samples had been obtained from transplant donors 
from a number of hospitals in the North East of England by collaboration with the 
transplant coordinator. Clinical details of the human subjects can be seen on table 14.1. 
None of the liver donors were receiving medication except number 3 who was 
receiving ampicillin. The smoking status was not available. Liver samples were stored 
in liquid nitrogen as soon as possible before analysis. 
Venous blood samples were obtained from 10 healthy male volunteers 
who were drawn from scientific staff of the Division of Environmental and 
Occupational Medicine, University of Newcastle upon Tyne. Clinical details of the 
178 
Table 14.1. Human liver information 
Liver sample 
number 
Sex Age Liver function 
test 
Cause of death 
I male 55 normal head injury 
2 female 63 normal cerebral haemorrhage 
3 female 47 subarachnoid haemorrhage 
4 male 35 normal subarachnoid haemorrhage 
5 male 55 normal head injury 
6 female 45 normal subarachnoid haemorrhage 
7 female 47 normal subarachnoid haemorrhage 
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human subjects can been seen on table 14.2. The study had the approval of the relevant 
Hospital Ethics commitee. The nature and purpose of the studies were explained in 
detail to all subjects. 
Separation of Blood 
10ml of blood was obtained from 10 healthy male volunteers by 
intravenous puncture. This blood was put into heparinized tubes and placed on a 
Luckham rolling mixer. Plasma and red blood cells were separated by centrifugation 
using a Mistral 3000 centrifuge, at 880 xg for 5 minutes. The plasma was removed and 
stored at -800C before analysis. The red blood cells were washed using an equal 
volume of isotonic saline. After centrifugation at 880 xg for 10 minutes the upper 
layer was removed and discarded. This procedure was again repeated. The red blood 
cells were then stored at -800C before analysis. 
Preparation of Liver Homogenate and Subcellular Fractions 
The liver was washed in ice cold 50mM trisma HCI buffer pfl 7.5.0.4 g 
portions of liver were weighed and finely n-ftced using scissors and forceps in 4mls of 
50mM trisma HCI buffer pH 7.5. Tissue homogenate was prepared in a glass to glass 
homogenizer, cooled on ice. 
Tissue homogenates were centrifuged in a Sorvall RC 5B refrigerated 
centrifuge at 1,800 xg for 5 minutes at 40C to remove tissue debris. The supernatant 
was further centrifuged at 10,000 xg for 10 minutes at 40C to remove mitochondria 
and nuclei. 
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Table 14.2. Human plasma information 
Plasma sample number Sex Age Smoker 
I male 23 no 
2 male 22 no 
3 male 24 no 
4 male 25 no 
5 male 19 no 
6 male 39 no 
7 male 28 no 
8 nmle 30 no 
9 male 31 no 
10 male 24 no 
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Ile post mitochondrial fraction was centrifuged in a Kontron ultra- 
centrifuge at 100,000 xg for 1 hour and 10 minutes. The supernatant was removed 
(4mls) and the resulting pellet was resuspended by glass to glass homogenization in 
50mM trisma. HCI buffer pH 7.5. The resulting pellet from the second spin was 
resuspended into Iml of 50mM trisma HCL buffer, plI 7.5. Cytosolic protein was 
equivalent to O. lg tissue/ml and niicrosomal enzymes equivalent to OAg tissue/nil. The 
microsomal and cytosoic fractions of the liver were stored in ependorf tubes at -800C 
before analysis. 
14.3. GENERAL HUMAN ASSAY METHODS 
The following enzymatic assays were set up to examine the hydrolysis of 
a number of xenobiotic esters by the human liver and blood. Using the analytical 
techniques of HPLC and spectrophotometry, the formation of product was measured 
over a range of substrate concentrations to establish the Vmax and apparent values for 
the esterase enzyme, after conditions of linearity had been established. 
The methods applied to determine the enzyme activity in rat subcellular 
fractions were adapted for measurement of activity in human microsomes and cytosol, 
where activities were generally lower. 
Fluazifop-butyl esterase assay 
Chemicals (see chapter 9.2. i. ) 
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Incubations 
NEcrosomal or cytosolic protein, equivalent to 1-5mg of liver original wet 
weight or 10-50gl of plasma or red blood cells was incubated with fluazifop-butyl 
(0.05-ImM final concentration). Incubations were carried out in a final volume of 
500glof 50mM trisma buffer pH8.0, containing 0. ImM calcium chloride at 370C. 
Reactions were started by the addition of fluazifop-butyl (5-50gl of a 
ImM and lOmM stock in acetonitrile) and stopped with the addition of 500111 of 6% 
perchloric acid, containing lOgg/mI p-toluic acid (internal standard). Tubes were 
vortexed and centrifuged at 5440 xg for 5 minutes. 80gl of supernatant was injected 
onto reverse phase HPLC. Conditions for the HPLC assay of fluazifop-butyl and 
fluazifop were as previously described (see chapter 9.2. iii. ). 
Using a fixed concentration of fluazifop-butyl (ImM) and time of 
incubation (10 min), varying amounts of microsomal and cytosolic protein (see figure 
14.3.1. ) were used in the incubations to establish conditions of linearity for protein. 
The amount of plasma was also varied, with a constant time (10 min) and constant 
fluazifop-butyl concentration (ImM) (see Figure 14.3.2. ). Having established the 
optimal conditions for incubation, the time of hydrolysis was varied (0-30 minutes) 
with a fixed fluazifop-butyl concentration (I mM) to establish conditions of linearity for 
time for the following tissues: liver (see Figure 14.3.3. ) and plasma (see Figure 
14.3.4. ). 
Ile optimal conditions selected for the study with a constant time of (10 
mins) and fluazifop-butyl concentration (ImM) for microsomal and cytosolic protein 
were 2mg of liver original wet weight or 50gl of plasma. The conditions of, linearity for 
time, with constant protein and fluazifop-butyl concentration were 4 minutes for liver 
and plasma. The lower limit of detection of the fluazifop-butyl assay was I nmol/ 
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Figure 14.3-1. 
Rate of fluazifop-butyl ( ImM ) hydrolysis to fluazifop ( nmol/n-ýinute ) in the presence 
of varying human liver microsomes (q) and cytosol (a) ( 0- 10 mg/incubation 
Each point represents a mean of duplicate determinations. 
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Figure 14.3.2. 
a 
Rate of fluazifbpý-butyl ( ImNI ) hydrolysis to fluazifop ( nmol/minute ) in the presence 
of varying human plasma (a) (0-50 gOincubation). 
Each point represents a mean of duplicate determinations. 
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Figure 14.3.3. 
Fluazifop-butyl (ImM ) hydrolysis to fluazifop ( nmolfincubation ) by human liver 
microsomes (c) and cytosol (0) ( 2mg/incubation ) for varying times of hydrolysis 
Each point represents a mean of duplicate determinations. 
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Figure 14.3.4. 
Fluazifop-butyl (Im. M) hydrolysis to fluazifop (nmol/incubation ) by human plasma ( 
50gl/incubation ) for varying times of hydrolysis 
Each point represents a mean of duplicate determinations. 
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incubution. 
Paraoxonase assay 
Chemicals (see chapter 9.4. i. ) 
Incubations 
Microsomal or cytosolic protein, between 1-20mg of liver original wet 
weight was incubated with paraoxon (0.05-ImM). Incubations were carried out in a 
final volume of 500gl of 50mM trisma buffer pH8.0, containing O. ImM calcium 
chloride at 370C. 
Reactions were started by the addition of paraoxon and stopped with the 
addition of an equal volume of 6% perchloric acid, containing lOgg/ml p-toluic acid 
(internal standard). Tubes were vortexed and centrifuged at 5440 xg for 5 minutes. 
80gl of supernatant was injected onto reverse phase HPLC. Control incubations 
containing 50: mM trisma buffer pH 8.0 and paraoxon, but no tissue were carried out in 
parallel to access spontaneous hydrolysis. Conditions for the HPLC assay of paraoxon 
and p-nitrophenol were as previously described (see chapter 9.4. iii. ). 
Using a fixed concentration of paraoxon and time of incubation, varying 
amounts of microsomal protein from liver microsomes (see Figure 14-3.5. ). were used 
in the incubation to establish conditions of linearity for protein. Having established a 
fixed amount of protein for the incubation, the time of hydrolysis was varied (0-30 
minutes) with a fixed paraoxon concentration to establish conditions of linearity for 
time with liver microsomes (see Figure 14.3.6. ). No cytosolic paraoxonase activity 
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Figure 14.3.5. 
3 
Rate of paraoxon ( ImM ) hydrolysis to p-nitrophenol ( nmol/n-dnute ) in the presence 
of varying human liver microsomes ( 0-10 mgtincubation ). 
Each point represents a mean of duplicate determinations. 
189 
10 
8 
0 
CL 
0 
E 
c 
0 
Time ( minutes ) 
Figure 14.3.6. 
Paraoxon OmM ) hydrolysis to p-nitrophenol ( nmol/incubation ) by human liver 
microsomes ( 5mg/incubation ) for varying times of hydrolysis 
Each point represents a mean of duplicate determinations. 
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was detectable. 
The conditions of linearity for liver tissue, with constant time (10 mins) 
and paraoxon concentration (ImM) were 2mg of liver original wet weight or 50gl of 
plasma. Ile conditions of linearity for time, with constant protein and paraoxon 
concentration were 15 minutes for liver and plasma. The sensitivity of the paraoxon 
assay was I mnol/ incubation. 
Ile results for the spontaneous hydrolysis of paraoxon were the same as 
those found in the rat studies (see Table 14.3. ). 
Incubation of Human Plasma and Red Blood Cells 
The hydrolysis of paraoxon to p-nitrophenol in the plasma was measured 
using a modification of the Eckerson et al, (1983) method. 10-50gl of plasma or red 
blood cells were incubated with paraoxon. Incubations were carried out in a final 
volume of 3ml 50mM glycine buffer pH10.5, containing ImM calcium chloride at 
300C. Reactions were started by the addition of paraoxon. Cuvettes were inverted and 
placed in the spectrophotorneter. 
The formation of p-nitrophenol was monitored continuously at a 
wavelength of 412nm on a Kontron UV spectrophotometer. Control incubations 
containing 50mM glycine/ I mM calcium chloride buffer ph 10.5, but no plasma were 
conducted in parallel. Measurements were converted from absorbance units / min to 
nmol p-nitrophenol / min / ml by using the absorbance coefficient for p-nitrophenol. 
The amount of plasma was varied until a linear plot was obtained over 3 
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Table 14.3. Spontaneous hydrolysis of paraoxon. 
Substrate concentration (gM) Activity (mnol/min) 
50 0.33±0.06 
100 1.33±0.14 
250 7.70±1.0 
500 17.0±2.1 
1000 35.0±2.8 
mean-+SEM (n=2) 
limit of sensitivity > 0.3nmol/min 
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minutes. Ile reaction rate was detected on the linear portion of the curve. Spontaneous 
hydrolysis rates for paraoxon are shown on Table 14.3. 
14.3. iii. Phenylacetate esterase assay 
Chemicals (see chapter 9.51) 
Incubations 
The method of Kitchen et al, (1983) was used in the experiment. 
Microsomal or cytosolic protein, between 0.5-10mg of liver original wet weight or 10- 
50gl of plasma or red blood cells was incubated with phenylacetate (0.5-4mm). 
Incubations were carried out in a final volume of 3ml of 5OmM trisma buffer pH8.0, 
containing O. 1m. M calcium chloride at 370C. Reactions were started with the addition 
of phenylacetate. The cuvettes were inverted and placed in the spectrophotometer. 
Control incubations containing 50mM trisma buffer pH8.0 and phenylacetate were 
carried out in parallel to access spontaneous hydrolysis. The monitoring of phenol 
formation was the same as described in chapter 9.5. iii. The amount of protein or 
plasma was varied until a linear plot was obtained over 3 minutes. The reaction rate was 
detected on the linear portion of the curve. The spontaneous hydrolysis results for 
phenylacetate are shown on Table 14.4. 
14.4. PROTEIN ESTIMATION IN HUMAN LIVER FRACTIONS 
Protein estimations in the rnicrosomal and cytosolic fractions of the human 
liver were carried out to determine the recoveries of protein in the experiment after 
tissue subcellular fractions were prepared from the initial tissue homogenate. 
193 
Table 14.4. Spontaneous hydrolysis of phenylacetate 
Substrate concentration (mM) Activity ( nmol/rnin ) 
0.2 3.9±0.42 
0.5 9.8±1.0 
1.0 19.5±1.6 
2.0 38.2±2.0 
3.0 54.1±2.4 
4.0 65.9±4.3 
mean-+SEM (n=2) 
limit of sensitivity > 0.23nmol/min 
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Methods 
Protein recoveries were made using a variation on the Lowry et al , (1956) 
method, by Peterson, (1977) (see chapter 7.5. ). 
Results 
Protein content of the Ever microsomal fraction was found to be lower than the 
cytosol.. The protein recoveries were approximately I% for liver microsomes (see 
Table 14.5. ) and 5% for liver cytosol (see Table 14.6. ). 
Discussion 
When comparing the protein recoveries from the rat and human liver it can 
be seen that there is a greater recovery of microsomal protein in the rat (rat: 27.8±2mg/g 
compared to human: 11.4±0.68mg/g) while in the cytosol there was more cytosolic 
protein in the human than in the rat (rat: 32.5± I mg/g and human: 46.6±5.3mg/g). 
14.5. FLUAZIFOP-BUTYL ESTERASE 
Human volunteer studies carried out by Wollen et al, (1990) have shown 
that following absorption fluazifop-butyl is rapidly hydrolysed to fluazifop acid and 
only the acid is detectable in the blood and urine. Experiments were carried out to 
determine what role liver and blood esterases play in its metabolism. 
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Table 14.5. Protein recoveries for human liver microsomal fraction. Results were 
expressed as mg/g of tissue protein. 
Tissue number Protein recovery ( mglg ) 
12.2 
2 12.4 
3 13.9 
4 10.6 
12.4 
6 10.4 
7 8.2 
mean+-SEM 11.4±0.68 
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Table 14.6. Protein recoveries for the human liver cytosolic fraction. Results 
were expressed as mglg of tissue protein. 
Tissue number Protein recovery ( mglg ) 
1 
2 
3 
4 
5 
6 
7 
mean±SEM 
59 
60 
47 
49 
56 
30 
25 
46.6±5.3 
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Methods 
Nficrosomal and cytosolic protein equivalent to 0.8mg original wet weight 
or 50gl of plasma and 50gl of lysed red blood cells were incubated with a final 
concentration of 0.02-ImM fluazifop-butyl. Incubations were carried out in a final 
volume of 500gl in 50mM trisma buffer pH8, containing O. ImM calcium chloride at 
370C. Reactions were started by the addition of fluazifop-butyl (5-20gl of a ImM and 
lOmM fluazifop-butyl stock in acetonitrile) and stopped after 4 minutes by the addition 
of 6% perchloric acid, containing lOgg/ml p-toluic acid (internal standard). Tubes were 
vortexed and centrifuged at 5440 xg for 5 minutes. 80gl of the supernatant was 
injected onto reversed phase HPLC. 
Results were expressed as of gmol/min/g wet weight for liver microsomes 
and cytosol, gmol/min/n-A for plasma and gmol/min/ml lysed cell volume for 
erythrocytes. Values for Vmax and apparent Km were calculated using the direct linear 
plot. 
Results 
In all the tissues studied increases in activity with substrate concentration 
were seen over the range of concentrations studied. Figure 14.5.1. shows the 
hydrolysis of fluazifop-butyl by liver cytosolic esterases. Substrate activity curves were 
similar for liver microsomal and plasma esterase hydrolysis of fluazifop-butyl. Activity 
increases could be described by Michaelis Menton Kinetics. Values for Vmax and the 
apparent Km's were calculated for liver microsomes (see Table 14.7. ), liver cytosol 
(see Table 14.8. ), plasma (see Table 14.9. ) and erythrocytes (see Table 14.10. ). 
Results show that fluazifop-butyl hydrolysis is equally distributed in the 
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Figure 14.5.1. 
Hydrolysis of fluazifop-butyl in human liver cytosol ( number I ). Calculation of Vmax 
( gmol/min/g wet weight ) and Krn (gM) by (i) plot of activity versus substrate 
concentration and (ii) direct linear plot. 
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Table 14.7. The hydrolysis of fluazifop-butyl to fluazifop by human liver microsomes. 
The activities at the substrate concentrations were measured in pmol/min/g wet weight. 
results were expressed as the Vmax ( gmol/min/g wet weight ) and the apparent Km (gM) 
were detected by direct linear plot. 
Sample no. Substrate concentration ( gM ) Vmax Km 
10 50 100 200 500 
1 2.0 7.8 9.1 11.2 13.8 17 45 
2 1.8 5.0 5.3 6.4 7.0 10.0 40 
3 1.3 5.6 6.5 6.6 5.9 10.0 45 
4 1.8 6.9 7.2 7.5 8.4 10.0 40 
5 1.9 5.8 6.6 6.9 8.8 10.9 40 
6 1.2 2.2 2.6 2.8 2.7 3.8 20 
7 4.7 5.0 5.3 5.6 5.4 6.8 20 
mean+-SEM 9.8±1.6 36±4.2 
limit of sensitivity > Inmol/min/g wet weight 
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Table 14.8. The hydrolysis of fluazifop-butyl to fluazifop by human liver cytosol. The 
activities at the substrate concentrations were measured in pmol/min/g wet weighL Results 
were expressed as the Vmax (. umol/min/g wet weight) and the apparent Km (gM) were 
detected by direct linear plOL 
Sample no. Substrate concentration ( pM )0 Vmax Km 
10 50 100 200 500 
1 3.0 6.8 8.1 8.2 8.6 9.7 25 
2 1.4 6.1 7.2 7.3 7.8 8.3 30 
3 1.5 5.8 6.9 7.4 8.0 8.9 25 
4 2.1 8.9 14 11.6 12.2 12.2 30 
5 1.6 6.9 8.4 9.1 11.1 11.3 50 
6 1.9 7.3 7.9 8.9 10.1 11.2 40 
7 1.6 5.3 6.6 7.5 8.1 8.4 25 
mean±SEM 
Emit of sensitivity > Inmol/min/g wet weight 
10±0.52 32±3.7 
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Table 14.9. Ibe hydrolysis of fluazifop-butyl to fluazifop by human plasma. The activities 
at the substrate concentrations were measured in nmollmin/ml plasma. Results were 
expressed as the Vmax ( nmol/min/rnI plasma) and the apparent Krn (gM) were detected 
by direct linear plot. 
Sample no. Substrate concentration ( gM ) Vmax Km 
20 50 100 200 400 600 
1 8.2 12.8 17.4 29.0 25.6 25.4 29 65 
2 20.0 25.2 73.5 87.0 65.4 65.6 82 65 
3 17.0 22.4 66.2 72.5 72.5 81.2 101 65 
4 12.8 16.4 37.5 65.0 61.0 65.0 78 110 
5 9.0 18.5 34.0 85.0 90.0 80.0 89 140 
6 18.0 23.0 52.5 60.0 72.5 70.0 84 80 
7 11.0 17.5 35.0 46.2 43.8 45.0 58 90 
8 15.0 22.5 48.8 57.5 63.8 75.0 88 110 
9 17.5 26.2 65.0 90.0 104 72.5 104 90 
10 21.2 32.5 72.5 83.8 95.0 95.0 112 65 
mean±SEM 
limit os sensitivity > 1nmol/min/mI plasma 
88.3±5.6 88±7.8 
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Table 14.10. The hydrolysis of fluazifop-butyl to fluazifop by human red 
blood cells Me activity in nmollmin/ml was measured at a concentration of 
400gM, by direct linear plot. 
Tissue 
number 
Activity at 400gM 
(nmol / min / ml) 
1 3.31 
2 4.23 
3 5.36 
4 3.86 
5 5.58 
6 4.76 
7 3.26 
8 4.38 
9 3.56 
10 4.1 
mean±SEM 4.35±0.25 
limit of sensitivity > Inmol/min/ml 
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microsomal and cytosolic fraction of the liver. The liver seems to contain around a 100 
times more esterase activity than the plasma. The red blood cells contain a very small 
amount of esterase activity. The activity of the fluazifop-butyl esterase expressed in mg 
of protein were 0.86±0.12 for liver microsomes and 0.21±0.0111mol/min/rng protein 
in cytosol 
Ile apparent Km's for the liver microsomal (see Table 14.7. )and cytosolic 
(see Table 14.8. ) esterase were found to be very similar. The apparent Krn for plasma 
esterase (see Table 14.9. ) was found to be around 2 fold greater than that of the liver 
fractions. 
Discussion 
As was found in the rat, esterase activity was equally distributed between 
the microsomes and cytosol. Comparing the activities it was found that human liver 
was more active at hydrolysing fluazifop-butyl than the rat esterase. This was found to 
be the case in both the microsomal (human: 9.8±1.57 and rat: 6.29±0.4gmol 
fluazifop/min/g) and cytosol (human: 10±0.52 and 6.84±0.85gmol fluazifop/min/g) 
fractions of the liver Expressing the results in terms of mg of protein, activities in the 
rat and human liver cytosol were the same (0.21gmol fluazifop/min/mg protein), 
whereas they were found to be 4 times as high in the human liver microsomes as in the 
rat (rat: 0.22±0.005 and human: 0.86±0.13pmol fluazifop/min/mg protein). 
I Earlier studies carried out in the rat suggested that the enzyme 
responsible for the hydrolysis of fluazifop-butyl was the 'B' esterase, carboxylesterase. 
Hydrolysis of fluazifop-butyl in rat by cholinesterase was found to play a minor role. 
Fluazifop-butyl hydrolysis in human plasma was found to be much lower than that of 
the rat (human: 0.09-+0.02 and rat: 5. Z, ±O. Sgmol fluazifop/min/ml). This is not 
surprising considering it has been reported that there is very little, if no 
carboxylesterase activity in the human plasma. Rat plasma does contain a large amount 
205 
of carboxylesterase activity, and this is why the fluazifop-butyl hydrolysis activity is 
greater than in the human plasma. To determine whether carboxylesterase or 
cholinesterase is responsible for this reduced hydrolytic activity inhibitory studies will 
need to be carried out. 
The apparent Km's of the esterase enzyme for the fluazifop-butyl substrate 
in the human and rat liver varied by 2 fold in both microsomal (human: 36±4.2 and rat: 
14.4±21. LM) and cytosol (human: 32±3.7 and rat: 22±5gM) but were similar in the plasma 
(human: 88±6.6 and rat: l 82±2.2 gM). 
14.6. PARAOXON HYDROLYSIS 
Paraoxon hydrolysis in the human plasma has been well documented, 
however, there is not much information on how much hydrolysis takes place in human 
liver. Experiments were carried out to compare paraoxonase activities in the liver 
microsomes and cytosol and the plasma and red blood cells of humans. 
Method 
Liver microsomal and cytosolic protein equivalent to 10mg original wet 
weight or 50gl of plasma was incubated with a final concentration of 0.1-ImM 
paraoxon. Incubations were carried out in a final volume of 500pl in trisma buffer pH8, 
containing 0.1 mM calcium chloride at 370C. 
Reactions were started with the addition of paraoxon (5-50gl of JOmM 
paraoxon stock, freshly prepared in trisma buffer) and stopped after 15 minutes by the 
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addition of 6% perchloric acid, containing lOgg/ffil p-toluic acid. Tubes were vortexed 
and centrifuged at 5440 xg for 5 minutes. 80gl of the supernatant was injected onto 
reversed phase HPLC as described (see chapter 9.4. iii. ). 
Results were expressed as gmol/min/g wet weight for liver microsomes 
and cytosol, pmol/min/ml for plasma and grnol/miniffil lysed red blood cells. Values for 
Vmax and apparent Krn were calculated using the direct linear plot. 
Results 
In all the tissues studied increases in activity with substrate concentration 
were seen over the range of concentrations studied. Figure 14.6.1. shows the 
hydrolysis of paraoxon by human liver microsomal paraoxonase. This figure was 
representative of plasma paraoxonase hydrolysis of paraoxon. Activity increases could 
be described by Michaelis Menton Kinetics. Values for Vmax and the apparent Km's 
for were calculated. 
Results show that in the human there is paraoxonase activity in the liver 
microsomes (see Table 14.11. ) and plasma (see Table 14.12. ). No paraoxonase activity 
was found in the cytosolic fraction of the liver or in the red blood cells. The plasma was 
found to contain 4 times more paraoxonase activity than the liver microsomes. When 
expressed on a weight/volume basis. Ibese results can be seen on Figure 14.6.2. The 
liver microsomal paraoxonase, expressed in nmol/min/mg of protein was found to be 
4.2±1. 
The apparent Km for liver microsomal paraoxonase (see Table 14.11. ) 
and plasma paraoxonase ( see Table 14.12. ) for paraoxon was found to be similar. 
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Figure 14.6.1. 
Hydrolysis of paraoxon in human liver microsomes ( number 4 ). Calculation of Vmax 
( nmol/min/g wet weight ) and Km (gM) by (i) plot of activity versus substrate 
concentrationand (ii) direct linear plot. 
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Table 14.11. The hydrolysis of pararoxon to p-nitrophenol by human liver microsomes. 
The activities at the substrate concentrations were measured in gmol/min/g wet weight. 
Results were expressed at the Vmax ( nmol/min/g wet weight ) and the apparent Km (gM) 
by direct linear plot. 
I 
Sample no. 
100 
Substrate concentration ( gM 
200 300 500 600 
Vmax K M. 
1 16 10.0 13.1 16.3 22.5 28 340 
2 7.3 10 14.7 16.3 23.3 48 280 
3 5.3 10.6 11.3 16.7 28.3 45 360 
4 6.7 13.3 18.3 21.7 20.7 42 260 
5 22.5 39.0 43.5 47.0 58.4 74 180 
mean+-SEM 
limit of sensitivity: ý 0.5nmol/minIg wet weight 
47.4±7.5 280±23 
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Table 14.12. The hydrolysis of pararoxon to p-nitrophenol by human plasma. The 
activities at the substrate concentrations were measured in ýunol/min/ffil plasma. Results 
were expressed at the Vmax ( nmol/min/ml plasma) and the apparent Km (pM) by direct 
plot. 
Sample no. Substrate concentration ( gM ) Vmax Km 
50 100 200 500 1000 
1 23 31 116 143 166 190 200 
2 30 39 149 188 207 245 170 
3 27 35 135 171 198 245 220 
4 20 32 84 112 132 170 260 
5 28 36 153 185 202 230 140 
6 21 28 98 128 141 190 230 
7 31 44 194 234 263 295 140 
8 22 32 106 137 161 200 220 
9 12 17 52 78 89 135 400 
10 17 27 74 109 130 200 440 
mean+-SEM 
limit of sensitivity > 0.5nmol/min/mI plasma 
210±14 240±31 
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Figure 14.6.2. 
Vmax values of paraoxon hydrolysis for comparison between human tissues. 
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Discussion 
Paraoxon hydrolysis in the plasma of the rat and the human was found to 
be similar (human: 0.21±0.01ý and rat: 0.25±0.012gmol p-nitrophenol/min/ml). The 
apparent Km's for rat and human plasma paraoxonase for the paraoxon substrate were 
found also to be similar (human: 240±31 and rat: MaMmM). These results suggest 
that human and rat plasma contain the same sort of paraoxonase enzyme. 
However, paraoxon hydrolysis in the liver microsomes of the rat was 
around 8 times that of human (human: 0.047±0.00'75 and rat: 0.33±0.25 gmol p- 
nitrophenol/min/g tissue). When this was expressed as mg of protein the rat liver 
microsomes was found to contain only 3 times as much activity as the human (rat: 
11.8-+-0.68 and human: 4.2±lnmol/min/mg protein). A possible contribution to the 
large difference in paraoxonase activity between liver microsomal paraoxonase and 
plasma paraoxonase activity is due to the pH used in the paraoxon assays. In the 
plasma paraoxonase assay a pH of 10.5 was used, whereas in the liver paraoxonase 
assay the pH was 8.0. Work carried out by Mallinckrodt and Diepgen, (1988) and 
Orfigoza-Ferado. cLd, (1984) showed that using p1l 10.5 there was an increase of 60% ' 
in paraoxonase activity compared to the activity at ph8.0. Ile apparent Km's for rat and 
human liver microsomal paraoxonase for the paraoxon substrate were found to be 
similar (human: 280±23 and rat: 200±7.5mM). Human and rat liver contain a similar 
paraoxonase enzyme with different activities. 
As was found in the rat liver cytosolic fraction, no paraoxonase activity 
was found in the human liver cytosolic fraction of the liver. These results seem to 
indicate that the distribution of paraoxonase in the rat and human liver and plasma is 
very similar Work carried out by Fredricksson&L21, (196 1) had found that although 
no paraoxonase activity was detected in the sIdn of the rat activity was detected in the 
sldn of the human. These results, however, do not seem to fit in to the general picture 
of esterase activity in the human compared to that of the rat. Throughout the study with 
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the exception of nuazifop-butyl esterase in the liver microsomes, esterase activity in the 
human has been lower than in the rat. If this is in fact the case we would not expect to 
see any paraoxonase activity in the skin of the human. 
14.7. PHENYLACETATE HYDROLYSIS 
Phenylacetate hydrolysis was monitored in the microsomal and cytosolic 
fractions of the liver and in the plasma and erythrocytes to determine the amount and 
distribution of arylesterase activity in the human. 
Methods 
Microsomal and cytosolic protein equivalent to 3mg or 50gl of plasma and 
50gl of red blood cells were incubated with a final concentration of 0.5-4mM 
phenylacetate. Incubations were carried out in a final volume of 3mls in 50mM trisma 
buffer pH8, containing 0.1 mM calcium chloride at 370C. Reactions were started with 
the addition of phenylacetate (5-20W of a 6OOmM phenylacetate stock in DMSO). The 
cuvettes were inverted and then placed in the spectrophotometer. Results were 
expressed in terms of grnol/min/g wet weight for liver microsomes and cytosol, 
gmol/min/ml for plasma and gmol/min/ml for lysed red blood cells. Values for Vmax 
and apparent Km were calculated using the direct linear plot. 
Results 
In all the tissues studied increases in activity with substrate concentration 
were seen over the range of concentrations studied. Figure 14.7.1. shows the 
hydrolysis of phenylacetate by human liver inicrosomes. This figure is representative of 
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Figure 14.7.1. 
Hydrolysis of phenylacetate in human liver microsomes ( number 7 ). Calculation of 
Vmax ( gmol/min/g wet welight ) and Km (gM) by (i) plot of activity versus substrate 
concentration and (ii) direct linear plot. 
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liver cytosol and plasma esterase hydrolysis of phenylacetate. Activity increases could 
be described by Michaelis Menton Yinetics. Values for Vmax and the apparent Km's 
for liver microsomes (see Table 14.13. ), cytosol (see Table 14.14. ) and plasma (see 
Table 14.15. ) were calculated. 
Results seem to indicate that arylesterase is equally distributed in the liver 
microsomes and cytosol. Expressed in terms of mg of protein the activities of 
phenylacetate esterase in the liver cytosol were 0.8±0.13gmol/min/mg and liver 
microsomes 5.0±1. Olimol/min/mg of protein. Plasma arylesterase was found to be 
much greater than that found in the liver (see Figure 14.7.2. ). 
The apparent Km's for liver microsomal (see Table 14.13. ) and cytosolic 
(see Table 14.14. ) esterase for phenylacetate were found to be very similar. In the 
plasma (see Table 14.15. ) the apparent Km value of plasma esterase for phenylacetate 
was found to be much greater (8 fold) than that found in the liver fractions. 
Discussion 
Arylesterase activities in the human liver microsomes were much less than 
those found in the rat (human: 57± 8 and rat: 800±75gmol phenol/min/g), whereas in 
the liver cytosol activities for human and rat arylesterase were similar (human: 37±2.9 
and 30.7±3. Ogmol phenol/min/g). When these results were expressed in mg of protein 
results in the liver cytosol were similar (rat: 0.85±0.1 and human: 
0.8±0.13ýtmol/min/mg), whereas in the microsomes there was 5 times as much activity 
in the rat as in the human (rat: 28.6±4.5 and human: 5±1. Ogmol/min/mg). Arylesterase 
in the human and rat plasma were similar (human: 250±17 and rat: 290±40gmol 
phenol/min/ml). 
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Table 14.13 The hydrolysis of phenylacetate to phenol by human liver microsomes. The 
activities at the substrate concentrations were measured in pmol/min/g wet weight. Results 
were expressed as the Vmax (I=ol/min/g wet weight) and the apparent Km (jiM) were 
detected by direct linear plot. 
Sample no. Substrate concentration ( gM ) Vmax Km 
50 100 200 500 1000 
1 10.0 16.2 23.5 40.0 62.6 72 380 
2 8.7 15.0 21.1 32.7 40.5 50 240 
3 11.2 19.2 25.7 40.4 56.4 66 350 
4 11.0 17.2 27.1 46.7 55.8 74 340 
5 10.4 18.6 27.6 42.9 54.8 72 340 
6 6.9 8.6 10.7 13.4 16.9 16 100 
7 9.3 12.6 23.5 33.0 39.0 48 240 
mean-+SEM 
limit of sensitivity > 0.3gmol/rrAn/g wet weight 
57±8 280±35 
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Table 14.14. The hydrolysis of phenylacetate to phenol by human liver cytosol. The 
activities at the substrate concentrations were measured in gmol/niin/g wet weight. Results 
were expressed as the Vmax (ýunol/rnin/g wet weight) and the apparent Km (gM) were 
detected by direct linear plot. 
Sample no. 
50 
Substrate concentration ( gM ) 
100 200 500 1000 
Vmax Km 
1 12.0 18.0 25.0 28.5 39.0 39 200 
2 8.0 12.6 19.2 29.0 30.0 40 220 
3 7.5 12.2 11.0 26.0 29.0 33 170 
4 8.2 14.0 24.4 36.0 40.0 52 280 
5 8.2 12.0 17.5 29.4 30.0 36 220 
6 9.5 14.6 17.8 26.0 29.4 32 130 
7 9.4 12.4 14.8 24.7 26.0 28 140 
mean±SEM 37±2.9 190±25 
limit of sensitivity > 0.3pLmol/mirxIg wet weight 
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Table 14.15. The hydrolysis of phenylacetate to phenol by human plasma. The activities 
at the substrate concentrations were measured in ýanol/ffiin/ml plasma. Results were 
expressed as the Vmax ( pmol/min/ml plasma) and the apparent Km (MM) were 
detected by direct linear plot. 
Sample no. Substrate concentration ( gM ) Vmax Km 
0.2 0.5 1234 
1 26 43 107 166 176 181 320 1.55 
2 30 50 129 176 194 232 250 1.55 
3 27 43 126 139 110 150 190 1.10 
4 19 32 88 119 131 146 195 1.35 
5 32 50 116 153 204 240 310 1.70 
6 21 33 85 134 146 177 240 1.60 
7 34 54 143 180 187 227 300 1.20 
8 24 37 93 145 163 183 280 1.70 
9 21 43- 101 151 175 186 145 1.10 
10 25 40 95 145 165 185 275 1.90 
mean+-SEM 250±17 1.48±0.09 
Emit of sensitivity > 0.3Wol/minjml plasma 
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Figure 14.7.2. 
Vmax values of phenylacetate hydrolysis for comparison between human tissues. 
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Ile apparent Km's for liver microsmal. arylesterase in the human and rat 
are very different (human: 0.28±0.035 and rat: 1.43±1. ýmM) as are values for liver 
cytosoI (human: 0.19±0.02 S and rat: 0.9±0.5mM). Apparent Krn values for human 
and rat plasma arylesterase were similar (human: 1.48±0.09 '. and rat: 2.34±0. ýmM). 
The results indicate that the enzymes hydrolysing phenylacetate in the 
liver microsomes are different in the human and rat. The apparent affinities of the 
enzymes for phenylacetate vary 5 fold between the human and rat. Enzymatic activities 
also show less - arylesterase in the human sample compared to the rat, with the rat 
having more than 15 times the activity of the human. In the cytosol the activities were 
found to be the same in the human and rat, although apparent affinities varied by 4 fold 
between the human and rat. Plasma arylesterase activities were similar in the human and 
rat with apparent affinities only varying slightly. 
Inhibitory studies should be carried out to distinguish the actual enzymes 
acting to hydrolyse phenylacetate in the liver microsomal and cytosolic fractions as well 
as the plasma. 
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CHAPTER 15: INHIBITORY STUDIES IN THE HUMAN 
15.1. INTRODUCTION 
Having already established that there is esterase hydrolysis of the 
fluazifop-butyl, paraoxon and phenylacetate substrates in the human liver and plasma, 
inhibitory studies were carried out using paraoxon, BNPP, HgC12 and physostigmine. 
15.2. FLUAZIFOP-BUTYL ESTERASE INHIBITION 
Inhibitory studies in the rat indicated that fluazifop-butyl hydrolysis to 
fluazifop was due to carboxylesterase. Using the inhibitors paraoxon, BNPP, mercury 
chloride and physostigmine the esterase enzymes responsible for fluazifop-butyl 
hydrolysis in the human liver microsornal and cytosolic fraction as well as the plasma 
were determined. 
Method 
Incubations were caiTied out in a final volume of 500gl in 50mM trisma 
buffer pl18.0, at 370C. Microsonial or cytosolic protein equivalent to 2mý or 50gl of 
plasma were incubated along with a final concentration of 0.1 mM paraoxon, 0.1 MM 
mercuric chloride, 0.1 mM BNPP or 0.1 mM physostigmine and 25gM fluazifop-butyl 
as substrate. Control incubations without any inhibitors in the incubation were carried 
out in pamHel. 
Reactions were started by the addition of fluazifop-butyl (12.5gl of lmM 
stock in acetonitrile) and stopped after 10 minutes by the addition of 6% perchloric acid 
containing 10lig/ml p-toluic acid (internal standard). Tubes were vortexed and 
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centrifuged at 5440 xg for 5 minutes. 80gl of the supernatant was injected onto 
reversed phase HPLC (see chapter 9.2. iii. ). 
Incubations containing the inhibitors of paraoxon, BNPP, mercuric 
chloride and physostigmine were compared directly to control incubations. Conversion 
to product in the presence of inhibitor was determined as previously described (see 
chapter 9.2. ii. ). Inhibition was estimated by expressing remaining activity in the 
presence of the inhibitor as a percentage of the control activity. 
Results 
Paraoxon completely inhibited fluazifop-butyl hydrolysis in the human 
liver microsomes, cytosol and plasma (see Figure 15.1. ). Inhibition of the liver 
microsomal. an cytosolic fractions and plasma were very similar to those found with 
paraoxon (inhibition of the liver microsomal and cytosolic fraction by BNPP was 86% 
and 92%, whereas in the plasma it was 66% ). Mercuric chloride did not significantly 
inhibit the hydrolysis of fluazifop-butyl by esterases in the human liver microsomal and 
cytosolic fractions (inhibition of the liver microsomal and cytosolic fractions by 
mercury chloride was 3%). Inhibition of the liver microsomal and cytosolic esterase by 
physostigmine was lower than that of BNPP inhibition (Inhibition of the liver 
microsomes and cytosol fraction by physostigmine was 14% and I I%), whereas in the 
plasma the inhibition was found to be greater (inhibition was 41 %). These results can 
be seen on Table 15.1. and Figure 15.1. 
Discussion 
Paraoxon is an inhibitor of 'B' esterases, and the results show that there 
is complete inhibition of fluazifop-butyl hydrolysis in the liver microsomal and 
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Table 15. L Inhibition of fluazifop-butyl hydrolysis to fluazifop in human liver 
microsomal and cytosolic fractions and plasma by 0.1MM paraoxon, BNPP, 
physostigmine and HgC12. Results were expressed as the remaining activity as a% of 
the control. 
Tissue Substrate % Remaining activity 
(Wvl) control +Pararoxon +BNPP +Physostigmine +HgC12 
Liver microsomes 25 100 0±0 14±1.3 86±5.2 97±1.8 
Liver cytosol 25 100 4±1.0 8±0.52 89±3.1 97±2.4 
Plasma 100 100 0±0 44±2.4 59±4.2 - 
liver mean±SEM (n=7) 
plasma: mean±SEM(n=10) 
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Figure 15.1. 
Inhibition of fluazifop-butyl hydrolysis to fluazifop in human liver microsomes (a) and 
cytosol and by plasma by 0.1 mM paraoxon, B NPP, physostigmine and 
mercuric chloride ( HgC12 ). Results were expressed as the % remaining activity of the 
control. Each point represents the mean of duplicate determinations and the vertical 
lines represent mean±SEM ( n=7 for liver and n=10 for plasma ). 
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cytosolic fractions of the liver and the plasma. These results indicate that the esterase 
hydrolysing fluazifop-butyl is a 'B' esterase. Mercuric chloride is an inhibitor of SH 
containing enzymes (containing the cysteine amino acid at the active centre) and 
therefore, acts to inhibit 'A' type esterases. Results from the experiments show that little 
(3%) if no inhibition of fluazifop-butyI hydrolysis took place in the liver microsomal 
and cytosolic fractions by mercuric chloride. These results indicated that 'A' esterase 
was not responsible for fluazifop-butyl hydrolysis in the liver. 
As has already been stated, BNPP is a specific inhibitor for 
carboxylesterase. The results show that in the human liver microsomes 86% inhibition 
of carboxylesterase takes place, whereas in the liver cytosol the value was 92%. The 
results indicate that human fluazifop-butyl hydrolysis is due to carboxylesterase. These 
results agree with inhibitory studies carried out in the rat liver. Inhibition due to 
physostigmine was very small in the microsomal (14%) and cytosol (11%) fractions of 
the lung and this small amount of inhibition is most probably due to inhibition of the 
carboxylestemse enzyme. 
Physostigmine is a highly specific inhibitor of cholinesterase. In the 
plasma, inhibition of fluazifop-butyl was only 50%, suggesting the contribution of 
other esterases in the plasma. This hydrolysis of fluazifop-butyl could be as a result of 
either carboxylesterase or albumin. Work carried out by Mackness et al, (1987) seem to 
agree with this. Using the substrate, -naphthylacetate the presence of carboxylesterase 
in human plasma was characterized by gel-filtration. These esterase activities were then 
further separated from the 'A' esterases by anion-exchange chromatography. 
15.3. ARYLESTERASE INHIBITION 
After arylesterase activity had been identified in the human liver 
microsomal. and cytosolic fractions and plasma, inhibitory studies were carried out to 
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detemiine the rype of esterase acting to hydrolyse phenylacetate to phenol. 
Method 
Incubations were carried out in a final volume of 500gl in 50mM trisma. 
buffer pH8.0, at 371C. Mcrosomal and cytosolic protein equivalent to 3mg original wet 
weight or 30gI of plasma were incubated with a final concentration of O. ImM 
paraoxon, O. ImM mercuric chloride, O. ImM BNPP or O. ImM physostigmine and 
2mM phenylacetate. Control incubations without any inhibitors in the incubation were 
carried out in parallel. 
Reactions were started with the addition of phenylacetate (10gl of a 
600mM stock in DMSO). The cuvettes were inverted and then placed in a 
spectrophotometer (see chapter 9.5. iii. ). 
Incubations containing the inhibitors of paraoxon, BNPP, mercury 
chloride and physostigmine were compared directly to control incubations. Conversion 
to product in the presence of inhibitor was determined as previously described (see 
chapter 9.51i. ). Inhibition was estimated by expressing remaining activity in the 
presence of the inhibitor as a percentage of the control activity. 
Results 
Using the inhibitor paraoxon there is 62% inhibition of phenylacetate 
hydrolysis in the liver microsomes, 68% in liver cytosol and 7% inhibition in the 
plasma. Inhibition due to mercuric chloride was found to be 41 % in the liver 
microsomes and 10% in the liver cytosol. Inhibition due to BNPP was very similar to 
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that of paraoxon with high inhibition of the liver microsomal (52%) and cytosolic 
esterases (76%), whereas little inhibition of the plasma esterase (3%). In the liver 
microsomes inhibition of arylesterase due to physostigmine was 52%, whereas in the 
cytosol it was 26%. It was found that no physostigmine inhibition of the plasma 
arylesterase took place. These results can be seen on Table 15.2. and Figure 15.2. 
Discussion 
The inhibitory studies in the human were very similar to those found in 
the rat. Inhibition due to paraoxon ,a 'B' esterase inhibitor was significant in the liver 
microsomal and cytosolic fractions, whereas in the plasma there was little inhibition. It 
would seem that in the liver cytosol and microsomes most phenylacetate hydrolysis is 
due to the carboxylesterase and not the arylesterase. The lack of arylesterase activity 
would explain why in the human the activity of phenylacetate esterase was lower in the 
liver microsomal fraction than the liver microsomes of the mt. Since the enzymes in the 
microsomal fraction of the human and rat liver are different (in rat phenylacetate is 
hydrolysed mainly by arylesterase, whereas in the human this is due to mainly 
carboxylesterase) this could explain the low phenylacetate hydrolysis and low apparent 
Krn values that were seen in the human liver microsomes compared to that of the rat 
liver microsomes. Results from mercuric chloride, an 'A' type inhibitor, showed that 
there was hydrolysis of phenylacetate by arylesterase in the liver microsomes, whereas 
in the liver cytosol hydrolysis due to arylesterase was very small. It would therefore 
seem that in the liver microsomes hydrolysis of phenylacetate is due to both 'A' and 'B' 
type esterases, whereas in the cytosol of the liver hydrolysis seems to be as a result of 
'B' esterases. 
As would be expected most if not all phenylacetate hydrolysis in the 
human plasma was due to the arylesterase, since very little if no inhibition was seen 
with either paraoxon, BNPP or physostigmine inhibitors. This result is not surprising 
considering there is very little if any carboxylesterase activity contained in the human 
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Table 15.2. Inhibition of phenylacetate hydrolysis to phenol in human liver microsomal 
and cytosolic fractions and plasma by 0.1 mM paraoxon, BNPP, physostigmine and 
HgC12. Results were expressed as the remaining activity as a% of the control. 
Tissue Substrate % Remaining activity 
(mW control +Paraoxon +BNPP +Physostigmine +HgC12 
Liver rrAcrosomes 2 100 38±10 48±2.9 48±2.9 59±6.3 
Liver cytosol. 2 100 32±4.7 24±1.8 74±1.8 90±3.1 
Plasma 2 100 94±2.1 97±2.6 99±1.0 - 
liver mean±SEM (n=7) 
plasma: mean±SEM(n=10) 
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Figure 15.2. 
Inhibition of phenylacetate hydrolysis to phenol in human liver microsomes (a) and 
cytosol (M ) and by plasma ([ý] ) by 0.1 mM paraoxon, B NPP, physostigmine and 
mercuric chloride ( HgC12 ). Results were expressed as the % remaining activity of the 
control. Each point represents the mean of duplicate determinations and the vertical 
lines represent mean-+SEM ( n=7 for liver and n=10 for plasma ). 
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plasma. This result confirms earlier inhibitory studies that hydrolysis of fluazifop-butyl 
in the plasma of the human is as a result of the carboxylesterase enzyme. 
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CHAPTER 16: GENERAL DISCUSSION 
The main aim of these studies was to identify and quantify the esterase 
enzymes responsible for hydrolysis and subsequent detoxification of aýnumber of 
pesticide substrates. Having initially determined the extent of esterase activity in the 
liver, lung, skin and blood of the rat for the pesticides fluazifop-butyl, carbaryI, 
paraoxon and, the marker substrate phenylacetate the aim was to characterize these 
enzymes as 'A' or 'B' esterases by the use of specific inhibitors and inducers. Having 
initially characterised and quantitated esterase activity in the rat, parallel studies were 
then to be carried out in human tissue to establish whether the rat was an approprite 
model for study of the detoxification of pesticides by esterases. 
Fluazifop-butyl, an alkoxyphenoxy herbicide was found to be hydrolysed 
in all the tissues from the rat studied. Most hydrolysis took place in the liver and 
plasma, however, there was significant hydrolysis in the extra-hepatic tissues of the 
skin and lung. Fluazifop-butyl esterase activity was equally distributed between the 
microsomal and cytosolic fraction of the liver, whereas in the lung and skin most 
activity was found in the cytosol. 
ne distribution of carbaryl esterase activity was found to be very similar 
to that of fluazifop-butyl esterase distribution. Most activity was found in the liver and 
plasma and again there was significant activity in the skin and lung. In the liver most 
hydrolysis of carbaryl was found in the cytosol, with the microsomal esterase having 
only a 1/3 the activity of the cytosol. As has ah-eady been discussed, in the microsomal 
fraction of the liver, carbaryl is metabolised both by hydrolysis and oxidation, therefore 
competition may exist for the substrate. In the cytosol, however, carbaryl metabolism is 
entirely due to hydrolysis. The apparent Km values for the microsomal and cytosolic 
esterase enzyme hydrolysing fluazifop-butyl and carbaryl in the tissues studied were 
similar, suggesting the involvement of similar types of esterase isoenzyme. 
To determine whether the iso, zymes responsible for the hydrolysis of 
carbaryl and fluazifop-butyl were similar, inhibitory studies were carried out. Paraoxon 
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was used in the study, because it inhibits 'B' esterases and mercuric chloride because it 
inhibits 'A' esterases. The differential inhibitor for carboxylesterase (BNPP) and the 
specific cholinesterase inhibitor physostigmine were also used to attempt to identify the 
specific isoenzyme, type of 'B' esterase responsible for hydrolysis. 
With rat liver, lung and sIdn tissues and with plasma there was complete 
inhibition of fluazifop-butyl hydrolysis by paraoxon, indicating the involvement of 
serine hydrolases. Mercuric chloride had little effect; thus the enzyme acting on 
fluazifop-butyl bears no SH (cysteine) group essential for hydrolysis. BNPP caused 
widespread inhibition of both fluazifop-butyl and carbaryl hydrolysis in the tissues 
studied, whereas physostigmine had little effect. 
Results therefore showed that both fluazifop-butyl and carbaryl were 
hydrolysed by carboxylesterase in the rat microsomal and cytosolic fractions of the 
liver, lung and skin and the plasma. In the lung microsomes inhibition of 
carboxylesterase by BNPP was low compared to the other tissues studied, using both 
fluazifop-butyl and carbaryl as substrates. This could be as a result of the involvement 
of specific carboxylesterase isoenzymes in the lung microsomes which were not 
susceptible to inhibition by BNPP, but which were still inhibited by paraoxon. 
77he distribution of paraoxon hydr-olysing enzymes was different between 
rat tissue was different from the distribution of carbaryl and fluazifop-butyl esterase. 
Most paraoxonase activity was found in the liver microsomes and the plasma. A very 
small amount of paraoxonase activity was found in the lung microsomes and none was 
detected in the skin. No activity was found in any cytosolic fraction of any of the 
tissues studied. Differences in metabolism might be expected as paraoxonase is an W 
esterase, and fluazifop-butyl and carbaryl esterases are '13' esterases. 
Most phenylacetate esterase activity was found in the liver microsomes 
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and the plasma of the rat, with a smaller amount in the lung and skin. There was 
however some activity in the cytosolic fractions of the tissues studied. Ile distribution 
of phenylacetate esterase activity had similarities to both carbaryl and fluazifop-butyl 
esterase and to paraoxonase. Phenylacetate has been used in the past as a marker for 
arylesterase activity. If this was the case then the distribution of paraoxonase and 
arylesterase would be expected to be similar These studies have shown that although 
distribution in the microsomal fraction of tissues and plasma is similar there is a 
marked difference in the cytosolic fractions. Phenylacetate hydrolysis took place in the 
cytosol of the liver, lung and skin, whereas no paraoxonase activity was found in these 
cytosolic fractions. Phenylacetate appears to be a non-specific substrate for esterase 
enzymes. The esterase activity in the cytosolic fractions of the tissues studied could be 
due to isoenymes of 'A' esterase not not involved in paraoxon hydrolysis, or or due to 
phenylacetate hydrolysis by carboxylesterase. The inhibitory studies carried out 
showed that phenylacetate hydrolysis in the cytosolic fractions of the liver, lung and 
skin was as a result of carboxylesterases rather than arylesterase, whereas in the 
microsmal fraction hydrolysis was due to arylesterase rather than 'B' esterases. These 
results shed doubt on using phenylacetate as a marker enzyme for arylesterase activity 
as can clearly be seen that phenylacetate was a substrate for cytosolic carboxylesterase. 
Having established the type of esterase enzyme involved in hydrolysing a 
range of pesticides in the rat, studies were carried out to establish whether esterase 
activity was inducible. The classical inducers phenobarbitone, B-naphthoflavone and 
clofibric: acid were used in thestudies. Previous work by Satoh and Moroi, (1973), 
using the substrate isocarboxazid reported induction of hepatic microsomal 
carboxylesterase by phenobarbital, but not by the 3-methylcholanthrene type inducers. 
Using the substrate naphthyl propionate, Raftell et al, (1977) found no induction of 
lung microsomal carboxylesterase by phenobarbital. The results presented here were 
similar to these earlier studies. All the esterase enzymes studied were induced by 
phenobarbitone in the liver microsomes. The treatment with phenobarbitone has been 
shown to activate gene transcription of a range of enzymes including P450b and e, 
epoxide hydrolase and glutathione transferase (Hardwick and Gonzalez, 1983; Ding 
and Pickett,, 1985). These results suggest that esterases may be induced in a similar 
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manner, however, the mechanism remains to be fully elucidated. B-naphthoflavone on 
the other hand has a more specific effect involving the binding to a specific cytosolic 
receptor followed by translocated into the nucleus to stimulate gene transcription (Okey 
and Vella, 1982). Induction bf B-naphthoflavone is therefore more specific for mono- 
oxygenase isoenzymes and appears to have little effect on the esterase activity in the 
liver microsomes using any of the substrates. 
Hosokawa et al, (1987) found that after administration of clofibrate, there 
was a significant increase in the activities of the p-nitrophenylacetate, isocarboxazid and 
palmitoyl-CoA hydrolases in the rat liver microsomes, whereas in the liver cytosol only 
palmitoyl-CoA hydrolase was induced. Results from these studies indicated no 
induction of these three carboxylic acid isoenzymes in either of the microsomal or 
cytosolic fractions of the liver, lung and skin. Phenobarbitone did not induce cytosolic 
esterase activity in the liver or skin, but was found to induce fluazifop-butyl and 
phenylacetate hydrolysis in the lung cytosol. These results show that in the liver 
microsomes phenobarbitone induces both 'A' and 'B' type esterases, whereas in the 
lung cytosol the carboxylesterase activity is induced. Although phenylacetate'esterase 
activity in the lung cytosol was induced, previous inhibitory studies have indicated that 
in the lung cytosol phenyl acetate hydrolysis is entirely due to carboxylesterase and not 
arylesterase. The induction in the lung microsomes could be as a result of the activation 
of a specific lung paraoxonase 13-naphthoflavone and clofibric acid inducible isoenzyme 
not expressed in liver at significant levels. In the skin no activation was found in 
microsomal or cytosolic fractions with any of the inducers. This could be as a result of 
low sensitivity of esterase activity in the skin to inducers or that inadequate 
concentrations of the inducers reached the esterase enzymes of the skin. Studies in 
which inducers were locally applied to the skin, thus ensuring high concentrations 
would indicate the absolute induction potential of the skin esterases. 
The relevance of the induction studies were to aid in the classification of 
esterases and to determine the implications in vivo following prior exposure to 
inducers. Atmospheric induction generally occurs with the polycyclic hydrocarbons, 
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whereas phenobarbital and clofibric acid induction would only take place following 
drug therapy. Although induction by phenobarbital and clofibric acid have little 
implication in vivo, differential induction in the extra-hepatic tissues might influence the 
relative prehepatic metabolism. The effect of the inducers on the levels of circulating 
plasma enzymes probably parallel the liver levels (site of synthesis of plasma enzymes) 
although this was not confronted here. 
One of the overall aims of the study in the rat is to obtain information 
which can be extrapolated to man, in this case to man exposed to chemicals such as 
pesticides in the work place. On this project it was possible to study the equivalent 
esterases in human blood and human liver samples. As was found in the rat, fluazifop- 
butyl esterase activity was equally distributed between the microsomal and cytosolic 
fractions of the human liver. Expressing specific activities in terms of Rmol/min/mg 
protein fluazifop-butyl esterase activity was similar in the human and rat liver cytosol 
(i. e. approximately 0.21gmol/min/mg) and 4 times higher in human liver microsomes 
(rat: 0.22 and human: 0.86gmol/min/mg). In the rat however, there was far greater 
fluazifop-butyl esterase activity in the plasma than in the human (rat: 5.8 and human: 
0.088gmoVmin/ml plasma). This low plasma fluazifop-butyl esterase activity was 
consistent with low levels of carboxylesterase, for which fluazifop-butyl is a 
preferential substrate. Lack of inhibition with physostigmine indicated that 
cholinesterase did not hydrolyse fluazifop-butyl. These results compare to studies 
conducted by Clark, 1991 (personal communication) who found a5 fold range in 
fluazifop-butyl esterase activity (0.04-0.15pmoVmin/g wet weight tissue) in the human 
skin. This was a 1/10 the fluazifop-butyl activity of the rat skin. The apparent Km 
values for the microsomal and cytosolic fluazifop-butyl esterase in the liver and plasma 
of the rat and human were very similar (1-2 fold difference), again suggesting the 
existence of a similar enzyme in the human and rat liver and plasma responsible for 
fluazifop-butyl hydrolysis. 
Paraoxonase activity in human plasma was similar to that of the rat (rat: 
0.244 and human: 0.2lOgmol/rnin/rnI plasma), however, in the liver microsomes there 
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was 3 times more paraoxonase activity in the rat (I 1.8nmol/min/mg) compared to the 
human ( 4.2nmol/min/mg) when the activity was "pressed in terms of mg protein. 
Values for human paraoxonase activity agree with previous work carried out by Mutch 
-a--a, 
] (199 1), who found that in a population of 127 males paraoxonase activity varied 
between 90-300nmol/min/ml plasma. These results however are different from those 
found by Losch et al, (1982) who found human paraoxonase activity to be 
30nmol/min/ml plasma, whereas, in the liver it was 350nmol/min/g wet weight tissue. 
There is controversy as to whether the enzymes hydrolysing paraoxon and phenylacetate 
in the human plasma 1, are different or part of the same enzyme. A lack of 
correlation between paraoxon and phenylacetate hydrolysis in a serum population was 
reported by Mallinckrodt, (1988). This however, is contrary to that found by Eckerson 
et a]. (1983 a and b), who found high correlation for the hydrolysis of paraoxon and 
phenylacetate by human plasma and subdivision into 3 modes representing 3 
phenotypes, suggesting that these activities might be the property of the same enzyme. 
The apparent Km values for paraoxonase in human plasma in this study indicate that the 
apparent affinities of the Westerase for the paraoxon and phenylacetate substrates are 
very different. A possible explanation for this could be the involvement of different 
esterase isoenzymes. 
Apparent Krn values for paraoxonase in liver microsomes and plasma 
were similar for both the human and the rat, indicating the possible involvement of the 
same enzyme. 
Phenylacetate esterase activity in human liver microsomes was much 
lower than the rat (rat: 25.6 and human: 5gmol/min/mg of protein), whereas the liver 
cytosol and plasma activities for human and rat were similar. Apparent Km values in 
human and rat livers differed in both microsomal and cytosolic fractions. A possibly 
reason for this could be the involvement of different enzymes. Inhibitory studies in the 
rat supported this. From the study it would seem that in human liver microsomes 
phenylacetate is hydrolysed by mostly '13' esterases, whereas in the rat hydrolysis was 
due to arylesterase. In the cytosol of the liver phenylacetate hydrolysis in both human 
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and rat is due to 'B' esterases. It is only in the plasma of the human that the 
arylesterase is entirely responsible for the hydrolysis of phenylacetate. 
One of the overall aims of these studies was to predict whether or not 
following exposure to xenobiotic pesticide via dermal or inhalation the tissues of the 
lung, skin or plasma would play an important role in the first pass detoxification. 
Following exposure to fluazifop-butyl it was seen that in the rat a 
significant amount of hydrolysis took place in the lung and the skin. A degree of 
hydrolysis would therefore take place in these tissues before the fluazifop-butyl was 
transported to the blood supply where further hydrolysis could take place. Finally the 
fluazifop-butyl would then be transported to the liver where most hydrolysis has been 
shown to take place. 'In practice the most important route of exposure to fluazifop-butyI 
is through absorption through the skin, because if fluazifop-butyl was inhaled, the 
fluazifop-butyl would be deposited as droplets in the upper airways of the lung and so 
would not be absorbed ( Chester and Hart, 1986). The reason for the lack of absorption 
is that the particle size of the fluazifop-butyl used in its spray form exceeds 54m in 
diameter and so would deposits in the upper airways before reaching the alveoli. Tlis 
same picture would apply to exposure to carbaryl. Following exposure local 
hydrolysis would be expected to occur in the lung and the skin tissues. Since the 
carbaryl particle in its spray form is between 15-20gm in diameter (Johnstone, 1969; 
1970) the absorption through the skin is the more important route of exposure 
compared to that of inhalation. 
I The rat skin and lung tissue have little capacity to hydrolyse paraoxon. 
Therefore following initial exposure to parathion and activation to paraoxon little first 
pass metabolism would be expected to occur in skin or lung. The plasma paraoxonase 
activity would play the most important role in the detoxification of paraoxon. The 
pesticide generally used parathion, is an inherently weak organophoshate 
anticholinesterase, as it must be activated via a cytochrome P450-dependant 
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desulphuration reaction to the reactive phosphate (oxon) metabolite Lie. paraoxon 
(Gage, 1953; Neal, 1967). Activation of parathion to paraoxon has not been shown but 
it is activated in the lung (Norman and Neal, 1975) and liver (Neal, 1967). Parathion is 
known to be absorbed easily through the lung and skin (Neal, 1967). It is known that 
paraoxon irreversible inhibits acety1cholinesterase in the nervous system and respiratory 
centre of the brain, therefore following exposure, paraoxon would be transported from 
the lung by the blood through the circulation to the nervous system and respiratory 
centre of the brain to have its effect. Only after inhibition the onset of 
acetylcholinesterase inhibition at the target sites would there be any hydrolysis of 
paraoxon due to paraoxonase in the liver microsomes. In the case of parathion exposure 
through the lung it would therefore, seem that the plasma has an important role to play 
in the detoxification of the paraoxon. This may be even more important in man due to 
the lower paraoxonase activity in the liver microsomes, compared to plasma. Following 
exposure through the dermal absorption, if there was no activation of the parathion in 
skin, the liver would be the major site for activation of parathion and detoxification of 
paraoxon. No activation would take place in the plasma. Therefore following paraoxon 
exposure through the lung, the liver would play a far less important role in 
detoxification, because the onset of action of the paraoxon on the target tissues would 
appear before second pass metabolism would occur, however, if the paraoxon was 
orally ingested or absorbed through the skin then the liver microsomes be involved in 
the first pass metabolism of the pesticide. The brain has the ability to activate parathion 
to paraoxon due to the presence of the cytochrome P450-desulphation reaction so that 
parathion absorbed through the skin could be transported by the blood to the brain 
causing inhibition of the brain acety1cholinesterases at the respiratory centre before it 
reached the liver for detoxification. The extra-hepatic tissues of the lung and skin and 
blood do indirectly play a role in preventing the irreversible inhibition of the 
acetylcholinesterase. Carboxylesterase in the lung and skin and plasma is inhibited by 
paraoxon, which binds irreversibly, therefore decreasing the amount of intact paraoxon 
in the circulation. 
The studies have shown that there is considerable similarity in the nature 
of human and rat esterase enzymes, although there are significant differences in 
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absolute activities. The rat therefore, seems to be a good model for studying pesticide 
detoxification by esterase hydrolysis and extrapolation of results to the human would be 
possible. 
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CHAPTER 17: APPENDIX 
Table 17.1. The hydrolysis of fluazifop-butyl to fluazifop in rat liver, lung and skin 
microsomes. Results were expressed at: (i) Vmax ( Amol/min/g wet weight or ml ) and 
(ii) the apparent Km ( gM ) by direct linear plot. 
(i) Vmax values: 
Rat number Liver Lung Skin 
1 6.25 0.7 0.021 
2 7.5 0.21 0.019 
3 5.3 0.21 0.031 
4 6.52 0.24 0.023 
5 5.7 0.14 0.014 
6 6.1 0.21 0.0173 
mean±SEM 6.29±0.4 0.38±0.1 0.02±0.0015 
(i) App=nt Km: 
Rat number Liver Lung Skin 
1 20 43 8 
2 12 60 8 
3 15 43 17 
4 10 30 11 
5 15 25 14 
6 13 29 15 
mean+-SEM 14.4±2.8 33±5.5 14±2.8 
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Table 17.2. The hydrolysis of fluazifop-butyl to fluazifop in rat liver, lung and skin 
cytosol and plasma and erythrocytes. Results were expressed at: (i) Vmax 
gmol/min/g wet weight or ml ) and (ii) the apparent Km ( pM ) by direct linear plot. 
(i) Vmax values: 
Rat number Liver Lung Skin Plasma Erythrocytes 
1 5.8 1.34 0.35 5.25 0.028 
2 9.7 1.13 0.34 5.5 0.048 
3 6.6 1.16 0.46 5.2 0.026 
4 6.9 1.92 0.38 6.5 0.033 
5 5.2 0.67 0.58 6.0 0.048 
6 6.8 0.60 0.34 5.7 0.038 
mean+-SEM 6.84±0.85 1.5±0.32 0.4±0.06 5.8±0.48 0.03±0.05 
(i) Apparent Km: 
Rat number Liver Lung Skin Plasma Erythrocytes 
1 10 120 36 15 38 
2 20 80 44 17 43 
3 20 54 13 14 30 
4 25 60 40 25 34 
5 35 42 30 20 40 
6 23 20 47 19 23 
mean±SEM 22±4.5 63±14 42±2.8 18.2±2.2 33±1.2 
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Table 17.3. The hydrolysis of carbaryl to I-naphthol in rat liver, lung and skin 
microsomes . Results were expressed at: (i) Vmax ( mnol/minIg wet weight ) and (ii) 
the apparent Km ( pM ) by direct linear plot. 
(i) Vmax values: 
Rat number Liver Lung Skin 
1 2.64 1.6 0.132 
2 2.15 2.36 0.167 
3 2.38 1.68 0.26 
4 1.58 1.35 0.188 
5 2.3 1.84 0.182 
6 1.9 1.97 0.20 
mean+-SEM 2.07±0.25 1.64±0.25 0.19±0.035 
(i) Apparent Km: 
Rat number Liver Lung Skin 
1 11 34 33 
2 24 22 22 
3 22 34 36 
4 18 28 38 
5 15 31 30 
6 20 27 31 
mean+-SEM 20±3.5 30±3.5 32±4.2 
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Table 17.4. The hydrolysis of carbaryl to 1 -naphthol in rat liver, lung and skin cytosol 
and plasma and erythrocytes. Results were expressed at: (i) Vmax ( nmol/min/g wet 
weight or ml ) and (ii) the apparent Krn ( gM ) by direct linear plot. 
(i) Vmax values: 
Rat number Liver Lung Skin Plasma Erythrocytes 
1 5.7 0.96 0.82 2.40 0 
2 8.4 1.65 0.78 3.60 0 
3 6.1 0.78 0.38 2.36 0 
4 6.4 1.79 0.38 3.47 0 
5 6.6 1.10 0.40 3.40' 0 
6 7.0 1.40 0.54 3.00 0 
mean+-SEM 6.7±0.75 1.36±0.25 0.5±0.12 2.98±0.25 0.0±0.0 
(i) Apparent Km: 
Rat number Liver Lung Skin Plasma Eryflu-ocytes 
1 64 25 21 54 0 
2 44 23 28 77 0 
3 50 28 18 52 0 
4 53 27 30 63 0 
5 55 24 22 68 0 
6 51 18 32 61 0 
mean±SEM 53±4.5 26±1.2 36±3.8 64±4 0±0 
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Table 17.5. The hydrolysis of paraoxon to p-nitrophenol in rat liver, lung and skin 
microsomes and plasma and erythrocytes . Results were expressed at: (i) Vmax 
ILmol/min/g wet weight ) and (ii) the apparent Km ( mM ) by direct linear plot. 
W Vniax values: 
Rat number Liver Lung Skin Plasma Erythrocytes 
1 0.37 0.0021 0 0.22 0 
2 0.34 0.0029 0 0.215 0 
3 0.33 0.0018 0 0.25 0 
4 0.32 0.0016 0 0.25 0 
5 0.35 0.0024 0 0.24 0 
6 0.31 0.0015 0 0.30 0 
mean±SEM 0.33±0.025 0.002±0.00025 0±0 0.246±0.012 0±0 
(i) Apparent Km: 
Rat number Liver Lung Skin Plasma Erythrocytes 
1 0.18 0.33 0 0.26 0 
2 0.33 0.43 0 0.22 0 
3 0.19 0.28 0 0.22 0 
4 0.19 0.46 0 0.22 0 
5 0.24 0.44 0 0.26 0 
6 0.22 0.34 0 0.17 0 
mean+-SEM 0.2±0.035 0.38±0.013 0±0 0.225±0.015 0±0 
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Table 17.6. The hydrolysis of phenylacetate to phenol in rat liver, lung and skin 
microsomes . Results were expressed at: (i) Vmax ( gmol/min/g wet weight ) and (ii) 
the apparent Km ( mM ) by direct linear plot. 
(i) Vmax values: 
Rat number Liver Lung Skin 
1 745 6.2 1.75 
2 1100 6.6 0.74 
3 845 4.5 1.24 
4 800 4.2 1.10 
5 530 4.0 0.84 
6 780 3.6 1.09 
mean±SEM 800±75 4.86±3.1 1.13±0.025 
(i) Apparent Km: 
Rat number Liver Lung Skin 
1 1.5 1.33 1.0 
2 2.0 1.71 1.25 
3 1.4 1.64 0.85 
4 1.4 1.3 0.70 
5 0.9 1.67 0.95 
6 1.4 1.14 0.90 
mean±SEM 1.43±0.11 1.46±0.58 0.95±0.1 
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Table 17.7. The hydrolysis of phenylacetate to phenol in rat liver, - lung and skin 
cytosol and plasma and erythrocytes. Results were expressed ýat: (i) Nmax 
gmol/min/g wet weight or ml ) and (ii) the apparent Km ( mM ) by direct linear plot. 
(i) Vmax values: 
Rat number Liver Lung Skin Plasma Erythrocytes 
1 34.5 11.5 4.0 230 0 
2 20.5 12.6 4.0 230 0 
3 37 16.7 3.7 268 0 
4 30 13.7 2.9 294 0 
5 24 13.4 3.4 244 01 
6 38 17.0 2.7 425 0 
mean±SEM 30.7±3 14.2±5.5 3.44±1.4 290±40 0. o±O. 0 
(i) Apparent Km: 
Rat number Liver Lung Skin Plasma Erythrocytes 
1 1.0 1.2 0.15 1.6 0 
2 1.0 1.6 0.3 1.8 0 
3 0.7 1.4 0.6 2.2 0 
4 1.0 1.6 0.4 2.7 0 
5 0.8 1.3 0.38 1.8 0 
6 0.9 1.0 0.2 4.1 0 
mean+-SEM 0.90±0.5 1.33±0.55 0.34±0.05 2.34±6.4 0±0 
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Table 17.8. Protein recoveriers fi-om rat liver subcellular fractions after induction with 
phenobarbitone, 8-naphthoflavone and clofibric acid. Results were expressed as mgjg 
of tissue protein. 
(i) Liver Nficrosomes: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 14.8 16.5 16.0 13.8 
2 18.0 29.1 14.6 12.9 
3 19.0 18.6 18.0 15.8 
4 13.7 13.8 18.2 16.8 
mean+-SD 16.4±1.5 19.6±3.4 16.6±0.96 14.6±0.12 
(i) Liver Cytosol: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 51.0 45.5 40.8 43.2 
2 44.0 59.6 41.0 42.0 
3 49.3 47.6 40.5 60.8 
4 52.2 43.0 50.5 64.1 
mean+-SD 49.1±1.8 49.3±3.6 43.3±2.6 52.5±5.0 
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Table 17.9. Protein recoveriers from rat lung subcellular fractions after induction with 
phenobarbitone, B-naphthoflavone and cloflbric acid. Results were expressed as mglg 
of tissue protein. 
(i) Lung Nficrosomes: 
Rat number Saline Phenobarbitone 6-naphthoflavone Clofibric acid 
1 11.3 9.3 10.4 113 
2 12.2 12.0 9.2 11.7 
3 10.6 8.1 9.2 11.7 
4 14.2 9.0 7.9- 11.9 
mcan+-SD 12.1±1.0 9.60±1.1 9.20±3.0 11.3±3.0 
(i) Liver Cytosol: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 57.8 57.2 80.3 56.6 
2 46.8 53.8 45.0 75.9 
3 52.6 58.6 40.8 64.0 
4 48.2 62.9 68.3 50.3 
mean+-SD 51.3±2.6 56.2±3.4 58.7±9.0 58.7±4.0 
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Table 17.10. Protein recoveriers from rat sIdn subcellular fractions after induction with 
phenobarbitone, B-naphthoflavone and clofibric acid. Results were expressed as mg/g 
of tissue protein. 
(i) Skin NEcrosomes: 
Rat number Saline - Phenobarbitone 13-naphthoflavone Clofibric acid 
1 
2 
3 
4 
mean±SD 
(i) Skin Cytosol: 
1.45 1.0 1.80 1.28 
1.83 0.92 1.39 1.06 
1.26 0.88 0.92 1.23 
1.36 1.32 1.22 1.48 
1.50±0.12 1.10±0.2 1.33±0.26 1.26±0.12 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 19.8 22.0 21.1 19.8 
2 20.0 27.3 23.7 20.0 
3 19.2 14.7 20.8 19.0 
4 17.2 20.2 20.2 19.0 
mean+-SD 19.3±0.1 21.0±0.2 21.5±0.08 
19.4±0.2 
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Table 17.11. Induction of fluazifop-butyl hydrolysis to fluazifop in rat liver. Results 
expressed in Mol/min/g wet weight. 
(i) Liver Nficrosomes: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 0.93 2.52 0.82 1.10 
2 1.34 2.10 0.95 0.98 
3 1.30 1.96 0.91 1.56 
4 1.28 1.3 1.16 1.07 
5 - 1.91 - 1.09 
meaa+-SD 1.21±0.18 1.94±0.53 0.96+-+0.14 1.10±0.14 
(i) Liver Cytosol: 
Rat nunber Saline Phenobarbitone 8-naphthoflavone Clofibric acid 
1 1.07 1.06 0.70 1.24 
2 0.63 1.21 0.72 0.91 
3 1.12 0.87 0.67 1.30 
4 0.65 0.73 0.36 0.80 
5 - 0.33 - 0.26 
mean+-SD 0.86±0.27 0.97±0.21 0.66±0.19 1.06±0.22 
sensidvity >I mnol/incubation 
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Table 17.12. Induction of fluazifop-butyl hydrolysis to fluazifop in rat lung. Results 
expressed in pmol/min/g wet weight. 
(i) Lung NUcrosomes: 
Rat number Saline Phenobarbitone 3-naphthoflavone Clofibric acid 
1 0.28 0.13 0.32 0.33 
2 0.30 0.30 0.29 0.30 
3 0.26 0.27 0.19 0.32 
4 0.30 0.33 0.30 0.30 
5 - 0.33 - 0.25 
mean±SD 0.28±0.019 0.27±0.03 0.27+-+0.08 0.30±0.03 
(i) Lung Cytosol: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 1.33 1.52 1.40 1.45 
2 1.33 1.50 0.57 1.21 
3 1.31 1.42 0.85 1.32 
4 1.30 1.45 1.08 1.10 
5 1.41 - 1.46 
mean±SD 1.31±0-09 1.47±0.07 0.98±0.32 1.31±0.14 
sensitivity > InmoLrincubadon 
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Table 17.13. Induction of fluazifop-butyl hydrolysis to fluazifop, in rat skin . Results 
expressed in pmol/min/g wet weight. 
(i) Sldn NEcrosomes: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 0.28 0.13 0.32 0.33 
2 0.30 0.30 0.29 0.30 
3 0.26 0.27 0.19 0.32 
4 0.30 0.33 0.30 0.30 
5 - 0.33 - 0.25 
mean+-SD 0.28±0.019 1.94+-+0.53 0.27±0.08 0.30±0.03 
(i) Skin Cytosol: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 0.59 0.64 0.60 0.66 
2 0.62 0.45 0.54 0.56 
3 0.62 0.59 0.58 0.57 
4 0.57 0.65 0.59 0.6 
5 - 0.57 - 0.59 
mean-+SD 0.60±0.026 0.58±0.9 0.58±0.09 0-59±0.046 
sensitivity > Irunol/incubation 
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Table 17.14. Induction of carbaryl hydrolysis to 1-naphthol in rat liver . Results 
expressed in nmol/min/g wet weight. 
(i) Liver Nficrosomes: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 1.4 2.2 0.76 1.5 
2 1.1 1.97 1.08 1.8 
3 1.25 2.33 1.01 0.93 
4 0.81 1.12 1.33 2.4 
mean+-SD 1.14±0.25 1.90±0.54 1.04±0.23 1.66±0.61 
(i) Liver Cytosol: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 1.26 0.44 0.53 0.66 
2 1.13 0.39 1.58 0.80 
3 1.44 1.78 1.55 1.02 
4 1.38 0.99 1.30 0.60 
mean+-SD 1.30±0-14 0.90±0.65 0.99±0.51 0.77±0.19 
sensidvity > 20pmoLrmcubadon 
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Table 17.15. Induction of carbaryl hydrolysis to 1-naphthol in rat lung . Results 
expressed in nmol/minlg wet weight. 
(i) Lung Nficrosomes: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 0.65 
2 1.01 
3 0.72 
4 0.50 
mean±SD 0.72±0.21 
(i) Lung Cytosol: 
0.49 0.49 0.66 
0.74 0.68 1.01 
1.39 0.65 1.34 
1.0 0.83 0.61 
0.90±0.38 0.66±0.14 0.90±0.34 
Rat number Saline Phenobarbitone 6-naphthoflavone Clof ibric acid 
1 0.49 0.23 0.60 0.80 
2 0.82 0.62 0.22 1.04 
3 0.42 0.43 1.13 0.73 
4 0.91 0.62 1.09 0.74 
mean±SD 0.69±0.26 0.48±0.19 0.76±0.43 0.83±0.14 
sensitivity > 20pmolfincubadon 
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Table 17.16. Induction of carbaryl hydrolysis to 1-naphthol in rat skin . Results 
expressed in nmol/minlg wet weight. 
(i) Skin Nficrosomes: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 0.059 0.051 0.008 0.032 
2 0.074 0.011 0.049 0.033 
3 0.086 0.037 0.037 0.025 
4 0.023 0.018 0.055 0.027 
mean±SD 0.06±0.027 0.029±0.018 0.037±0.02 0.029±0.004 
(i) Skin Cytosol: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 0.21 0.22 0.22 0.17 
2 0.39 0.38 0.34 0.28 
3 0.29 0.28 0.18 0.16 
4 0.3 0.31 0.28 0.13 
mean±SD 0.30±0.07 0.28±0.05 0.26±0.07 0.19±0.07 
sensitivity > 20pmoLrincubadon 
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Table 17.17. Induction of paraoxon hydrolysis to p-nitrophenol in rat liver and lung . 
Results expressed in pmol/min/g wet weight. 
(i) Liver Nlicrosomes: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 0.073 0.129 0.075 0.078 
2 0.081 0.136 0.084 0.107 
3 0.074 0.09 0.085 0.098 
4 0.058 0.171 0.075 0.099 
5 - 0.134 - 0.098 
mean+-SD 0.07±0.011 0.132±0.032 0.080±0.008 0.096±0.012 
(i) Lung Mcrosomes: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 0.0082 0.0095 0.0092 0.0094 
2 0.009 0.0094 0.0094 0.0097 
3 0.0074 0.0095 0.01 0.01 
4 0.0088 0.0079 0.0098 0.0099 
5 - 0.009 - 0.0099 
meaa+-SD 0.0082±0.01 0.0091+-+0.0008 0.0096±0.0005 0.0098±0.0004 
sensitivity > InmoLfincubation 
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Table 17.18. Induction of phenylacetate hydrolysis to phenol in rat liver. Results 
expressed in ý=ol/min/g wet weight. 
(i) Liver Nlicrosomes: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 177 222 154 182 
2 190 171 158 184 
3 161 269 142 162 
4 196 244 166 159 
5 - 228 - 169 
mean+-SD 179.5±16 226.5±42 155±10 171.8±13 
(i) Liver Cytosol: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 63 68 31 69 
2 61 62 53 65 
3 49 43 67 53 
4 87 38 56 67 
5 - 53 - 63 
mean-+SD 65±16 52.8±14 50.2±13 63.5±7 
sensitivity > 0.3grnoLlincubation 
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Table 17.19. Induction of phenylacetate hydrolysis to phenol in rat lung. Results 
expressed in Mol/min/g wet weight. 
(i) Lung NEcrosomes: 
Rat number Saline Phenobarbitone B-naphthoflavone Clofibric acid 
1 4.43 4.79 2.85 3.75 
2 3.82 3.58 3.67 4.88 
3 4.10 4.11 4.38 3.63 
4 5.05 4.75 4.16 4.23 
5 - 3.14 - 4.06 
mean-+SD 4.38±0.58 4.08±0.68 3.77±0.64 4 . 11±0.5 
(i) Liver Cytosol: 
Rat number Saline Phenobarbitone B-naphthoflavone' Clofibric acid 
1 14.5 22.2 7.6 10.0 
2 16.4 19.3 11.2 13.4 
3 13.3 27.4 16.6 11.1 
4 15.7 14.4 7.8 20.1 
5 - 21.0 - 12.2 
mean+-SD 14.95±1.27 21.37±4.8 10.76±4.0 13.49±3.8 
sensitivity > 0.3grnoLrincubation 
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Table 17.20. Induction of phenylacetate hydrolysis to phenol in rat skin. Results 
expressed in jimol/minIg wet weight. 
(i) Lung Ma-osomes: 
Rat number Saline Phenobarbitone 13-naphthoflavone Clofibric acid 
1 0.126 0.111 0.111 0.239 
2 0.130 0.136 0.128 0.243 
3 0.136 0.10 0.147 0.096 
4 0.148 0.134 0.124 0.135 
5 - 0.122 - 0.182 
mean±SD 0.135±0.024 0.12±0.022 0.127-+0.021 0.179±0.07 
(i) Liver Cytosol: 
Rat number Saline Phenobarbitone 13-naphthoflavone Clofibric acid 
1 7.75 7.25 5.72 5.67 
2 6.38 7.17 5.75 5.05 
3 6.85 5.04 6.36 5.04 
4 6.75 9.58 5.12 5.15 
5 - 7.31 - 5.23 
mearl±SD 6.93±0.54 7.26±1.73 5.74±0.47 5.20±0.27 
sensitivity > 0.3gmol/incubation 
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